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ABSTRACT 
 
In this thesis high intensity focused ultrasound (HIFU) is utilized for cancer 
treatment (thermal mode) and treatment of ischaemic stroke (mechanical mode). 
These two applications were investigated in vitro and in vivo models. MRI was 
utilized to monitor the lesions created by HIFU either in thermal or cavitation 
mode in freshly excised lamb brain tissue in vitro, and in rabbit brain in vivo. 
Additionally, MRI was used to monitor lesions deep in tissue for both in vitro and 
in vivo exposures. All three MRI sequences used (T1-W FSE, T2-W FSE and 
FLAIR) were able to detect lesions. Both thermal and bubbly lesions were best 
monitored using T1-W FSE with excellent contrast, proving the potential of HIFU 
to treat reliably tumours in the brain. A HIFU system was also used to assist 
thrombolysis in cooperation with a thrombolytic drug such as recombinant tissue 
plasminogen activator (rt-PA) in vitro and in vivo. It was shown that higher 
intensity results to higher volume of dissolved clot, but there is a limit of the 
intensity to be used in order to avoid heating of the clot and the surrounding 
tissue. The goal in this study was to achieve temperature elevation not exceeding 
1ºC (called safe temperature). It was found that the larger the beam area the larger 
the dissolved clot volume. Also, the lower the frequency, the larger the volume of 
the dissolved clot. The results reported herein point to the use of frequency around 
0.5 MHz and pulsing to optimize thrombolysis and skull penetration and at the 
same time avoiding unwanted heating. Finally, an Acrylonitrile Butadiene Styrene 
(ABS) phantom skull model was developed in order to evaluate the propagation of 
ultrasound using a single element transducer. The skull model was appropriately 
designed so that it has the same attenuation as a human skull. It was demonstrated 
that using a frequency of 0.5 MHz versus 1 MHz, ultrasound propagation through 
the phantom skull was higher.  Therefore, higher frequency has poor skull 
penetration and a small beam size at the focus, while low frequencies have better 
skull penetration but with the risk of reaching the unpredictable effect of 
cavitation. The developed system has proven to successfully create large lesions 
in the brain and at the same time, these lesions are successfully monitored with 
excellent contrast using MRI (T1-W FSE) enabling the accurate determination of 
the margins of these lesions. The results reported in this study point to the use of 
frequency around 0.5 MHz and pulsing to optimize thrombolysis and skull 
penetration and at the same time avoiding unwanted heating. For treating tumours 
located deep in the brain and for dissolving thrombus causing an acute ischaemic 
stroke, further extensive clinical studies will be needed before this technology is 
applied to humans.  
  
  
CHAPTER 1: INTRODUCTION 
 
Early studies on focused ultrasound treatment in the 1940s [1] and 1950s [2][3] 
have demonstrated the ability to perform precise lesioning in the human brain.  
However, the need for a craniotomy, as well as the lack of sophisticated imaging 
technology, resulted in limited growth of high-intensity focused ultrasound for 
neurosurgery. More recently, technological advances have permitted the 
combination of High Intensity Focused Ultrasound (HIFU) along with magnetic 
resonance imaging (MRI) guidance to provide an opportunity to effectively treat a 
variety of central nervous system disorders [4]-[5].   
 
The purpose of this research is to develop an ultrasonic system that is guided with 
MRI imaging. The effect of temperature and of thermal dose on the attenuation 
and absorption of tissues namely lamb brain in vitro were investigated.  The 
attenuation was measured using the transmission and reception method and the 
absorption was measured using the rate of heating method. The impact of 
variation of absorption due to tissue changes on the temperature elevation was 
demonstrated by temperature measurements and simulations. 
 
Following the results of the attenuation and the absorption, a computer model was 
developed that estimates the lesion size based on the transducer characteristics 
(frequency, diameter, degree of focusing), treatment protocol (pulse duration, 
acoustical power), and anatomical site (size, depth, mode of operation). In 
addition, temperature elevation at the focal point inside the tissue was recorded. 
Temperature elevation had to be controlled in order to avoid heating of the brain 
during sonothrombolysis. Acoustic parameters (power, pulse duration, duty factor 
and pulse repetition frequency) were extracted to maintain a temperature increase 
of less than 1ºC during the application of pulsed ultrasound. Based on the 
simulation results (for both cases), a transducer was designed that contains 
minimum amount of magnetic material so that it can function inside the MRI 
scanner without affecting the quality of the imaging. 
 
MRI was utilized for the investigation and monitoring of small and large lesions 
created by HIFU under thermal and cavitation or bubbly lesions in freshly excised 
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lamb brain tissue in vitro, and in rabbit brain in vivo. In addition, MRI was used to 
monitored lesions deep in tissue for in vitro and in vivo exposures. MRI images 
were taken using T1-W fast spin echo (FSE), T2-W FSE and fluid attenuated 
inversion recovery (FLAIR) sequences.  
 
A thrombus model was tested in the rabbit carotid and ear artery in vivo to 
investigate its functionality to blog the artery. A HIFU system was used to assist 
thrombolysis in cooperation with a thrombolytic drug such as recombinant tissue 
plasminogen activator (rt-PA) in vitro and in vivo.  An Ultrasonic Doppler system 
was also utilized to monitor the blood flow in the brain during sonothrombolysis. 
Various pulse protocols were investigated so that the temperature change at the 
clot does not exceed 1C (called safe temperature). 
 
An Acrylonitrile Butadiene Styrene (ABS) phantom skull model was developed in 
order to evaluate the propagation of ultrasound using a single element transducer. 
The skull model was appropriately designed so that it has the same attenuation as 
a human skull. Temperature was monitored at the focal point with and without the 
skull model.  
 
A brief outline of the chapters to follow is given below. 
 
Chapter 2 covers the basics of brain anatomy and physiology. It describes the 
cerebral circulatory system as well as some worldwide statistics on brain cancer. 
It also explains the different types of brain tumours and their different grading 
system based on the World Health Organization (WHO) classification.  Current 
state of the art in treating brain tumours is also discussed. Finally, the basics of 
stroke characteristics are described with an emphasis on Acute Ischaemic Stroke. 
Methods of treatments with the help of thrombolytic drugs are also explained and 
the feasibility of ultrasound to enhance thrombolysis is accentuated. 
 
Chapter 3 presents historically the technique of HIFU and explains its physical 
principles. The chapter also provides descriptions of HIFU applications in 
medicine and highlights the limitations of the technique and future prospects. 
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Chapter 4 describes the physical aspects of ultrasound such as basic quantities, 
power field calculations, temperature simulations, and thermal dose calculations. 
 
Chapter 5 presents the results from the in vitro measurements of the attenuation 
and absorption in animal brain tissue as a function of thermal dose.  Attenuation 
and absorption are the main physical parameters that affect the temperature rise in 
tissue.  Due to high temperatures induced in tissue and due to sonication, it is 
important to know the variation of attenuation and absorption at this high level of 
temperature. 
 
In chapter 6, the results derived from the simulation study are presented.  Based 
on the optimized size and shape of lesions and temperature elevation derived from 
the simulation studies, the ultrasonic transducer was developed with the minimum 
amount of magnetic material.  The transducer operated in thermal mode to 
produce tissue necrosis for the treatment of cancer. 
 
Chapter 7 presents experimental results of HIFU in vitro (lamb brain) and in vivo 
(rabbit brain) using MR imaging. The creation of single, large and deep lesions 
was demonstrated and the effectiveness of MRI to monitor therapeutic protocols 
of HIFU in the brain was investigated. 
 
In chapter 8 the simulations results are presented for the treatment of ischaemic 
stroke. The estimated temperature elevation derived from the simulation studies 
should not exceed 1ºC, so that thermal effects are eliminated. Temperature 
elevation should be controlled in order to avoid heating of the brain during 
sonothrombolysis. The transducer operated in mechanical mode in order to 
partition the thrombus into small pieces.  
 
Chapter 9 presents the results from the in vitro experiments in an effort to dissolve 
the clot using HIFU. At first, ultrasound alone (US) was used, then thrombolytic 
drug (rt-PA) alone was used and finally ultrasound combined with rt-PA (US + rt-
PA) were used. The goal was to achieve temperature elevation not exceeding 1ºC 
and at the same time to dissolve a large amount of clot. 
 
4 
 
Chapter 10 presents the results from the in vivo experiments. The ability to 
produce thrombus was tested in vivo. The ability to dissolve the thrombus created 
at the ear artery of a rabbit was presented using HIFU and rt-PA. A Doppler 
ultrasound was used to observe the blood flow in the brain and at the ear artery 
before and after the thrombus. Finally, chapter 11 presents conclusions and future 
work. 
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CHAPTER 2: THE PATHOLOGY AND TREATMENT 
OF BRAIN TUMOURS AND ACUTE ISCHAEMIC 
STROKE 
 
2.1 INTRODUCTION 
The human brain is the most important and the most complex organ in the human 
body. Brain cancer diseases or strokes are very difficult to treat even with the 
today’s technology. Finding new methods of dealing with these kinds of diseases 
makes it very challenging. Therefore, in this thesis a HIFU system is utilized for 
cancer treatment and treatment of ischaemic stroke. 
 
This chapter will discuss the main type of brain tumours and the various current 
state of the art treatment methodologies. Similarly, this chapter also covers the 
pathology and treatment of acute ischaemic stroke. Prior to the description of 
these, the basic anatomy and physiology of the anatomical parts related to these 
pathologies (i.e. brain) are also presented. 
 
2.2 PHYSIOLOGY AND ANATOMY OF THE HUMAN BRAIN  
2.2.1 HEAD ANATOMY 
The human nervous system consists of the central nervous system (CNS) and 
peripheral nervous system (PNS). The CNS consists of the brain and spinal cord, 
while the PNS is composed of the nerves extending to and from the brain and 
spinal cord. The primary functions of the nervous system are to monitor, integrate 
(process) and respond to information inside and outside the body. The brain 
consists of soft, delicate, non-replaceable neural tissue. It is supported and 
protected by the surrounding skin, skull, meninges and cerebrospinal fluid [6]. 
 
SKIN 
The skin constitutes a protective barrier against physical damage of underlying 
tissues, invasion of hazardous chemical and bacterial substances and it helps to 
maintain the body at a constant temperature. Together with the sweat and oil 
glands, hairs and nails it forms a set of organs called the integumentary system. 
Figure 2.1 shows a cross-section of the skin and underlying subcutaneous tissue.  
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Figure 2.1 Skin and underlying subcutaneous tissue [6] 
 
The skin consists of an outer, protective layer, the epidermis and an inner layer, 
the dermis. While the top layer of the epidermis, the stratum corneum, consists of 
dead cells, the dermis is composed of vascularised fibrous connective tissue. The 
subcutaneous tissue, located underneath the skin, is primarily composed of 
adipose tissue (fat) [6]. 
  
SKULL 
Depending on their shape, bones are classified as long, short, flat or irregular. 
There are two types of bones: compact and spongy bone. Compact has a smooth 
structure, whilst the spongy bone is composed of small needle-like or flat pieces 
of bone called trabeculae, which form a network filled with red or yellow bone 
marrow. Most skull bones are flat and consist of two parallel compact bone 
surfaces, with a layer of spongy bone sandwiched between. The spongy bone 
layer of flat bones (the diploë) predominantly contains red bone marrow and 
hence has a high concentration of blood [6]. 
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The skull is a highly complex structure consisting of 22 bones altogether. These 
can be divided into two sets, the cranial bones (or cranium) and the facial bones. 
The facial bones form the framework of the face, the cranial bones form the 
cranial cavity that encloses and protects the brain. All bones of the adult skull are 
firmly connected by sutures. Figure 2.2 shows the most important bones of the 
skull. The frontal bone forms the forehead and contains the frontal sinuses, which 
are air filled cells within the bone. Most superior and lateral aspects of the skull 
are formed by the parietal bones while the occipital bone forms the posterior 
aspects. The base of the occipital bone contains the foramen magnum, which is a 
large hole allowing the inferior part of the brain to connect to the spinal cord. The 
remaining bones of the cranium are the temporal, sphenoid and ethmoid bones [6]. 
 
MENINGES 
The meninges (Figure 2.3) are three connective tissue membranes enclosing the 
brain and the spinal cord. Their functions are to protect the Central Nervous 
System (CNS) and blood vessels, enclose the venous sinuses, retain the 
cerebrospinal fluid (CSF), and form partitions within the skull. The outermost 
meninx is the dura mater, which encloses the arachnoid mater and the innermost 
pia mater. A brief description of the various parts of the brain are described at the 
next page [7]; 
 
Figure 2.2 The most important bones of the Skull [6] 
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dura mater - The outermost and heaviest, most fibrous, layer of the meninges 
covering the brain and spinal cord, composed of dense irregular fibrous 
connective tissue, a structure which contains some of the larger blood vessels, 
particularly the venous sinuses; it forms a protective physical barrier for the CNS.   
epidural space - The anatomical location external to the dura is merely a 
"potential" space in the cranium, since the dura is fused to the cranial periosteum, 
while, in contrast, in the vertebral canal, it generally contains adipose tissue.  
subdural space - The anatomical location between the dura and the arachnoid is 
merely a "potential" space because under normal circumstances, the arachnoid is 
directly attached to the dura mater. 
arachnoid - The middle layer of the meninges, a thin, spongy membraneous 
covering of the brain and spinal cord with a spider-web-like appearance which 
does not conform to the irregularities of the surfaces of the brain and spinal cord. 
It is composed of a delicate loose fibrous connective tissue; the space under the 
arachnoid and above the pia mater, the subarachnoid space, contains cerebrospinal 
fluid.  
pia mater -The inner layer of the meninges, a thin, membraneous covering which 
adheres smoothly to the surface of the brain and spinal cord and conforms to all 
the irregularities of their surfaces. It is composed of a very thin layer of dense 
irregular fibrous connective tissue; the smaller surface blood vessels of the brain 
and spinal cord are contained within this layer; at spinal levels, the pia mater 
gathers laterally, pierces the arachnoid and attaches to the dura, forming the 
denticulate ligament.  This stabilizes the spinal cord within the vertebral canal and 
decreases the likelihood of cord damage when physical trauma occurs. 
subarachnoid space - The space under the arachnoid and above the pia mater 
which contains cerebrospinal fluid.  
meningitis - Inflammation of the meninges of the brain and the spinal cord, most 
often caused by a bacterial or viral infection and characterized by fever, nausea 
and vomiting, intense headache, and stiff neck; bacterial forms tend to have more 
severe prognosis.  
falx cerebri - The scythe-shaped mid-saggital fold of the dura mater occupying 
the longitudinal fissure between the two cerebral hemispheres and which contains 
the sagittal venous sinuses.  
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Figure 2.3 Various parts of the brain; meninges [7] 
 
CEREBROSPINAL FLUID (CSF) 
CSF is a watery liquid similar in composition to blood plasma. It is formed in the 
choroid plexuses and circulates through the ventricles into the subarachnoid 
space, where it is returned to the dural venous sinuses by the arachnoid villi. The 
prime purpose of the CSF is to support and cushion the brain and help nourish it. 
Figure 2.4 illustrates the flow of CSF through the central nervous system. CSF has 
several important functions. It cushions the brain within the skull, transports 
nutrients to brain tissue and carries waste away. CSF is produced at a site within 
the brain called the choroid plexus, which generates about 400-500 ml. (one pint) 
of the fluid each day or approximately 0.3 cc per minute. The total volume of CSF 
in the skull at any given time is around 140 ml. That means the body produces, 
absorbs and replenishes the total volume of CSF about 3-4 times daily [7]. 
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Figure 2.4 Cerebrospinal Fluid Circulation [7] 
 
2.2.2 BRAIN REGIONS AND FUNCTIONS 
The major regions of the brain (figure 2.5) are the cerebral hemispheres, 
diencephalon, brain stem and cerebellum. 
 
CEREBRAL HEMISPHERES 
The cerebral hemispheres (Figure 2.6), located on the most superior part of the 
brain, are separated by the longitudinal fissure. They make up approximately 83% 
of total brain mass, and are collectively referred to as the cerebrum. The cerebral 
cortex constitutes a 2-4 mm thick grey matter surface layer and, because of its 
many convolutions, accounts for about 40% of total brain mass. It is responsible 
for conscious behaviour and contains three different functional areas: the motor 
areas, sensory areas and association areas. Located internally are the white 
matter, responsible for communication between cerebral areas and between the 
cerebral cortex and lower regions of the CNS, as well as the basal nuclei (or basal 
ganglia), involved in controlling muscular movement [7]. 
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Figure 2.5 Major Regions of the Brain [7] 
 
Figure 2.6 Major Regions of the cerebral hemispheres [7] 
 
DIENCEPHALON 
The diencephalon is located centrally within the forebrain. It consists of the 
thalamus, hypothalamus and epithalamus, which together enclose the third 
ventricle. The thalamus acts as a grouping and relay station for sensory inputs 
ascending to the sensory cortex and association areas. It also mediates motor 
activities, cortical arousal and memories. The hypothalamus, by controlling the 
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autonomic (involuntary) nervous system, is responsible for maintaining the body’s 
homeostatic balance. Moreover, it forms a part of the limbic system, the 
‘emotional’ brain. The epithalamus consists of the pineal gland and the CSF 
producing choroid plexus [7]. 
 
BRAIN STEM 
The brain stem is similarly structured as the spinal cord: it consists of grey matter 
surrounded by white matter fibre tracts. Its major regions are the midbrain, pons 
and medulla oblongata. The midbrain, which surrounds the cerebral aqueduct, 
provides fibre pathways between higher and lower brain centres, contains visual 
and auditory reflex and subcortical motor centres. The pons is mainly a 
conduction region, but its nuclei also contribute to the regulation of respiration 
and cranial nerves. The medulla oblongata takes an important role as an 
autonomic reflex centre involved in maintaining body homeostasis. In particular, 
nuclei in the medulla regulate respiratory rhythm, heart rate, blood pressure and 
several cranial nerves. Moreover, it provides conduction pathways between the 
inferior spinal cord and higher brain centres [7]. 
 
CEREBELLUM 
The cerebellum, which is located dorsal to the pons and medulla, accounts for 
about 11% of total brain mass. Like the cerebrum, it has a thin outer cortex of 
grey matter, internal white matter, and small, deeply situated, paired masses 
(nuclei) of grey matter. The cerebellum processes impulses received from the 
cerebral motor cortex, various brain stem nuclei and sensory receptors in order to 
appropriately control skeletal muscle contraction, thus giving smooth, coordinated 
movements. 
 
2.2.3 THE CEREBRAL CIRCULATORY SYSTEM 
Blood is transported through the body via a continuous system of blood vessels. 
Arteries carry oxygenated blood away from the heart into capillaries supplying 
tissue cells. Veins collect the blood from the capillary bed and carry it back to the 
heart. The main purpose of blood flow through body tissues is to deliver oxygen 
and nutrients to and waste from the cells, exchange gas in the lungs, absorb 
nutrients from the digestive tract, and help forming urine in the kidneys. All the 
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circulation besides the heart and the pulmonary circulation is called the systemic 
circulation [7]. 
 
BLOOD SUPPLY TO THE BRAIN 
Figure 2.7 shows an overview of the arterial system supplying the brain. The 
major arteries are the vertebral and internal carotid arteries. The two posterior 
and single anterior communicating arteries form the circle of Willis, which 
equalises blood pressures in the brain’s anterior and posterior regions, and 
protects the brain from damage if one of the arteries become occluded. However, 
there is little communication between smaller arteries on the brain’s surface. 
Hence, occlusion of these arteries usually results in localized tissue damage [7]. 
 
Figure 2.7 Major cerebral arteries and the circle of Willis [7] 
 
2.2.4 BRAIN CANCER STATISTICS 
Table 2.1 shows approximately the incidence rate for brain tumour in adults 
within the populations of various countries and regions for the year 2004 [8].  
These incidences for brain tumour are only estimates and may have limited 
relevance to the actual incidence of brain tumours in adults in any region.  The 
sources or statistics have only been taken from the population in the countries 
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listed and as such, therefore, this information may be inaccurate (especially for the 
developing or third world countries) and only give a general indications as to the 
actual prevalence or incidence of brain tumours of adults in that region. 
 
Table 2.1 Incidence rate for brain tumour 
Region (Approximate Statistics)-
Brain Cancer 
Approximate 
Incidence  
Population 
Estimated  
North America 32,492 432,994,000 
South America 488,215 303,887,000 
Northern Europe 1499 19,908,27736,881 
Western Europe 16,200 215,014,622 
Central Europe 11,710 164,423,520 
Eastern Europe 15,769 209,272,527 
South western Europe 2063,386 1348,32536 
Southern Europe 5,177 2696,65072 
South eastern Europe 3,853 51,188,794 
Northern Asia 207 2,751,314 
Central Asia 4342,802 5448,34844 
Eastern Asia 8685,604 10896,69688 
South western Asia 17371,208 21793,39376 
South eastern Asia 34742,416 43586,78752 
Middle East 69484,832 87173,57504 
Northern Africa 138969,664 174347,15008 
Western Africa 277939,328 348694,30016 
Central Africa 555878,656 697388,60032 
Eastern Africa 1111757,312 1394777,20064 
Southern Africa 2223514,624 2789554,40128 
Oceania 4447029,248 5579108,80256 
 
2.3 CHARACTERIZATION AND TREATMENT OF HUMAN BRAIN 
TUMOURS 
The human body has the ability to reproduce new cells only when old and 
damaged cells need to be replaced.  A tumour will be formed when normal or 
abnormal cells keep multiplying when it is not needed.  This unwanted growth or 
multiplication of these cells will result in a brain tumour.   
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There are two basic kinds of brain tumours: primary brain tumours and metastatic 
brain tumours.  Primary brain tumours start, and tend to stay, in the brain.  
Metastatic brain tumours begin as cancer elsewhere in the body and spread to the 
brain.  Depending of the malignancy or aggressiveness, tumours are called benign 
or malignant. 
 
2.3.1 THE WHO BRAIN TUMOUR GRADING SYSTEM 
PRIMARY BRAIN TUMOURS 
A tumour that starts in the brain is a primary brain tumour. Glioblastoma 
multiforme, astrocytoma, medulloblastoma, and ependymoma are examples of 
primary brain tumours.  The most common of these tumours are gliomas. They 
begin in glial cells. There are many types of gliomas [9]: 
 Astrocytoma—The tumour arises from star-shaped glial cells called 
astrocytes. In adults, astrocytomas most often arise in the cerebrum. In 
children, they occur in the brain stem, the cerebrum, and the cerebellum. A 
grade III astrocytoma is sometimes called an anaplastic astrocytoma. A 
grade IV astrocytoma is usually called a glioblastoma multiforme. 
 Brain stem glioma—The tumour occurs in the lowest part of the brain. 
Brain stem gliomas most often are diagnosed in young children and middle-
aged adults. 
 Ependymoma—The tumour arises from cells that line the ventricles or the 
central canal of the spinal cord, and again they are most commonly found in 
children and young adults. 
 Oligodendroglioma—This rare tumour arises from cells that make the fatty 
substance that covers and protects nerves. These tumours usually occur in 
the cerebrum. They grow slowly and usually do not spread into surrounding 
brain tissue. They are most common in middle-aged adults. 
 
Some types of brain tumours do not begin in glial cells. The most common of 
these are: 
 Medulloblastoma—This tumour usually arises in the cerebellum. It is the 
most common brain tumour in children. It is sometimes called a primitive 
neuroectodermal tumour. 
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 Meningioma—This tumour arises in the meninges. It usually grows 
slowly. 
 Schwannoma—A tumour that arises from a Schwann cell. These cells line 
the nerve that controls balance and hearing. This nerve is in the inner ear. 
The tumour is also called an acoustic neuroma. It occurs most often in 
adults. 
 Craniopharyngioma—The tumour grows at the base of the brain, near the 
pituitary gland. This type of tumour most often occurs in children. 
 Germ cell tumour of the brain—The tumour arises from a germ cell. Most 
germ cell tumours that arise in the brain occur in people younger than 30. 
The most common type of germ cell tumour of the brain is a germinoma. 
 Pineal region tumour—This rare brain tumour arises in or near the pineal 
gland. The pineal gland is located between the cerebrum and the 
cerebellum. 
 
Primary brain tumours can be grouped into benign tumours and malignant 
tumours. 
 
BENIGN BRAIN TUMOURS 
A benign brain tumour consists of very slow growing cells, usually has distinct 
borders, and rarely spreads. When viewed under a microscope, the cells have an 
almost normal appearance. Surgery alone might be an effective treatment for this 
type of tumour. A brain tumour composed of benign cells, but located in a vital 
area, can be considered to be life-threatening — although the tumour and its cells 
would not be classified as malignant [9]. 
 
MALIGNANT BRAIN TUMOURS  
A malignant brain tumour is usually rapid growing, invasive, and life-threatening. 
Malignant brain tumours are often called brain cancer [9]. However, since primary 
brain tumours rarely spread outside the brain and spinal cord, they do not exactly 
fit the general definition of cancer.  
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Cancer is a disease defined by:  
 unregulated growth of abnormal cells  
 abnormal cells that grow into/around parts of the body and interfere with 
their normal functioning 
 spread to distant organs in the body  
Brain tumours can be called malignant if they:  
 have the characteristics of cancer cells or  
 are located in a critical part of the brain or  
 are causing life-threatening damage 
 
Malignant brain tumours that are cancerous can spread within the brain and spine. 
They rarely spread to other parts of the body. They lack distinct borders due to 
their tendency to send “roots” into nearby normal tissue. They can also shed cells 
that travel to distant parts of the brain and spine by way of the cerebrospinal fluid. 
Some malignant tumours, however, do remain localized to a region of the brain or 
spinal cord. 
 
METASTATIC BRAIN TUMOURS 
Cancer cells that begin growing elsewhere in the body and then travel to the brain 
form metastatic brain tumours [9]. For example, cancers of the lung, breast, colon 
and skin (melanoma) frequently spread to the brain via the bloodstream or a 
magnetic-like attraction to other organs of the body. All metastatic brain tumours 
are, by definition, malignant. 
 
TUMOUR GRADING 
Tumours are diagnosed and then named based on a classification system. Most 
medical centres now use the World Health Organization (WHO) classification 
system for this purpose. Tumours are graded to facilitate communication, to plan 
treatment, and to predict outcome. The grade of a tumour indicates its degree of 
malignancy. 
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Grading is based on the tumour’s microscopic appearance using some or all of the 
following criteria:  
 similarity to normal cells (atypia)  
 rate of growth (mitotic index)  
 indications of uncontrolled growth 
 dead tumour cells in the center of the tumour (necrosis)  
 potential for invasion and/or spread (infiltration) based on whether or not it 
has a definitive margin (diffuse or focal)  
 blood supply (vascularity) 
 
Using the WHO grading system [9];  
Grade I: are the least malignant tumours and are usually associated with long-
term survival. The tumours grow slowly, and have an almost normal 
appearance when viewed through a microscope.  Surgery alone might 
be an effective treatment for this grade of tumour. Pilocytic 
astrocytoma, craniopharyngioma, and many tumours of neurons - for 
example, gangliocytoma and ganglioglioma - are examples of grade I 
tumours.  
Grade II: are relatively slow tumours growing and have a slightly abnormal 
microscopic appearance.  Some can spread into nearby normal tissue 
and recur. Sometimes these tumours recur as a higher grade.  
Grade III: are by definition, malignant tumours although there is not always a 
sharp distinction between a grade II and a grade III tumour.  The cells 
of a grade III tumour are actively reproducing abnormal cells which 
grow into nearby normal brain tissue. These tumours tend to recur, 
often as a higher grade. 
Grade IV: are the most malignant tumours. They reproduce rapidly, can have a 
bizarre appearance when viewed under the microscope, and easily 
grow into surrounding normal brain tissue. These tumours form new 
blood vessels so they can maintain their rapid growth. They also have 
areas of dead cells in their centre. The glioblastoma multiforme is the 
most common example of a grade IV tumour. 
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Tumours often contain several grades of cells. The highest or most malignant 
grade of cell determines the grade, even if most of the tumour is a lower grade. 
Some tumours undergo change. A benign growth might become malignant. In 
some tumours, a lower-grade tumour might recur as a higher-grade tumour [9].  
 
2.3.2 TYPES AND SIZES OF BRAIN TUMOURS 
BRAIN TUMOUR TYPE 
A comprehensive review of the most common brain and spinal cord tumours, their 
typical symptoms and locations, and how they might be treated is presented in the 
tables shown below. The tumour names that have been used in this project are 
based on the WHO brain tumour classification system described above [9].   
 
The following outline has been adapted from the WHO classification.  Tumours 
of glial origin are grouped under a common heading, and tumours limited to the 
peripheral nervous system have been excluded. 
 Neuroepithelial tumours (table 2.2) 
 Meningeal tumours (table 2.3) 
 Germ cell tumours (table 2.4) 
 Tumours of the sellar region (table 2.5) 
 Tumours of uncertain histogenesis (table 2.6) 
 Primary CNS lymphoma (table 2.7) 
 Tumours of peripheral nerves that affect the CNS (table 2.8) 
 Metastatic tumours (table 2.9) 
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Table 2.2 Neuroepithelial tumours [9] 
Neuroepithelial tumours: 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
1. Glial tumours: 
Astrocytic tumours 
Pilocytic 
astrocytoma 
Occurring throughout the 
neuraxis. the optic nerve, optic 
chiasm/hypothalamus, thalamus 
and basal ganglia, cerebral 
hemispheres, cerebellum, and 
brain stem 
Grade I Surgery, 
Surgery - Radiation 
Benign Typically affects 
children, cystic 
tumour,  
is often curable 
Diffuse astrocytoma 
(including fibrillary, 
protoplasmic, and 
gemistocytic). 
Are composed of well-
differentiated fibrillary or 
gemistocytic neoplastic astrocytes 
May be located in any region of 
the CNS but most commonly 
develop in the cerebrum 
Grade II Surgery – Radiation, 
Surgery (age < 35) 
Has a 
tendency for 
Malignant  
Typically affects 
young adults 
Anaplastic 
astrocytoma 
Possess an intrinsic tendency 
to progress to glioblastoma. 
Affects the cerebral 
hemispheres 
Grade 
III 
Surgery – Radiation, 
Surgery – Radiation – 
Chemotherapy 
 
Malignant  
Glioblastoma Primarily affects the cerebral 
hemispheres 
Grade 
IV 
Surgery–Radiation, 
Radiotherapy plus 
continuous daily 
temozolomide. 
Malignant Is the most frequent 
brain tumour 
Pleomorphic 
xanthoastrocytoma 
Arise from a type of cell of the 
central nervous system known as 
a glial cell. 
Grade II Surgery, Radiation, Surgery-
Radiation 
Benign Rarely do these 
tumours arise from 
the spinal column 
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Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Subependymal giant 
cell astrocytoma 
Occurs almost exclusively in 
patients with tuberous sclerosis 
complex (TSC) 
Grade I Surgery Benign  
Oligodendroglial tumours: Begin in the brain cells called oligodendrocytes, which support and nourish nerve cells 
Oligodendroglioma Composed predominantly of 
cells morphologically 
resembling oligodendroglia, 
which grows diffusely in the 
cortex and white matter.[ 
Grade II Radiation, Chemotherapy slow-
growing 
Most 
oligodendrogliomas 
occur in adults 
Anaplastic 
oligodendroglioma 
An oligodendroglial tumour 
with focal or diffuse histologic 
features of malignancy 
Grade 
III 
Surgery, Radiation, 
Chemotherapy 
grow 
quickly 
 
Mixed gliomas: Brain tumours that contain more than one type of cell 
Oligoastrocytoma Is composed of two distinct 
neoplastic cell types that 
morphologically resemble tumour 
cells in oligodendroglioma and 
diffuse astrocytoma 
Grade II Surgery – Radiation, 
Chemotherapy 
slow-
growing 
 
Anaplastic 
oligoastrocytoma 
Anaplastic oligoastrocytomas are 
predominantly hemispheric 
tumours, and the frontal lobes are 
more commonly involved than 
the temporal lobes 
Grade 
III 
Surgery-Radiation, 
Surgery-Radiation-
Chemotherapy 
 Mixed Gliomas 
Ependymal tumours: Ependymal cells line the vertical of the brain and the center of the spinal cord. 
Myxopapillary 
ependymoma 
Occur in the lower part of the 
spinal column. 
 
Grade I Surgery, Radiation   
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Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Subependymoma These tumours are usually 
located in the fourth and lateral 
ventricle, and sometimes in the 
spinal cord 
Grade I Microsurgical Benign  
Ependymoma 
(including cellular, 
papillary, clear cell, 
and tanycytic) 
These tumours occur at any 
site in the ventricular system 
and in the spinal canal. 
Grade II Surgery,  
Radiation-Surgery 
  
Anaplastic 
ependymoma 
Commonly develop in the 
posterior fossa (the portion of 
the skull containing the 
cerebellum and brain stem). 
 
Grade 
III, IV 
Surgery-Radiation Malignant  
Neuroepithelial tumours of uncertain origin 
Astroblastoma The cerebral hemispheres are 
most affected; tumours may also 
develop in the corpus callosum, 
cerebellum, optic nerves, brain 
stem, and cauda equine 
no 
WHO 
grade 
Surgery, Radiation, 
Chemotherapy 
 This is a rare 
tumour for which 
no reliable 
epidemiological 
data exist. 
Chordoid glioma of 
the third ventricle 
low-grade tumour located in 
the third ventricle-
hypothalamic region. 
Grade II Surgery   
Gliomatosis cerebri Is characterized by a diffuse, 
or broad, spread of glial 
tumour cells in the brain. 
 
Grade 
III 
Radiation, Chemotherapy Malignant Widespread low-
grade glioma 
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2. Neuronal and mixed neuronal-glial tumours (some glial component may be present) 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Gangliocytoma 
(ganglioneuromas) 
Arise from ganglia-type cells, 
which are groups of nerve cells. 
 
Grade 
I 
Surgery Benign Locate in the 
temporal lobe of the 
cerebral hemispheres 
and the third 
ventricle, and also in 
the spine. 
Ganglioglioma Occur most commonly in the 
cerebrum (the largest and upper 
most section of the brain), but may 
occur in any part of the brain and 
spinal cord. 
Grade 
I, II 
Surgery, Radiation  May rarely undergo 
transformation into a 
higher grade, more 
malignant tumour. 
Desmoplastic infantile 
astrocytoma/gangliogli
oma 
Located in the deep white matter, 
under the solid part of the tumour 
attached to the dura mater of the left 
frontal lobe 
Grade 
I 
Surgery   
Dysembryoplastic 
neuroepithelial 
tumour 
a group of tumours that occur in 
the tissues that cover the brain 
and spinal cord. 
Grade 
I 
 
Surgery Benign  
Central neurocytoma Occur in the lateral ventricles with 
the foramina of Monro as the most 
common sites, and in the third 
ventricles. 
Grade 
II 
Surgery, 
Surgery-Radiation 
Benign  
Cerebellar 
liponeurocytoma 
 Grade 
I, II 
Surgery, Radiation Benign  
Paraganglioma 
(Glomus fugulare) 
Located in the lining of a large vein 
in the neck called the jugular vein. 
Grade 
I 
Surgery (neurosurgeon) – 
“Head and Neck” surgeon. 
Benign Can spread to the 
bone close to the 
inner and middle ear. 
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3. Nonglial tumours 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Embryonal tumours 
Ependymoblastoma Brain tumour that consists of 
small round cells and is 
believed to originate from 
primitive nerve cells in the 
brain. 
Grade 
IV 
Chemotherapy, Radiation, 
Surgery 
Malignant  
Medulloblastoma Originate in the cerebellum are 
referred to as infratentorial 
because they occur below the 
tentorium,  
Grade 
IV 
Surgery, Radiation, 
Chemotherapy, 
Cerebrospinal fluid diversion 
Malignant Has a tendency to 
metastasize via 
CSF pathways 
Supratentorial 
primitive 
neuroectodermal 
tumour (PNET) 
Is an embryonal tumour in the 
cerebrum or suprasellar region 
that is composed of 
undifferentiated or poorly 
differentiated neuroepithelial 
cells. 
Grade 
IV 
Surgery-Craniospinal 
Radiation 
Malignant Considerable 
controversy exists 
regarding the 
histogenesis of 
these tumours. 
Choroid plexus tumours 
Choroid plexus 
papilloma 
Commonly invade or grow into 
nearby tissue and spread widely 
via the cerebrospinal fluid. 
Grade I Surgery, Chemotherapy, 
Radiation 
Malignant  
Choroid plexus 
carcinoma 
The choroids plexus papilloma 
grows slowly within the 
ventricles. It eventually blocks 
the flow of cerebrospinal fluid, 
causing hydrocephalus and 
increased intracranial pressure. 
Grade 
III 
Surgery, Shunt Benign  
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Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Pineal parenchymal tumours: Located at the rear of the third ventricle. 
Pineoblastoma Rapidly growing and have 
worse prognoses. 
Grade 
IV 
Surgery-Radiation, 
Chemotherapy 
Malignant  
Pineocytoma Slow growing and carry 
variable prognoses for cure. 
Grade II Surgery-Radiation   
 
Table 2.3 Meningeal tumours [9] 
Meningeal tumours 
Type of Tumour Description Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Meningioma Attached to the dura mater and 
composed of neoplastic 
meningothelial (arachnoidal) 
cells. 
Grade I-
III 
Conservative management, 
Surgery, Radiation (external 
beam RT, radiosurgery SRS, 
radiotherapy SRT). 
I-II: Benign 
III: 
Malignant 
The second most 
frequent primary 
brain tumours after 
gliomas. 
Hemangiopericytoma occurring in soft tissue and 
with a tendency to recur and to 
metastasize outside the CNS. 
Grade 
II, III 
Surgery, Radiation Benign  
Melanocytic lesion Located directly over 
fibrohistiocytic proliferations. 
 Surgery Benign  
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Table 2.4 Germ cell tumours [9] 
Germ cell tumours: Arise in the pineal or suprasellar regions of the brain 
Type of Tumour Description Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Germinoma Occurs in the pineal or 
suprasellar region of the brain 
and tends to spread via the 
cerebrospinal fluid. 
No 
Grade 
Surgery, Radiation, 
Chemotherapy 
  
Embryonal 
carcinoma 
It grows with its cells dividing 
rapidly and indefinitely. 
  Malignant The embryonal 
carcinoma is a 
reproductive cell 
gone out of control. 
Yolk-sac tumour 
(endodermal-sinus 
tumour) 
Often occurs as small 
"malignant foci" within a 
larger tumour, usually 
teratoma. 
 Surgery-Chemotherapy Malignant  
Choriocarcinoma   Surgery, Chemotherapy Malignant  
Teratoma Teratomas derived from 
embryonal cells usually occur 
on the body midline: in the 
brain, elsewhere inside the 
skull, in the nose, in the 
tongue, under the tongue, and 
in the neck. 
 Surgery, Chemotherapy Benign  
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Table 2.5 Tumours of the sellar region [9] 
Tumours of the sellar region 
Type of Tumour Description Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Pituitary adenoma, 
 
Found in the pituitary gland, a small organ 
about the size of a pea in the center of the 
brain just above the back of the nose. 
The radiographical classification: 
 0: Normal pituitary appearance.  
 I: Enclosed within the sella turcica, 
microadenoma, smaller than 10 mm.  
 II: Enclosed within the sella turcica, 
macroadenoma, 10 mm or larger .  
 III: Invasive, locally, into the sella.  
 IV: Invasive, diffusely, into the sella.  
 
Surgery, Radiation, 
Medication 
Benign Grow very slowly 
and do not spread 
from the pituitary 
gland to other parts 
of the body. 
Pituitary carcinoma Malignant Spread in the 
central nervous 
system (brain and 
spinal cord) or 
outside of the 
central nervous 
system. 
Craniopharyngioma Occur in the sellar region, near 
the pituitary gland. They often 
involve the third ventricle, 
optic nerve, and pituitary 
gland. 
Grade I Surgery, Shunt, Radiation 
(Radio-Surgery, Conformal 
Radiation, radioactive 
Phosphorous) 
Benign These localized 
tumours grow by 
expansion and may 
reach a large size 
before they are 
diagnosed. 
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Table 2.6 Tumours of uncertain histogenesis [9] 
Tumours of uncertain histogenesis 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Capillary 
hemangioblastoma 
May occur in any part of the 
CNS, sporadic tumours occur 
primarily in the cerebellum. 
Grade I Microsurgical techniques Benign  
 
Table 2.7 Primary CNS lymphoma [9] 
Primary CNS lymphoma 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Is defined as lymphoma limited to the cranial-spinal 
axis without systemic disease.  It is usually confined to 
the CNS and/or the eye. 
 Preradiotherapy (RT), 
Methotrexate (MTX), 
barrier-dependent 
chemotherapy. 
Malignant  
 
Table 2.8 Tumours of peripheral nerves that affect the CNS [9] 
Tumours of peripheral nerves that affect the CNS 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
Schwannoma Is a benign (noncancerous) 
tumour on the 8th cranial nerve. 
This nerve leads from the 
brainstem to the ear and is 
involved in hearing and 
maintaining balance. 
Grade I Observation, microsurgical 
removal, Radiation 
Benign Peripheral nerves 
that accounts for an 
estimated 8% of 
brain tumours and 
29% of primary 
spinal tumours 
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Table 2.9 Metastatic tumours [9] 
Metastatic tumours 
Type of Tumour Description / Location Grade Treatment 
(Surgery/Radiation/Chemical/etc.) 
Benign / 
Malignant 
Comments 
SPINAL FLUID METASTASES 
METASTATIC SPINAL TUMOURS 
The types of cancer that commonly spread to the brain 
are melanoma and cancers of the lung, breast, 
unknown primary site, and colon. 
 
 Surgery, Radiation, 
Ambulation after treatment. 
 The most common 
primary cancers 
metastasizing to the 
brain are lung cancer 
(50%), breast cancer 
(15%–20%), cancer 
of unknown primary 
site (10%–15%), 
melanoma (10%), 
and colon cancer 
(5%) 
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BRAIN TUMOUR SIZE 
The following literature summarizes brain tumour size (table 2.10).  Either the 
diameter or volume is given.  The literature covers most of the popular tumour 
types in the brain including metastasis.  The information regarding tumour size is 
very critical for determining the range of motion of the 3D robotic system used in 
this project.  It is concluded that by selecting a range of motion of 10 cm is more 
than enough to cover all tumour types in the brain.  Basically a 5 cm range will 
cover most of the tumour types except high grade gliomas, Boisserie G. et al [12].  
The mean average brain lesion type according to, Gralla J. et al [14] and 
Paleologos T. et al [16] was found to be between 3.3-3.6 cm.  The average depth 
from skin based on Paleologos T. et al [16] is around 3.6 cm.  
Table 2.10 brain tumour: diameter or volume  
Type of tumour Diameter 
(cm) 
Volume 
(cm
3
) 
Reference No. of 
Subjects 
Intracerebral cavernous 
hemangiomas. 
0.7-4.5  Woydt M et al [10] 35 
Glioma  12.7 Julow J et al [11] 19 
High grade gliomas 2.1-10.1 
(median: 6.4 
cm) 
2-122 cm3 
(median: 22 
cm3). 
Boisserie G et al 
[12] 
20 
Pituitary adenomas 1.92 (mean) 5.4 (mean) Kobayashi T et al 
[13] 
67 
Brain lesions 3.3 (mean)  Gralla J et al [14] 57 
Brain metastasis 2.1  0.06-4.58 
Median 0.67 
Chang EL et al [15] 135 
Brain lesions 3.6 (mean) 
Distance from 
skin 3.6 (mean) 
 Paleologos TS et al 
[16] 
125 
Brain metastasis MRI:1.28+/-
0.91 
CT 2.03+/-0.7 
 Yokoi K et al [17] 332 
Ependymomas 
Subependymomas 
4 (mean) 
2.6 (mean) 
 Furie DM et al [18] 14 
Glioblastoma 
multiforme Anaplastic 
astrocytoma 
Equivalent 
diameter= 3.5 
22.5 Buatti JM et al [19] 11 
Malignant skull base 
tumours 
3.35 (mean)  Tanaka T et al [20] 19 
Malignant intracranial 
tumours. 
 17.1 Hou Y et al [21] 281 
Recurrent 
glioblastomas 
1.2-10.1 
median: 5.7  
1.6-122 
median: 23  
Simon JM et al [22] 42 
Astrocytomas Grade I 
Astrocytomas Grade II 
2.54 (mean) 
2.37 (mean) 
 Kida Y et al [23] 51 
Gliomas 3-7  Landy HJ et al [24] 18 
Meningocerebral 
astrocytomas 
6-12  Taratuto AL et al 
[25] 
6 
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2.3.3 CURRENT STATE OF THE ART IN TREATING BRAIN TUMOURS 
Treatment depends on a number of factors, including the type, location, size, and 
grade of the tumour. For some types of brain cancer, the clinician also needs to 
know whether cancer cells were found in the cerebrospinal fluid.  Depending on 
the tumour type and stage, there are several treatment options such as [26]:  
 Surgery  Neurosurgery, 
 radiation therapy,  
 chemotherapy, 
 hyperthermia 
These types of treatment have been mentioned above in the various tables. This 
section gives a brief description of each treatment type. 
SURGERY 
Surgery is the usual treatment for most brain tumours. Surgery to open the skull is 
called a craniotomy. It is performed under general anesthesia. Before surgery 
begins, the scalp is shaved. The surgeon then makes an incision in the scalp and 
uses a special type of saw to remove a piece of bone from the skull. After 
removing part or all of the tumour, the surgeon covers the opening in the skull 
with that piece of bone or with a piece of metal or fabric. The surgeon then closes 
the incision in the scalp.  Sometimes surgery is not possible. If the tumour is in the 
brain stem or other areas, the surgeon may not be able to remove the tumour 
without damaging normal brain tissue. Patients who cannot have surgery may 
receive radiation or other treatment [26].  
 
NEUROSURGERY 
When treating brain tumours, tumour resection (tumour removal by operation) is 
still a common treatment. Until recently, open neurosurgery meant a fairly high 
risk for patients in terms of damaging important structures of the brain. Today, 
computer-based image-guided surgery assists the surgeon during all phases of the 
operation. This allows the surgeon to keep the operation minimally invasive and 
to avoid critical structures of the brain, reducing risks and hospital time while at 
the same time improving the success rate [26].  
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RADIATION THERAPY 
Radiation therapy (also called radiotherapy) uses high-energy rays to kill tumour 
cells. The radiation may come from x-rays, gamma rays, or protons. A large 
machine aims radiation at the tumour and the tissue close to it. Sometimes the 
radiation may be directed to the entire brain or to the spinal cord. Radiation 
therapy usually follows surgery. The radiation kills tumour cells that may remain 
in the area. Sometimes, patients who cannot have surgery, have radiation therapy 
instead. The treatment schedule depends on the type and size of the tumour and 
the age of the patient. Each treatment lasts only a few minutes [26]. 
Necessary steps to protect the healthy tissue around the brain tumour:  
 Fractionation—Radiation therapy usually is given five days a week for 
several weeks. Giving the total dose of radiation over an extended period 
helps to protect healthy tissue in the area of the tumour. 
 Hyperfractionation—The patient gets smaller doses of radiation two or three 
times a day instead of a larger amount once a day. 
 Stereotactic radiation therapy—Narrow beams of radiation are directed at 
the tumour from different angles. For this procedure, the patient wears a rigid 
head frame. An MRI or CT scan creates pictures of the tumour's exact 
location. The doctor uses a computer to decide on the dose of radiation 
needed, as well as the sizes and angles of the radiation beams. The therapy 
may be given during a single visit or over several visits. 
 3-dimensional conformal radiation therapy—A computer creates a 3-
dimensional image of the tumour and nearby brain tissue. Multiple radiation 
beams aim to the exact shape of the tumour. The precise focus of the 
radiation beams protects normal brain tissue. 
 Proton beam radiation therapy—The source of radiation is protons rather 
than x-rays. The proton beams are aimed at the tumour. Protons can pass 
through healthy tissue without damaging it. 
 
CHEMOTHERAPY 
Chemotherapy is a well-known treatment and it uses chemotherapeutic substances 
to either inhibit the division of tumour cells or kill timorous cells. They are given 
to the patient intravenously or taken orally over an extended period of time. Many 
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chemotherapeutic drugs are less suitable for the treatment of brain tumours as they 
often cannot pass the blood-brain barrier [26].  
 
HYPERTHERMIA 
Hyperthermia therapy is a type of treatment in which body tissue is exposed to 
high temperatures (up to 106ºF), to damage and kill cancer cells, or to make 
cancer cells more sensitive to the effects of radiation and certain anticancer drugs. 
Local hyperthermia treatment is when heat is applied to a very small area (such as 
a tumour). This is a well-established cancer treatment method that when 
temperature rise to 106ºF and last for one hour within a cancer tumour then the 
cancer cells will be destroyed. 
 
Hyperthermia therapy is usually used with other forms of therapy (radiation 
therapy, chemotherapy, and biological therapy) to increase their effectiveness. 
With hyperthermia therapy the area may be heated externally with high-frequency 
waves aimed at a tumour from a device outside the body. To achieve internal 
heating, one of several types of sterile probes may be used, including thin, heated 
wires or hollow tubes filled with warm water; implanted microwave antennae; and 
radiofrequency electrodes. 
 
High intensity focus ultrasound can be used to produce heat within the tumour. 
Ultrasound is more easily focused than other energy modalities, and can be 
applied to tumours located from the skin to 10 cm within your body. This allows 
the treatment of tumours unreachable by other external modalities [26].  
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2.4 THROMBOLYSIS FOR ACUTE ISCHAEMIC STROKE; 
CHARACTERIZATION AND TREATMENT 
2.4.1 Acute Ischaemic Stroke 
Acute Ischaemic Stroke is considered to be the third most common cause of death 
in the United States, Europe, and in many other countries from the rest of the 
world.  A large number of new cases are reported every year, and approximately 
20% out of these new cases died [8]. Table 2.11 shows statistically the percentage 
of stroke incidence worldwide and the rate of survival [9]. 
Table 2.11 Stroke statistics 
Consequences of Stroke  
 Worldwide, stroke is the second leading cause of death, responsible for 4.4 million (9 
percent) of the total 50.5 million deaths each year. 
 Stroke is the No. 3 cause of death in the U.S., behind heart disease (with which it is 
closely linked) and cancer. 
 Stroke affects more than 700,000 individuals annually in the United States 
(approximately one person every 45 seconds). About 500,000 of these are first attacks, 
and 200,000 are recurrent attacks. 
 Someone in the U.S. dies every 3.3 minutes from stroke 
 Stroke is the leading cause of disability among adults in the U.S. 
 More than 4 million people in the United States have survived a stroke or brain attack and 
are living with the after-effects. 
 Four out of five families will be somehow affected by stroke over the course of a lifetime.  
Survival rates  
 10 percent of stroke victims recover almost completely. 
 25 percent of stroke victims recover with minor impairments. 
 40 percent of stroke victims experience moderate to severe impairments requiring special 
care. 
 10 percent of stroke victims require care in a nursing home or other long-term care 
facility. 
 15 percent die shortly after the stroke. 
 7.6 percent of ischaemic strokes and 37.5 percent of hemorrhagic strokes result in death 
within 30 days. 
 While subarachnoid hemorrhage (SAH) represents only about 7 percent of all strokes, it 
is the most deadly 
 With more than a 50 percent fatality rate. Of the survivors, approximately half will suffer 
permanent disability. 
 22 percent of men and 25 percent of women die within a year of their first stroke. 
 14 percent of people who have a stroke or TIA will have another within a year. 
 About 25 percent of stroke victims will have another within five years.  
 
Stroke is the leading cause of serious, long-term disability in the United States. 
Each year, about 795,000 people suffer a stroke. About 600,000 of these are first 
attacks, and 185,000 are recurrent attacks. Among adults age 20 and older, the 
prevalence of stroke in 2005 was 6,500,000 (about 2,600,000 males and 3,900,000 
females). On average, every 40 seconds someone in the United States has a stroke 
[27]. Each year, about 55,000 more women than men have a stroke. Men’s stroke 
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incidence rates are greater than women’s at younger ages but not at older ages. 
The male/female incidence ratio is 1.25 at ages 55–64; 1.50 for ages 65–74; 1.07 
at 75–84 and 0.76 at 85 and older [27]. Stroke accounted for about one of every 
17 deaths in the United States in 2005. Stroke mortality for 2005 was 143,579 
(56,586 males, 86,993 females). From 1995–2005, the stroke death rate fell 29.7 
percent and the actual number of stroke deaths declined 13.5 percent. For the rest 
of the world, according to the World Health Organization, 15 million people 
suffer stroke worldwide each year. Of these, 5 million die and another 5 million 
are permanently disabled. Europe averages approximately 650,000 stroke deaths 
each year [27]. 
 
Stroke is caused when the blood flow to the brain is interrupted (an ischaemic 
stroke) causing  brain cells in the affected area to die, or when there is rupture of 
blood vessels in the brain (a hemorrhagic stroke), which in turn causes moderate 
to severe damage to the brain. The majority of strokes are ischaemic due to the 
occlusion of arteries that deliver essential nutrients and oxygen to the brain. 
Seventy seven percent of strokes are ischaemic and twenty-three percent are 
hemorrhagic (17% intracerebral and 6% subarachnoid hemorrhage) [28][29]. 
 
So far, the only pharmacologic treatments proven effective following ischaemic 
stroke are administration of aspirin and acute thrombolysis using tissue-
Plasminogen Activator ( t-PA). Since the study of intravenous (i.v.) rt-PA in acute 
ischaemic stroke in 1995 by the National Institute of Neurological Disorders and 
Stroke [31], many clinical trials have tried to define the ideal patient population 
for this therapeutic strategy and to extend the therapeutic time window through a 
more detailed understanding of the pathophysiology of ischaemic stroke.  
 
2.4.2 Thrombolysis 
Many studies since the late 1950s have used pharmacologic thrombolysis in the 
treatment of patients following acute ischaemic stroke [30]. However, these 
studies showed that the potential benefits of re-establishing circulation to an 
ischaemic area must be weighed against an increased risk of hemorrhagic 
complications [32]. Orso et al [30] in 1995, in a Phase III trial, successfully 
identified a population of stroke patients who significantly benefited from 
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thrombolysis. At that time, interest in thrombolysis was at its peak following the 
earlier success of thrombolytic strategies in the treatment of acute myocardial 
infarction [33]. This had enthused similar investigations of thrombolysis in the 
setting of ischaemic stroke such as Streptokinase and rt-PA. 
 
Streptokinase: The first of the tested thrombolytic compounds, streptokinase, is a 
direct plasminogen activator produced by β-hemolytic streptococcus. 
Streptokinase was investigated in three large multi-center trials of acute stroke: 
the Multicentre Acute Stroke Trial – Italy (MAST-I) [34], Multicenter Acute 
Stroke Trial – Europe (MAST-E) [35] and the Australian Streptokinase Trial [36]. 
The experimental designs of these trials varied significantly; nevertheless, all 
three attempted to select their patients to minimize hemorrhagic sequel and 
maximize the possibility of clinical benefit. As a result an increase rate of 
mortality caused by symptomatic intracranial haemorrhage made the two of the 
three trials (MAST-E and MAST-I) to prematurely terminated and further 
investigation of streptokinase in the treatment of ischaemic stroke ceased. 
 
rt-PA: Clinical trials of rt-PA showed success, beginning with the National 
Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study, a 
randomized, placebo-controlled trial in which patients were randomized to receive 
intravenous i.v. rt-PA (0.9 mg/kg) or placebo in < 3 h of symptom onset. This 
study clearly excluded patients with a certain level of hypertension, low levels of 
platelets, hypoglycaemia, or recent history of certain haemorrhages or invasive 
procedures. There was an increase in symptomatic intracranial haemorrhages 
(ICH) in the patients receiving rt-PA but this did not lead to a statistical difference 
in 90-day mortality. The Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST) by Wahlgren et al [37] have shown that this 
course of therapy is safe and effective even in centres with little previous 
experience with thrombolytic stroke therapy. 
 
Much of the more recent work has focused on broadening the patient population 
that can safely receive rt-PA thrombolysis. Despite these efforts, treatment of 
patients is still limited, particularly by advanced age (greater than 80 years). Thus, 
research has involved expanding the therapeutic time window in which patients 
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can receive the drug as well as the setting in which the patient can receive 
treatment. Thus, while it seems safe and effective to administer rt-PA in any 
setting in which pre-treatment radiological evaluation can be made, it seems that 
the maximal benefit for patients with acute ischaemic stroke derives from 
treatment in a specialized stroke unit. 
 
Several clinical trials have examined the use of rt-PA beyond the 3-h treatment 
window. The European Cooperative Aneurysm Acute Stroke Study (ECASS) [38] 
examined administration of 1.1 mg/kg of rt-PA in 6 h of onset of stroke in a 
randomized, double-blind, placebo-controlled trial. The treated patients exhibited 
improved 90 day neurological recovery, no difference in mortality or ICH, but 
larger ICH. However, ECASS-II, a larger placebo-controlled trial that followed by 
Hacke et al [39], did not achieve the same positive results. In that study, i.v. rt-PA 
(0.9 mg/kg) was administered in the 6 h post-ictus period to patients with no or 
minor early signs of infarction on initial CT scan and < 33% swelling in the 
middle cerebral artery (MCA) territory. There was a significantly greater 
incidence of large ICH in the rt-PA group. 
 
ATLANTIS, the Alteplase ThromboLysis for Acute Non-interventional Therapy 
in Stroke randomized, double-blinded study, examined patients who were treated 
with i.v. rt-PA (0.9 mg/kg) in a 3 – 5 h window [40]. This study revealed no 
significant difference in 90 day recovery between groups, but again showed 
significantly more ICH, symptomatic ICH and fatal ICH in the rt-PA cohort. 
However, pooled analysis of the NINDS stroke study, ECASS, ECASS II, 
ATLANTIS and the Part A of ATLANTIS revealed that treatment of acute stroke 
even between 3 and 4.5 h imparts a significantly favourable 90-day outcome and 
improved mortality [41]. ECASS III then sought to clarify this point through a 
randomized, placebo-controlled trial by enrolling patients treated with i.v. rt-PA 
between 3 and 4.5 h after the onset of stroke symptoms [42]. This trial revealed 
improved outcome at 90 days, however, also a higher rate of ICH without a 
difference in mortality in the rt-PA cohort. Thus, in an appropriately selected 
patient population, the window of treatment of acute stroke with i.v. rt-PA may 
now be extended to 4.5 h post-ictus. This important finding has subsequently led 
to the change in treatment protocols in many parts of Europe and North America. 
38 
 
There remains the possibility that administering rt-PA up to 6 h after onset of 
stroke is beneficial. The Third International Stroke Trial (IST III), a large, open-
label study, is currently enrolling patients receiving i.v. rt-PA up to 6 h after 
stroke beginning to determine if there is, in fact, a small benefit of treating 
patients with this extended window and to identify factors that may be associated 
with a better outcome in this group [43]. 
 
2.4.3 Sonothrombolysis  
The feasibility of ultrasound to enhance thrombolysis was reported in the mid 70s 
by Trubestein et al [44] and Tachibana et al [45]. Clinical application of this new 
therapeutic ultrasound method for producing thrombosis has already started since 
2001. Clinical trials in Europe and in the USA have been reported using miniature 
ultrasound transducers at the tip of catheters that approach the clots via arterial 
vessels (MicroLysUS infusion catheter, EKOS Corp, USA). Mahon [46] 
presented early experience with the MicroLysUS infusion catheter for acute 
embolic stroke treatment in North America. This study was designed to 
demonstrate the safety of the device and to determine if ultrasound accelerates 
thrombolysis and improves clinical outcomes. The EKOS catheter for leg 
peripheral arterial thrombolysis was approved by the FDA in 2004 and was 
probably the first drug/ultrasound combination product to be marketed in the 
cardiovascular field.  
 
Alexandrov et al. [48] reported findings from a large phase II clinical trial entitled 
“Combined Lysis of Thrombus in Brain Ischemia using Transcranial Ultrasound 
and Systemic tPA” (CLOTBUST). In this trial involving 126 patients, evidence 
was obtained for the existence of ultrasound-enhanced thrombolysis in the middle 
cerebral artery thrombus. The CLOTBUST aims were: (1) To compare 
recanalization and recovery in patients with standard IV tPA therapy and those 
receiving additional continuous targeted ultrasound monitoring. (2) Compare 
safety in the two groups. This large clinical trial concluded that continuous 
transcranial Doppler augmented t-PA-induced arterial recanalization, with a non 
significant trend toward an increased rate of recovery from stroke, as compared 
with placebo. More evaluation is needed to see if diagnostic level ultrasound 
intensity can truly penetrate the skull and accelerate thrombolysis.  
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Kimura et al [49] and Akiyama et al [50] have shown that therapeutic low-
frequency ultrasound in experimental models, using lower frequencies (20 kHz to 
1 MHz), tPA-mediated clot degradation was more efficient when ultrasound was 
added. Consequently, it has been postulated by Behrens et al [52] and 
Daffertshofer et al [51] [53][54] that the use of therapeutic low frequency 
ultrasound, in combination with rt-PA might be a efficient and safe for the 
treatment of acute stroke. This hypothesis was tested in the transcranial low-
frequency ultrasound-mediated thrombolysis in brain ischemia (TRUMBI) trial, a 
single-centre randomized-controlled trial by Daffertshofer et al [55]. The 
investigators used low-frequency ultrasound (300 kHz in order to avoid standing 
waves) with a Spatial Peak Temporal Average (SPTA) intensity of 700 mW/cm2. 
Ultrasound was applied simultaneously with intravenous administration of tPA.  
 
Currently, a phase I–II randomized placebo-controlled, international multi-centre 
study (TUCSON trial) using perfultren-lipid microspheres (MRX 801, Imarx 
Therapeutics, Inc., Tuscon, AZ) is underway [56]. A total of 72 patients with 
acute intracranial arterial occlusion will be randomized to microspheres- 
potentiated ultrasound-enhanced thrombolysis (4 groups with increasing doses of 
perfultren-lipid microspheres) versus tPA alone. 
 
Ishibashi et al. [47] have accepted the challenge of sonicating transcranially to 
accelerate thrombolysis. A noninvasive method was tested in an occlusion model 
of rabbit femoral artery, produced with thrombin after constriction of the artery 
led to stenotic flow and endothelial damage. After stable occlusion was 
confirmed, monteplase (t-PA) was administered intravenously, and ultrasound 
(490 kHz, 0.13W/cm2) was applied (TUS group). The recanalization ratio in the 
TUS group was higher than that in the t-PA group. 
 
Shaw et. al [167] has shown that using 120 KHz unfocused ultrasound exposure in 
an in vitro environment that the lytic efficancy of the of rt-PA is increased. The 
ultrasound-enhanced thrombolysis (UET) group was greater than that of rt-PA 
40 
 
group at all rt-PA concentrations with the maximum results over the concentration 
values of 1-3 μg/mL. 
 
Eggers et. al. [166] conducted experiments in vitro using 1.8-MHz PW US. Blood 
clots from 0.5-mL venous blood samples were insonated for 1 h. The experiments 
were performed with or without recombinant tissue-type plasminogen activator 
(rt-PA) at a concentration of 10 μg/mL. Thrombolysis was measured by means of 
clot weight loss after 1 h of insonation. A higher reduction in thrombus occurred 
when both US and rt-PA were combined together were thrombus reduction reach 
almost 79%. Eggers et. al. [57] has also demonstrated in an in vivo experiments 
using the same parameters as described above (frequency of 1.8 MHz, diagnostic 
US) and with rt-PA concentration of 0.9 mg/kg. Recanalization of almost 60% 
occurred when US and rt-PA were combined. When only rt-PA was used, 
recanalization was only at 22.2%. 
 
To improve the efficacy of this thrombolytic therapy, Holland et. al. [173] have 
used the effect of rt-PA and 120 kHz or 1.0 MHz ultrasound in an in vitro porcine 
clot model. They have shown that for rt-PA alone, the mass loss increased slowly 
as a function of rt-PA concentration up to approximately 0.050 mg/ml. With 
ultrasound and rt-PA exposure, clot mass loss increased by as much as 104% over 
rt-PA alone. Ultrasound without the presence of rt-PA did not significantly 
enhance thrombolysis.  
 
Daffertshofe et. al. [54] has shown that Ultrasound bio-effects can facilitate rt- PA 
mediated thrombolysis in peripheral arteries. They have used an embolic stroke 
model in the rat. In all rats, they have induced an ischaemic stroke by a selective 
occlusion of the middle cerebral artery with whole blood clots. Four different 
groups have been investigated. First group took no treatment, second group took 
full dose of rt-PA, third group took half dose of rt-PA and US, and the last group 
took full dose of rt-PA and US. Only the fourth group had significant reduction 
infarct volume and safe with regard to bleeding.  
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CHAPTER 3:  OVERVIEW OF HIFU 
 
3.1 INTRODUCTION 
The use of therapeutic ultrasound in medicine has a very promising prospect.  At 
present medical devices are being developed that use high intensity focus 
ultrasound to treat tumours and to stop bleeding [58],[59][60]].  The ability of 
therapeutic ultrasound to penetrate deep into the body and deliver a beam of 
thermal or mechanical energy to a specific part of the body with sub millimeter 
accuracy eliminates the need of invasive surgery.  However, realizing the full 
potential of acoustic therapy requires precise targeting and monitoring.  
Fortunately, several imaging devices can be used for this purpose thus leading to 
the concept of image-guided acoustic therapy. 
 
The field of medicine is undergoing a remarkable change towards minimally 
invasive and noninvasive therapy.  Compared with open surgeries, these 
minimally invasive approaches offer the advantages of reducingsurgery time, 
tissue damage associated with surgery, andtransfusion requirements and their 
associated infection risks. 
 
The result is a shorter recovery time and hospital stay, a reduction in cost of health 
care, and a generally superior therapeutic outcome.  However, not all brain 
tumours can be treated with this technology. Brain tumours located closed to 
sensitive nerves, or they have unbalanced shape are very difficult or impossible to 
treat. Many researchers and industries such as Jolesz et al [5], Kinoshita et al [61] 
and Hynynen et al [62] are engaged in the research and development of 
noninvasive, image-guided therapy systems. 
 
Such systems will increase the trend toward noninvasive surgery by enabling 
therapy to be delivered from outside of the body.  It is envisioned that devices that 
can stop the internal bleeding of a trauma victim using a HIFU beam will be used 
without surgery. HIFU can generate a lot of heat quickly causing biological 
tissues where the ultrasound is focused to shrink and fuse together, stopping 
bleeding. Noninvasive, bloodless surgery is close to realization.  Versions of this 
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technology are already in clinical application for the treatment of both malignant 
and benign tumours and a variety of other efforts are in various stages of scientific 
and clinical development [63]. Table 3.1 list several HIFU clinical systems that 
are used today for different clinical applications. 
 
Table 3.1 HIFU Systems for Clinical Use 
HIFU System Frequency 
(MHz) 
Focal Length 
(mm) / Focusing 
Method 
Clinical 
Applications 
No. of Patients 
Treated 
Sonablate 500 
(Focus Surgery 
Inc. USA) 
4 34, 40 
2 elements, back to 
back 
Prostate Cancer 241 
Ablatherm 
(Edap-
Technomed, 
France) 
3 45 
Single Concave 
Element 
Prostate Cancer 1414 
ExAblate 2000 
(InSightec Ltd, 
Israel) 
0.9, 1.3 150 
Phased Array 
Breast Tunour, 
Liver Cancer, Bone 
Metastic, Prostate 
Cancer 
290 
Model-JC 
(Chongquing 
Inc. China) 
0.8, 1.6, 3.2 90, 130, 160 
Flat Ceramic 
Liver, Kidney, 
Breast, Pancreatic, 
and Uterine Fibroid 
192 
FEP-BY02 
(Beijing 
Yuande Inc. 
China) 
1 255 
Phased Array 
Liver, Kidney, 
Breast, Pancreatic, 
and Uterine Fibroid 
251 
 
3.2 HISTORY OF HIFU 
The era of modern ultrasonic began in the early 20th century.  Table 3.2 shows the 
development of high intensity focused ultrasound technology throughout the 
century. 
 
The first time that high intensity focus ultrasound (HIFU) was used to cause tissue 
destruction was reported by Lyyn in 1942 [76].  However, the Fry brother’s [2] in 
1950 found that the lesion induced with HIFU was well bounded without any 
damage to the overlying and surrounding tissues.  In addition, William Fry and his 
team [3][77], have used HIFU to successfully produced lesions in the brain of 
animals such as cats and monkeys. Consequently, Fry [2] developed techniques to 
treat patients with Parkinson's disease and other neurological conditions after 
removing a piece of skull for creating an "acoustic window". 
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Table 3.2 The development of HIFU technology throughout the century 
Date Event 
1880 Piezoelectric effect, Jacques and Pierre [64] 
1907 Electronic vacuum tube, Lee De Forest [65] 
1918 Sonar (Langevin), Paul Langevin [66] 
1927  Effects on biological tissues, Ronald et al [67] 
1942 HIFU effects, Lynn et al [1]  
1950 – 1969 Molecular studies on HIFU effects, Fry and Fry et al [2][3][68]  
1951 – 1960 Radiofrequency generator and electrode development, Cosman 
[69] 
1951 – 1967 Radiosurgery and gamma knife development, Leksell [70] 
1960 – 1980 Clinical studies on HIFU surgery with open cranium, Fry et al 
[71][72], Heimburger [73] 
1980 – present MRI technology 
Early 1990s Ultrasound phased arrays, Hynynen et al [62] 
Mid – 1990s MRI thermometry, Jolesz et al [74] 
2001 First integrated MRgFUS machine, Insightec [75] 
2006 Report on MRgFUS for treatment of glioblastoma multiforme 
(GBM) after craniotomy, Ram et al [58] 
Present Trial on MRgFUS with cranium intact, Jolesz et al [4][5]  
 
Fred Lizzi's group [79][80], in the 1970s, spent significant time and effort into the 
use of HIFU in the field of ophthalmology.  They investigated the possibility of 
using HIFU to treat glaucoma, choroidal melanomas and capsular tears, and 
clinical results looked very exciting [78].  The introduction of medical lasers used 
in ophthalmology, which occurred at the same time and because of its ease of use, 
outdated HIFU in most ophthalmological applications.  
 
The developments of medical imaging modalities, such as computed tomography 
(CT), B-mode ultrasonography, and magnetic resonance imaging (MRI), have led 
to recent advances in HIFU technology in the past two decades, see table 3.1. 
Based on their experience with extracorporeal shock-wave lithotripsy, which was 
used for destroying calculi of the kidney, uterine and bladder by physical forces in 
clinical practice, Guy Vallancien and his colleagues constructed an extracorporeal 
focused ultrasound device with Dr Dory's help in the 1990s. His team used this 
pyrotherapy device to treat superficial bladder tumours under ultrasound imaging 
guidance. The disappearance of the tumour in two cases and coagulation necrosis 
in the remaining patients were noted by Vallancien et. al. 1993 [81], and 1996 
[82]. 
44 
 
Gail Ter Haar and her colleagues [83] developed a HIFU prototype in the 1990s. 
This device employed a spherical ceramic transducer of 10 cm diameter and 15 
cm focal length. It was driven at a frequency of 1.7 MHz and operated at free field 
spatial intensities between 1000W.cm
-2
 and 4660W.cm
-2
 [83]. In phase I trials, the 
results that Visioli [84] demonstrated using HIFU treatment of liver cancer were 
well tolerated.  
 
An initiation of HIFU research began in 1988 at the Chinese Institute of 
Ultrasonic Engineering in Medicine and the Clinical Centre for Tumour Therapy 
of Chongqing Medical University in Chongqing,. Laboratory and animal studies 
were carried out from 1988 to 1997. After finishing studies in animals, they 
designed and constructed an extracorporeal HIFU prototype for clinical trials. 
Until October 2001, a total of 1038 patients with solid tumours received 
extracorporeal HIFU (Model-JC HIFU system, Chongqing HAIFU, China) in 10 
Chinese hospitals [85]. From November 2001 to March 2004, approximately 2500 
patients underwent HIFU treatment in 20 Chinese hospitals. The same device 
(Model-JC HIFU system, Chongqing HAIFU, China) has been introduced into the 
UK by Kennedy and Roberts, and Kennedy and Phillips, 2004 [87][88] and in 
Japan by Okuno [89]. 
 
Ultrasound imaging was used in all the HIFU devices mentioned above to guide 
and monitor therapeutic procedure. However, Kullervo Hynynen's group [90] at 
the Brigham and Women's Hospital in Boston, USA incorporated HIFU into an 
MRI system, and constructed an MRI-guided HIFU device in 1993. With MRI 
thermometry techniques, the device can record focal temperature rises on the 
anatomical images during treatment procedure. This MRI-guided HIFU has been 
used clinically to ablate breast neoplasm and uterine fibroids, and the results 
shown by Hynynen et al [91] and Tempany et al [92], indicate successful ablation 
of targeted tumours. 
 
Besides extracorporeal HIFU treatment, the technique was also used to treat 
patients with prostate cancer using a transrectal HIFU device. Two commercially 
available devices are reported to treat prostate cancer in clinical practice. One 
transrectal device (Sonablate, Focused Surgery, USA) uses a 4 MHz PZT 
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transducer for both imaging and treatment [93], and another (Ablatherm, EDAP, 
France) uses a 2.25-3.0 MHz rectangular transducer for treatment and a retractable 
7.5 MHz probe for imaging guidance [94]. These devices have been widely used 
in the treatment of patients with prostate cancer, and clinical results are enthralling 
[95]. 
 
3.3 PHYSICAL PRINCIPLES OF HIFU 
Human tissue at a specific depth can be reformed with the use of a High Intensity 
Focus Ultrasound beam.  Various mechanisms which can be produced by HIFU 
have an effect on tissue, such as heating, cavitation and mechanical forces. 
  
Heat is created by absorption of the ultrasonic energy going through the human 
tissue.  The ultrasonic energy is continuously absorbed and produces a 
temperature elevation within the medium.  The temperature elevation is dependent 
on the intensity of the ultrasonic energy and the acoustic absorption coefficient of 
the tissue.  Using HIFU, the intensity at the focus is much higher than outside the 
focus.  If the temperature elevation is large enough and is maintained for a period 
of time (seconds), the exposure will result in tissue damage [96].  When ultrasonic 
energy passes through a viscous medium, such as human soft tissue, the intensity 
of the beam is attenuated. This attenuation depends on both the energy that is 
absorbed by the medium and the energy that is scattered from interfaces or 
inhomogeneities within the tissue. Because most of the attenuation is related to 
tissue absorption, it can be assumed that almost all of the energy from the primary 
ultrasound beam results in tissue heating [97].  
 
At high intensity levels, the biological effects are sometimes associated with the 
formation of small gas bubbles or the oscillation of those small bubbles already 
present.  This type of interaction is called cavitation, and it can cause complete 
destruction of the tissue located next to the gas bubble.  Cavitation occurs when 
the negative component of the acoustic wave causes liquid components to fail 
under tension, resulting in the formation of gas or bubbles. These bubbles will 
oscillate at large displacement amplitudes if the acoustic field is continued. The 
mechanically driven bubbles cause damage to their surroundings, particularly if 
they oscillate near tissue interfaces. Cell death may occur owing to acoustic 
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cavitation if the oscillating bubble disrupts the cell membrane. Cavitation damage 
tends to be more random than thermally mediated cell death because cavitation 
requires the existence of a nucleation site. 
 
When a bubble is sonicated at its resonance frequency it may intercept and 
eradiate energy, thereby absorbing much more acoustic power than would pass 
through normal tissue of its geometrical cross-section.  This type of bubble 
oscillation is called stable cavitation and can cause microstreaming of the fluids 
around the bubble.  When stable cavitation occurs, it can significantly increase the 
power attenuation and thus cause unexpected temperature elevations in tissue 
layers through which the tumour is sonicated.  Cavitation in tissues depends 
largely on ultrasound intensity and the frequency used by the device. The higher 
the frequency, the higher the intensity required to initiate cavitation. For example, 
cavitation thresholds have been measured to be 1000 W/cm
2
 for 1-MHz 
frequencies and 2800 W/cm
2
 for 3-MHz frequencies in dog thigh muscle, shown 
by Hynynen K [98]. Thus, by operating at a higher frequency cavitation may be 
avoided.  
 
Stable oscillations of bubbles induce fluid velocities and exert shear forces on the 
surrounding tissues. Collapse cavitation bubbles generate shock waves with 
amplitudes exceeding 10,000 atmospheres depending on the bubble size. 
Although cavitation induce shock waves persist for a very short period of time, 
the large spatio-temporal pressure gradients associated with shock waves can 
disrupt tissues. During the collapse, the temperature of the bubble core can 
increase by more than 1,000 K and induce chemical changes in the medium. 
Acoustic cavitation has the main role in sonophoresis, particularly under low-
frequency conditions. Experimental and theoretical studies have led to a 
mechanistic picture, which suggests that the shock waves generated after the 
collapse of cavitation bubbles microscopically disrupts the topmost layer of the 
skin, the stratum corneum, and thereby enhances skin permeability. The skin 
eventually recovers, possibly through natural barrier-recovery mechanisms [99]. 
 
Miller and Song [100] have shown that Pulsed-HIFU exposures, using low duty 
cycles (i.e. the relative time ‘ON’ during each pulse, or duty factor can be 10%), 
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generate energy deposition rates low enough that temperature elevations are well 
below the threshold for thermal damage in the tissues. The effects of pulsed-HIFU 
are more mechanical in nature, such as the creation of acoustic radiation forces. 
These forces, shown by Nightingale et al [101] and Lizzi et al [102], if high 
enough, can produce local displacements on the order of cellular dimensions. It 
has been suggested that repetitive displacements are capable of inducing structural 
alterations in the tissue, through the creation of locally induced strain. The strain 
results from shear forces produced between adjacent regions of tissue 
experiencing non-uniform displacement, and the alterations (i.e. widening of 
intercellular spaces between both endothelial and parenchymal cells) may increase 
the tissue's permeability [103]. 
 
3.4 APPLICATIONS OF HIFU IN MEDICINE 
The main goal of HIFU surgery is to destroy pathological tissue without affecting 
the surrounding normal tissue.  Focused ultrasound promises multiple therapeutic 
functions in the field of neurological diseases through both ablative tissue 
disruption and nonablative effects (e.g., delivery of therapeutic agents to a 
targeted volume by temporary opening of the Blood-Brain Barrier (BBB), 
enhanced immune response, or reversible blocking of neuronal functions). 
 
Tissue Ablation; The success of the Fry brothers’ experiments as discussed in 
section 3.1, demonstrates that successful tissue targeting is possible using HIFU 
treatment [2]. Cohen et al. [104] using a HIFU system (ExAblate 2000, Insightec 
Inc., Tirat Carmel, Israel) on a swine model showed that the HIFU-induced 
thermal lesions were sharply demarcated from the surrounding brain with no 
anatomic or histological abnormalities outside the target.  A current study at the 
Brigham and Women’s Hospital in USA is examining the effectiveness of 
Magnetic Resonance Imaging-Guided High Intensity Focused Ultrasound 
(MRgHIFU) treatment for glioma patients without a craniotomy. Regions of the 
brain close to the cranium remain a limitation of MRgHIFU because of cranial 
heating. This limitation may be partially circumvented by inserting ultrasound 
contrast agents (preformed microbubbles) into the bloodstream. These agents have 
been known to enhance focal heating during sonication and may reduce the time-
averaged power needed during transcranial focused ultrasound ablation. 
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Targeted Drug Delivery; The BBB (Blood-Brain Barrier) is a persistent obstacle 
for the delivery of macromolecular therapeutic agents to the central nervous 
system, even though many drugs have proven their potential for treating central 
nervous system diseases. It has been recognized that ultrasound can disrupt the 
BBB; the prospect of creating a controlled reversible process introduces 
significant promise for delivering agents that cannot currently be delivered into 
the brain. Hynynen et al. [105] first described a controlled, reversible, and 
reproducible manner of opening the BBB; MRI can monitor the process. The 
study by Kinoshita et al [61] and Treat et al [106] have demonstrated the potential 
use of focused ultrasound to deliver chemotherapeutic agents, antibodies, growth 
factors, or genes to the desired area of brain.  
 
Clot Lysis; Ischaemic and hemorrhagic strokes are the third most common cause 
of death in the United States. Recent studies have demonstrated the potential of 
ultrasound and microbubbles in thrombolysis. The effect can be increased through 
the administration of microbubbles. Enhanced effects of thrombolytic agents such 
as urokinase and tissue plasminogen activator with acoustic energy have been 
demonstrated. Recent clinical studies have demonstrated improved thrombolysis 
with the concomitant use of focused ultrasound and a thrombolytic agent for 
ischaemic stroke. Ultrasound enhanced the binding of tissue plasminogen 
activator to fibrin and also increased the activity of tissue plasminogen activator 
through hyperthermia. Clot Lysis followed by stereotactic needle aspiration might 
also be feasible for hemorrhagic stroke in the future [107][108]. 
 
Coagulation; Focused ultrasound has been demonstrated by Zderic et al [59] to 
provide an effective method for haemorrhage control of blood vessels in acute 
animal studies. The changes in the adventitia and tunica media recovered to 
normal appearance within 28 days. These results show that focused ultrasound can 
produce effective haemostasis while preserving normal blood flow and vessel wall 
structure. Post treatment histological observations of the ultrasound-treated 
arteries showed disorganization of adventitia and coagulation and thinning of the 
tunica media. It remains to be shown whether a higher acoustic intensity can cause 
endothelial proliferation and, thus, be used for the treatment of vascular 
anomalies. 
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3.5 LIMITATIONS AND FUTURE PROSPECTS OF HIFU: 
In 1954, Lindstrom [109] studied the effects of HIFU mediated lesioning as an 
alternative to a lobotomy procedure and reported on the pathological effects of 
ultrasound on human brain tissue in 25 patients with carcinomatosis and cancer-
related pain. In this study, autopsies on 14 of the 15 patients who had died of 
cancer indicated a satisfactory lobotomy procedure, with minimal disruption to the 
brain outside of the targeted region.  Following Lindstrom, Leksell [70] designed 
a specially adapted frame and ultrasound transducer for the purpose of HIFU 
lesioning, and he used it successfully on patients for periventricular lesioning. The 
major limitations for Leksell, however, in treating human patients were the 
accuracy in targeting deep-seated structures and the need for a craniotomy, 
because ultrasound could not permit visualization through the intact cranium. 
These limitations were compounded by the lack of reliable imaging tools to plan 
HIFU treatments.   
 
During the 1950s and 1960s, although progress had been achieved in selecting the 
most desirable acoustic parameters for ultrasound, it was difficult to focus the 
ultrasound to a precise location, thus limiting the efficacy of the procedure.  Lele’s 
insights [110][111] offered promise, as he had conducted a number of 
experiments using implanted thermocouples and had established that ultrasound 
could cause tissue damage by a temperature elevation at the beam’s focus.  Other 
limitations of focused ultrasound existed as well. These included the lack of real-
time imaging during the procedure and the need for a craniectomy operation 
because of beam distortion caused by an intact cranium. When the cranium 
distorts the ultrasound field, it absorbs energy, resulting in heating of the cranium 
and attenuation of the ultrasound beam. Attempts to address this problem were 
investigated in the 1970s by Fry and Goss [71] and Fry et al. [72], as they began 
experimenting on the use of HIFU without a craniectomy.  
 
The craniectomy problem was solved in the 1990s with the development of 
phased arrays of ultrasound transducers, which permitted the focusing of the 
ultrasound beams, with the use of a hemispheric transducer design, by correcting 
the phase aberrations induced by the different pathways. The early designs 
required an implantable hydrophone to determine these aberrations, but 
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technology that is more modern uses a preoperative computed tomographic scan 
to measure the thickness of the cranium along the various acoustic pathways, 
Hynynen et al [62]. These measurements then permit individual transducers to 
emit a specific phase and amplitude to reduce phase aberration induced by the 
variable cranial thickness. The other major revolution in the development of 
modern HIFU surgery came with improvements in MRI. Because the concept of 
an “ideal surgery” requires that, only the targeted tumour tissue is removed or 
destroyed without associated injury to the adjacent normal tissue, imaging 
verification of the target is vital.  
 
The first, and most obvious, method used for guiding focused ultrasound 
treatment was diagnostic ultrasound. However, ultrasound had two limitations: 1) 
less resolution than computed tomography or MRI in accurately detecting the 
location of the lesions, and 2) its inability to detect real-time temperature changes 
and confirm thermally induced tissue changes (although modern ultrasound 
technology may permit this). MRI, with its excellent sensitivity for imaging soft 
tissue tumours, was found to be preferable over other imaging modalities for 
localizing 3-dimensional tumour margins and targeting tumour volumes. In 
addition, MRI is capable of measuring temperature changes inside the body with 
accuracy in the range of ±3C at 1.5-T field strengths, and with even greater 
accuracy at higher field strengths. Because of its excellent temperature sensitivity, 
the HIFU focal volume can be imaged and localized well before irreversible tissue 
damage is induced. Moreover, the ability of MRI to capture the temperature 
change enables the physician to delineate temperature maps and tumour volume 
during the procedure [5][62].  
 
Thus, the development of the modern HIFU surgical device combined three 
technological advances into a single unit: 1) thermal ablation with HIFU, 2) 
intraoperative guidance by MRI and temperature-sensitive MRI, and 3) the use of 
ultrasound phased arrays to correct for cranial distortion. Two commercially 
available MRI-guided HIFU surgery (MRgFUS) units are currently being 
marketed by Insightec (Haifa, Israel). Another model has been developed by 
Supersonic Imagine (Aix-en-Provence, France). 
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3.6 CONCLUSION 
In practice, cancer therapy usually needs to have multiple treatment methods for 
long-term survival benefit in addition to local therapy such as surgery. For 
instance, in the treatment of patients with breast cancer, surgery, chemotherapy, 
radiotherapy and endocrine therapy must be provided in tandem, because many 
clinical results indicate that the combination of these modalities can provide better 
survival benefit than one in isolation. HIFU is a local therapy for non-invasive 
destruction of the tumour, and it is imperative that it is combined it with other 
therapies in clinical applications. There are two goals of HIFU in the treatment of 
patients with solid malignancy. The first goal is the ablation of the tumour in 
patients with early-stage cancer in order to affect a cure [85]. In order to achieve 
this, HIFU can be used as a local treatment to induce complete necrosis of the 
targeted tumour. Additional treatments such as chemotherapy, radiotherapy and 
endocrine therapy are essential to patients with breast cancer for conservation of 
the diseased breast, if HIFU is used locally in patients with early-stage breast 
cancer. In surgical oncology, it is necessary to resect the entire tumour along with 
an adequate tumour-free margin, to prevent local recurrence. In the same way, 
HIFU treatment should adopt a similar principle and aim to kill the entire 
malignant focus along with tumour-free margin of healthy tissue.  The other goal 
of HIFU treatment is palliative for patients with advanced-stage cancer [86]. They 
are usually those who have an unresectable tumour and for whom conventional 
tumour therapies, including chemotherapy and radiotherapy, have failed to control 
tumour growth. HIFU can be clinically used to impede tumour growth and to 
improve the quality of life for such patients. Symptoms such as pain caused by 
tumour disappear after HIFU, and survival time can be extended. 
 
The following chapter describes the physical aspects of ultrasound. The basic 
principles of ultrasound such as basic quantities, power field calculations, 
temperature simulations, and thermal dose calculations will be discussed. 
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CHAPTER 4: PHYSICAL ASPECTS OF ULTRASOUND 
 
4.1 INTRODUCTION 
This chapter describes the physical aspects of ultrasound waves and how 
temperature and thermal dose is calculated.  Ultrasound is an essential tool for 
diagnostic and therapeutic cancer diseases such as brain tumours.  The following 
section will describe the principles of ultrasound such as basic quantities, power 
field calculations, temperature simulations, and thermal dose calculations. 
 
4.2 BASIC QUANTITIES IN ULTRASOUND. 
The displacement amplitude u of a particle in simple harmonic motion from its 
rest position is given by; 
                    (1)  
where u0  is the peak displacement, ω is the angular velocity, t is the time and φ is 
the phase. 
The particle displacement repeats itself with certain time interval - the so called 
period of motion (τ) where τ is the reciprocal of the frequency f 
   
 
 
         (2)  
The particle velocity v which is the rate of change of displacement is given by 
   
  
  
                  (3) 
Similarly the particle acceleration a is the rate of change of velocity and is given 
by 
   
  
  
     
                  (4) 
which means that the acceleration is proportional, but in opposite direction to the 
particle displacement. 
 
The wavelength λ is the minimum distance between points with the same particle 
displacement.  The wavelength is related with frequency by  
             (5) 
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where c is the propagation velocity within a medium.  The propagation velocity 
relates the second spatial derivative of particle displacement with the second time 
derivative of the displacement through the well known wave equation: 
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        (6) 
The solution of the above equation gives the particle displacement with respect to 
time and the distance x by: 
                 
 
 
      (7) 
The propagation velocity is given in terms of physical parameters by 
    
 
 
 
 
 
        (8) 
where K is the bulk modulus of medium and ρ is the density of the medium.  
Thus, the propagation velocity is strictly dependent on the medium.  Knowing the 
frequency and the propagation velocity of the medium the wavelength can be 
found.  The wavelength is a very important parameter because it determines the 
shape of the power field.  Air has the lowest propagation velocity because the bulk 
modulus is the lowest.  Aluminium which is an example of solid has the highest 
propagation velocity (higher bulk modulus).  Water has an intermediate value.  
Soft tissues have values similar to water, except for lung which has the lowest 
(due to air spaces) and bone which has the highest (highest bulk modulus).  Table 
4.1 gives some typical values of propagation velocities of biological tissues. 
 
The compressive force at distance x is given by Hooke's law  
       
  
  
       (9) 
where A is the cross-sectional area and  
  
  
  is the longitudinal strain. 
 
The pressure then is given by  
   
  
 
   
  
  
    
  
  
              
 
 
         (10) 
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Table 4.1 Propagation velocities of some biological tissues [112], [113] 
Tissue type Propagation velocity c (m/s) 
Bone 1500-3700 
Tendon 1750 
Kidney 1564-1640 
Liver 1540-1640 
Muscle 1508-1630 
Testis 1595 
Brain 1516-1575 
Skin 1498 
Fat 1400-1490 
Lung 470-658 
 
A very important quantity in ultrasound is the acoustic impedance.  The acoustic 
impedance is defined as the ratio of pressure and particle velocity.  
   
 
 
 
   
 
                    (11) 
Thus, the acoustic impedance depends on the medium.  The concept of impedance 
is better understood by considering analogous quantities from electricity.  The 
pressure is equivalent to the voltage, the particle velocity is analogous to the 
current and the acoustic impedance is analogous to the electrical impedance.  
Table 4.2 shows typical values of impedances in tissue.  Most soft tissues have 
value similar to the water except lung which has the lowest value (lowest 
propagation velocity) and bone which has the highest (highest propagation 
velocity). 
 
Acoustic impedance is very important because its value determines the amount of 
reflection in the interface of two medium of different acoustic properties.  Figure 
4.1 shows that the incident wave is reflected and partially transmitted at the 
interface.   
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Table 4.2: Acoustical impedances of soft tissues [112], [113] 
Tissue type Acoustic impedance Z (10
6
 kgm
-2
s
-1
) 
Bone 3.75-7.38 
Tendon - 
Kidney 1.62-1.71 
Liver 1.7-1.74 
Muscle 1.61-2.07 
Testis - 
Brain 1.56-1.62 
Skin 1.8 
Fat 1.29-1.37 
Lung 0.188-0.263 
 
 
 
Figure 4.1 Demonstration of wave reflection and transmission at a plane interface 
between two media. 
 
By using the fact that the pressure is continuous the following expression is 
derived relating the ratio of incident and reflected pressure with respect to the 
acoustic impedances. 
 
  
  
 
               
               
                (12) 
where the subscript r denotes reflection and the subscript i denotes incidence. 
 
 
 
56 
 
Now, considering normal incident (θi=θr=0
 o
) then the expression is simplified to 
 
  
  
 
     
     
                  (13) 
Let's consider two important cases 
a) Z1Z2 then  
  
  
    This means that the reflected pressure tends to zero.  
This happen when the wave goes from soft tissue to soft tissue. 
b) When Z2>>Z1 then  
  
  
    Therefore, all the pressure is reflected.  This is 
seen when ultrasound travels from soft tissue to bone interface. 
 
The total energy of a particle is the sum of the kinetic energy (K.E.) and the 
potential energy (P.E.).  At the rest position the particle has only K.E., therefore, 
the energy is given by  
   
 
 
   
                   (14) 
where    is the particle velocity amplitude at rest. 
The total energy is the sum of the energies of all the particles.  The energy per 
volume is given by 
   
 
 
   
                   (15) 
The intensity I is the power per unit area and is defined as the product of the wave 
propagation velocity and the total energy.  
      
    
 
 
 
      
 
   
 
  
  
               (16) 
 
Thus, the intensity depends on the square of pressure and it is inversely 
proportional to the impedance.  In a real medium the ultrasound is attenuated 
according to an exponential law.  For the plane wave case the intensity as a 
function of depth in tissue is given by; 
                                (17) 
where I(x) is the intensity at depth x, I(0) is the intensity at the tissue interface, μ 
is the attenuation coefficient per unit length, and x is the depth. 
 
Now, for a continuous, single frequency, plane ultrasound wave, and neglecting 
the shear viscosity the temporal average absorbed power density <q> is given by 
57 
 
                         (18)   
where a is the absorption coefficient (Np/m/MHz).  The above relationship is 
valid also at the focal point of a focused transducer.  The absorbed power intensity 
is very important quantity because it is the primary factor determining the 
temperature elevation in tissue.   
 
Two terms that are often confused is attenuation and absorption.  Attenuation is 
due to absorption (energy loss due to heat conversion), scattering and reflection.  
Therefore, absorption is a subcategory of attenuation.  There are two theories to 
explain absorption.  The first one is the classical, which is based on viscosity.  
Due to shear forces in the medium there is lag between the pressure amplitude and 
the particle velocity which results to energy loss for every cycle.  However, this 
theory predicts quadratic relationship of the absorption coefficient with frequency 
which was not seen in tissues (at low frequencies).  The alternative theory of 
relaxation was proposed which explains the linear dependence of absorption 
coefficient with frequency.  During the compressive part of the cycle the 
acoustical energy is converted to kinetic energy (carried by the molecules).  This 
energy is redistributed in the system in the form of lattice vibrational energy, 
transnational energy, and molecular vibrational energy.  If there was no coupling, 
between these types of energy all the energy would have been sent back during 
the expansion cycle and the absorption would be zero.  However, due to coupling 
between the energy compartments there is a finite time associated with the 
redistribution of energy.  Thus, the returned energy is in phase with the 
transmitted energy and this will result to absorption.  Table 4.3 shows values of 
attenuation and absorption for some biological tissues.  The absorption values are 
smaller than the attenuation values.  
 
4.3 POWER FIELD CALCULATIONS 
The numerical calculation of the power field is based on the solution of the 
Rayleigh-Sommerfield diffraction integral [114], which relates the velocity 
potential Ψ with the normal velocity, by the following equation: 
    
  
   
                        (19) 
 
A 
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where k is the wave number (2π/λ),  u is the normal velocity and s is the  distance 
from a source point in the surface element ds on the transducer to a field point 
where Ψ is to be evaluated. 
The assumptions governing the solution of the above integral are: 
a) The amplitude is assumed small so that non-linear effects do not play any role 
b) The surface S should be slightly curved so that secondary diffraction due to 
the radiation of waves of the various transducer elements is neglected. 
 
Table 4.3 Attenuation and absorption values for biological tissue [112], [113] 
Tissue type Attenuation μ (Np/m/MHz) Absorption α (Np/m/MHz) 
Brain 4-29 1.2-6.4 
Kidney 3-10 3.3 
Liver 3.2-18 2.3-3.2 
Lung 4.3-480 7 
Muscle 4.4-15 2-11 
Bone 150-350 - 
 
The normal velocity is represented by  
      
                     (20) 
where ω is the angular velocity and U0 is a constant. 
 
The acoustic pressure is represented by 
    
  
  
                        (21) 
where ρ is the density of the medium and c is the propagation velocity.   
 
Figure 4.2 shows the geometrical arrangement of the transducer illustrating the 
various distances. z is the distance in the axial direction from the origin to the filed 
point Q, r is the distance from the central axis to point Q in the radial direction, R 
is the radius of curvature, d is the diameter of the transducer, h is the depth of the 
concave surface, α is the angle between the line connecting the focus and the 
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transducer boundary and the line of the central axis.  These, quantities are related 
by the following expressions: 
 
 
 
                        (22) 
                           (23) 
                         (24) 
The emmitance e (W/cm
2
) of the transducer is given by  
   
 
 
                   (25) 
where P is the acoustic power. 
 
 
 
 
 
Figure 4.2 Geometry of spherically focused transducer. 
 
SIMPLIFIED MODEL TO ESTIMATE POWER 
In this project in order to simplify calculations, only those elements of area on the 
transducer over which s is constant are considered.  This reduces the integral to a 
one-dimensional integral [115].  Another simplification used is associated with the 
effective attenuation distance s'.  In a weakly attenuating medium, the effect of 
attenuation is approximated using eq. (17).  In this model s' is assumed as the 
distance from the water-tissue interface to the point of interest.  (This is true for a 
planar transducer, good approximation for high F-number transducers and weaker 
approximation for low F-number transducers).  Because of the above 
simplifications the integral is reduced to 
 )
S
A
e(e
2
u
=(s)
m
msik-s- m 
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                (26) 
Transducer 
diameter 
R 
α 
h 
Axial direction (z) 
Radial direction (r) 
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where Am is the area of the m
th
 annular strip and M is the number of strips in 
which the transducer is divided into. 
 
A program was written in MatLab to calculate the power field. The program 
requires information such as the frequency, radius of curvature, diameter of the 
transducer, acoustic power, attenuation coefficient, distance of transducer from 
the skin (controls depth of focus in the tissue).  The dimensions of the field size 
can also be inputted by the user as well as the spatial step.  Numerical calculations 
of the temperature requires equal spatial step in the radial and axial direction. 
 
PARALLEL FLAT PLANE INTERFACE MODEL 
It was stated in section 4.2 that when sound waves cross the interface between two 
mediums of different acoustical properties, refraction and reflection takes place.  
The angle of the transmitted wave depends on the angle of incidence and 
propagation velocities of sound in the media as described by Snell's law.  A model 
was developed by Fan and Hynynen [116] which incorporates the refraction of the 
wave in the interface.  The model calculates the acoustic pressure in the second 
medium due to a point source located in the first medium.  The problem was 
simplified by assuming a plane interface between the media.  After a rigorous 
analysis the pressure in the second medium is calculated as a function of pressure 
transmission coefficient, amplitude diminution factor, ray length (proportional to 
medium thickness) and propagation velocities of the media.  The ray path length, 
transmission coefficient, and amplitude factor are determined from the angle of 
incident.  The model calculates the acoustic pressure in a given medium for the 
general case of n media and n-1 interfaces.  The above idea was applied for the 
case of a transducer by dividing the transducer into small elements (point 
sources).  The contribution of each element was added by using Huygen's 
principle. 
 
4.4 TEMPERATURE SIMULATIONS 
The temperature vs time history was obtained by solving numerically the bio-heat 
equation proposed by Pennes (1948) [117].  The explicit form of this equation is 
given by 
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                 (27) 
where ρt is the density of the tissue, ct is the specific heat of the tissue, T is the 
temperature of the tissue, t is the time, wb is the blood perfusion rate, cb is the 
specific eat of the blood, Ta is the arterial blood temperature, k is the thermal 
conductivity of the tissue, Qp is the ultrasonic power deposition rate, and Qm is the 
local metabolic rate which was neglected in the computer simulations.  The first 
term in the above equation represent the temperature rise with respect to time, the 
second term represents the conduction effect which tends to decrease the 
temperature, the third term represents the convection effect due to blood which 
decreases the temperature, and the fourth term represents the power absorbed due 
to the ultrasonic source which increases the temperature.  The blood perfusion is 
modelled as a uniform heat-sink with blood supplied by vessels into the tissue 
volume at body temperature Ta and exiting at tissue temperature T.  All units and 
values of the above parameters are given in Table 4.4. 
 
Tissue metabolic rate determines the precision of local blood flow. According to 
metabolic feedback theories of exercise hyperemia, the vasodilatation of muscle 
exercise results from an increase in tissue fluid concentration of vasodilators 
produced during muscle contraction. On the other hand, the fall in resting blood 
flow that accompanied depression of tissue oxygen consumption by cold suggests 
that reduced tissue metabolism causes a decrease in the tissue fluid concentration 
of vasodilator metabolites normally produced at rest [118]. For the experiments in 
vitro there is no blood flow and therefore metabolic rate was assumed to be zero. 
Since there is blood flow during the experiments in vivo, normally a small value 
of metabolic rate should be considered depending of the treatment location in the 
body. Including metabolic rate values into simulation program lower values of 
temperature should be encountered during an ultrasound exposure. 
 
The bioheat transfer equation was solved by using the finite difference method.  In 
order to demonstrate how the temperature is evaluated at a certain time the 
following subscripts are used: 
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z: variable representing distance in the axial direction. 
r: variable representing distance in the radial direction. 
t: Time 
l: adjacent spatial step (in positive direction) in distance if used in 
conjunction   with z or r, otherwise new time step. 
l: adjacent spatial step (in negative direction) in distance if used in 
conjunction with z or r. 
 
Table 4.4: Parameters used for the temperature vs. time simulations [121] 
Symbol Definition Value Units 
ρt Density of tissue 998 kg/m
3
 
Ct Specific heat of tissue 3770 J/kg
o
C 
t Time Variable s 
T Temperature Calculated 
o
C 
Wb Blood perfusion 0.5, 5, 10 kg/m
3
s 
cb Specific heat of blood 3770 J/kg
o
C 
Ta Arterial Temperature 37 
o
C 
K Thermal conductivity of tissue 0.5 W/m
o
C 
Qp Power deposition rate Variable W/m
3
 
Qm Local metabolic rate 0 W/m
3
 
 
The time derivative of the temperature is given by a two point finite difference  
 
t
)T-T(
=
t
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
                  (28) 
The Laplacian term of eq. (27) in cylindrical coordinates is given by 
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Now since it is assumed that there is no variation of T with Θ the last term in the 
Laplacian drops out.  
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The first term in the Laplacian is approximated by using a three point finite 
difference 
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                 (30) 
similarly the second term is given by 
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The bioheat equation is now written as; 
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Thus, the temperature at the new time step is given by 
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4.5 THERMAL DOSE CALCULATIONS 
The effect of hyperthermia depends on the temperature and the duration of the 
heating, if a constant temperature could be maintain then the duration of heating 
would be a reasonable way of expressing thermal dose, with units of time.  In 
reality, however a constant temperature is not maintained, so it is necessary to find 
a method of relating a treatment to an equivalent time at a specified reference 
temperature.  A mathematical relation between time and temperature is described 
by Dewey [119]. 
       
                        (34) 
where T1, T2 are temperatures at times t1 and t2 respectively, and R is a constant 
given by 
    
   
                         (35)  
where ΔH is the activation energy (cal/mol), T is the absolute temperature (oK) 
and the number 2 is the approximation to the universal constant (1.98 cal/
o
K-mol) 
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The calculation of the thermal dose for changing temperature exposure that cannot 
be described analytically was done by using the technique suggested by Separeto 
and Dewey [120].  The technique uses numerical integration to calculate the 
accumulated dose at a reference temperature under different temperature profiles.  
The reference temperature of 43 
oC has been chosen.  For small Δt the dose can be 
found by 
 tR=t )T-(43
final=t
=0t
43
t                   (36) 
where t43 is the equivalent time at 43 
oC , T is the average temperature during  Δt.  
The value of R equal to 0.25 was chosen for temperatures smaller than 43
 o
C and 
0.5 for temperatures higher than 43
 o
C [120]. Figure 4.3 shows the flowchart of 
the simulation model to calculate temperature, thermal dose and to estimate lesion 
size. In the flow chart, z denotes axial distance, r radial distance and t time. 
 
The concept and unit of thermal dose referenced to a certain temperature is best 
illustrated by means of Figure 4.4.  It is assumed that an idealized constant 
temperature of 43
o
C is maintained for 120 s.  Then the thermal dose is 2 min.  
Now, a high intensity ultrasound pulse of 5 s duration is applied.  This will cause 
temperatures elevations higher than 43
o
C.  By using the function of eq. (36), the 
thermal dose referenced at 43
o
C is 2 min (established by adjusting the power).  
Thus, the same thermal dose of 2 min (as in the case of low power and long 
duration) can be induced with high intensity and short durations. 
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Start 
Input Parameters definitions (table 4.4), 
attenuation/MHz 
Input Transducer Parameters (r, f, d, p), 
sonication (type, time, cooling period) 
T=0 
Calculate Power Density Q(z,r) 
Calculate Temperature T(z, r, t) 
Calculate Thermal Dose (z, r, t) 
Thermal Dose = Thermal Dose + t43 
Thermal Dose > 
240 min at 43°C 
Estimate Lesion Size (Length and Width) 
Print T(z, r, t) 
Print Lesion Size 
End. 
  
Figure 4.3 Flowchart of the simulation model to 
calculate temperature, thermal dose and to 
estimate lesion size 
Yes No 
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Figure 4.4 Demonstration of 2 min thermal dose at 43 
o
C using an idealized 
temperature profile and a typical temperature profile created using high intensity 
ultrasound. 
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CHAPTER 5:  IN VITRO MEASUREMENTS OF THE 
ATTENUATION AND ABSORPTION OF HIFU IN 
ANIMAL BRAIN TISSUES AS A FUNCTION OF 
THERMAL DOSE  
 
5.1 INTRODUCTION 
One of the most important issues for HIFU surgery is the understanding and 
control of thermal exposure in tissue.  It was shown by Damianou et al 
[121][122][123] that when tissue temperature is maintained between 50-100C
 
for 
a few seconds (<5 s), tissue necrosis occurs, and thermal lesions are created.  
There is now a very good understanding how thermal lesions vary with the 
amount of acoustical power applied and the pulse duration for some tissues (for 
example brain and liver), demostrated by Kennedy et al [88], Daum et al [96] and 
Vykhodtseva et al [124].  However, there is not enough information about the 
effect of heating on absorption (tissue variable) which also affects the size, shape 
and placement of the thermal lesions.  Absorption is an acoustical property of 
tissue with wide variation from tissue to tissue, and represents the rate at which 
energy in tissue is converted to heat.  For short pulses (<5 s) it is one of the 
primary factors contributing to the temperature elevation in tissue since the effect 
of blood flow is minimized.  Attenuation includes absorption, scattering and 
reflection but when minimizing scattering and reflection, attenuation will reflect 
mostly losses due to absorption.     
 
There are a number of studies on the effect of temperature on tissue attenuation or 
absorption.   Dunn [125] studied the effect of absorption with temperature (up to 
30
 
C) in the spinal cord of mice, where an increase of absorption with 
temperature was reported.  Dunn and Brady [126] studied the absorption as a 
function of temperature in mammalian central nervous tissue at different 
frequencies and it was shown that the absorption decreased for frequencies lower 
than 1 MHz and increased for frequencies higher than 1 MHz.  Gammel et al. 
[127] studied the effect of attenuation with temperature for excised porcine liver, 
kidney, backfat and spleen and for human liver.  The frequency was varied from 
1.5-10 MHz and three different temperatures were studied (4, 20, 37 C).  It was 
found that basically above 5 MHz the attenuation decreased with temperature for 
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all tissues including the human liver.  The pressure absorption was studied by Fry 
et al. [128] on rat liver, where for the temperatures studied (30, 37, and 41 C), 
there was no statistically significant differences in absorption in this temperature 
range. 
 
However, for tissue ablation the attenuation at higher temperatures (50-100C) is 
required. Robinson and Lele [129] studied the changes in attenuation (from 30C 
to 90 C) in cat brain and showed that the attenuation stays essentially constant up 
to 50C, and then increases rapidly.  Bamber and Hill [130] studied the effect of 
temperature on attenuation in the range of 5-65C on excised liver tissues.  Many 
trends were observed, for example the attenuation of bovine liver decreased and 
then increased until it reached 65C where it stayed constant.  In human liver the 
attenuation dropped with temperature and for frequencies lower than 2 MHz, the 
change was insignificant. 
 
Basically in the past years, some studies examined attenuation or absorption as a 
function of temperature (up to 37C) and some at higher temperatures.  However, 
there is no study that examined both attenuation and absorption (at least for one 
tissue) as a function of temperature (with maximum temperature reached close to 
temperatures seen in HIFU surgery) or as a function of thermal dose. 
 
This Chapter reports on the effect of temperature and of thermal dose on the 
attenuation and absorption of tissues namely lamb brain in vitro for temperatures 
from 23C up to 70C.  The attenuation was measured using the transmission and 
reception method (Kossoff et al. [131]), and the absorption was measured using 
the rate of heating method (Fry and Fry [132]).  The impact of variation of 
absorption due to tissue changes on the temperature elevation was demonstrated 
by temperature measurements and simulations.    
 
5.2 MATERIALS AND METHODS 
5.2.1 SAMPLE PREPARATION 
For all the animal experiments protocol, approval was taken by the national body 
in Cyprus responsible for animal studies (Ministry of Agriculture, Animal 
69 
 
Services). Tissue samples extracted from lamb brain, immediately after 
euthanasia, were immersed in 0.9 % saline at room temperature. Twenty lamb 
brain were used weighting approximately 140 g. The samples were placed in a 
small custom-made vacuum chamber until all the bubbles were removed 
(determined by visual inspection).  It was proven by Bamber and Nassiri [133], 
that this method is very successful in removing air inclusions from the tissue, 
especially in liver tissue.  After this procedure, the attenuation or absorption 
measurement was taken immediately because some reports indicated change in 
attenuation with time after excision [134].  When moving the tissue samples from 
the vacuum chamber to the water bath, they were submerged to minimize air 
exposure. 
  
5.2.2 ATTENUATION MEASUREMENT SYSTEM 
The attenuation coefficient was measured based on the transmission and reception 
method described by Kossoff et al. [131].  Initially, the signal through the water 
Vw was measured. Then, the signal Vs was measured with the presence of a tissue 
sample. The following equation gives the value of attenuation in dB/cm: 
 
 
 
Where d is the sample thickness measured in cm. 
Two unfocussed circular transducers of 8 mm diameter (T1 and T2; see Figure 
5.1) and frequency of 4.32 MHz were connected.  The transducer system with the 
sample in between was immersed in a degassed saline bath (Figure 5.1).  A 
controlled heat exchanger with adjustable temperature (HAAKE, model D1) was 
immersed in the bath to vary the tissue temperature and the thermal dose.  A 
needle type thermocouple (Physitemp Instruments, NJ, USA) was placed inside 
the tissue and the temperature was measured using an HP 7500 series B system 
and an HP 1326B multimeter.  The transmission transducer was driven by a signal 
generator (Textronix, Model TM 5003).  The applied voltage was typically 
(between 10-20 V) and the burst mode was used.  The resonant frequency of the 
transducer was 4.32 MHz.  Both the applied and received signals were monitored 
using a 150 MHz oscilloscope.  The received signal was sent from a 
pulse/receiver (Panametrics 5050 PR) through a signal amplifier (Panametrics 
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Model 5601) to a digitizer (Tektronix RTD 710).  The data was stored in a Dell 
PC.  The signal without and with the sample was measured and based on the 
decrease of the signal strength, the sample thickness and the frequency, the 
attenuation in Np/m-MHz was measured.   
 
One useful hint when measuring attenuation is that, the lower the value, the more 
reliable is the data.  High attenuation coefficients imply air inclusions or 
reflections in some interfaces, which should not be included in the ultrasonic path 
when measuring a specific type of tissue. 
 
 
Figure 5.1 Block diagram of the attenuation measurement system 
 
5.2.3 ABSORPTION MEASUREMENT 
The absorption was measured using the widely used rate of heating method (Fry 
and Fry [132]).  The principle of this method is based on relating temperature 
change with the absorption of ultrasound by the following equation: 
 
Tissue 
sample 
sample 
degassed saline 
 Haake D1  
Heat-exchanger 
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where α is the absorption coefficient (Np/m-MHz), ρt is the density of the tissue, 
ct is the specific heat of the tissue, T is the temperature of the tissue, t is the time, 
and Io is the focal intensity in tissue which varies exponentially with depth in 
tissue.  By measuring the temperature close to the surface of the tissue the 
exponential term is dropped.  The above equation is derived based on negligible 
thermal conduction. Therefore, to measure the absorption one needs to measure 
the rate of temperature rise in the focal spot of short pulse of known intensity, 
provided that the focal spot is placed at few mm depths in the tissue.  A 
spherically focused transducer of 20 mm was used to produce temperature 
elevation in the tissue for measuring absorption using a wide beam and thus, 
minimizing the conduction effect. The pulse applied was in the continuous mode 
with pulse duration of 1 s.  The power chosen was such that the temperature 
elevation was about 1-2 C, thereby, reducing the conduction effect.  The rate of 
temperature change was measured using finite differences.  The value used for 
density was 1100 kg/m
3
, and the value for specific heat was 3770 J/kg- C 
(Dumm [125], Gammel et al [127], Fry and Fry [132] and Frizzell et al [134]). 
 
The temperature was measured using a 50 µm, T-type, copper-constantan 
thermocouple (Physitemp).  The accuracy of the thermocouple was checked by 
using a mercury thermometer of 0.1 C resolution. The thermocouple was placed 
a few millimeters beneath the surface of the tissue and the temperature was 
measured every 0.1 s using an HP 7500 series B system and an HP 1326B 
multimeter.  In order to eliminate viscous heating, the rate of temperature change 
was measured 0.3 s after the ultrasound was turned on.  At that interval, the rate of 
temperature change was linear.  The tissue was submerged in saline when the 
thermocouple was placed.  Figure 5.2 shows the block diagram of the absorption 
measurement system.  It consists of a signal generator (Tektronix, Model TM 
5003) and an amplifier system (ENI, model 240L) for driving the transducer 
thereby elevating the temperature in the tissue, and the thermometry system 
described above for measuring the temperature. 
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The accuracy of measuring absorption depends on three factors: a) correct 
measurement of the peak intensity at the thermocouple site, b) correct 
measurement of the temperature derivative with respect to time and c) eliminating 
the effect of conduction which affects factor b).   The effect of conduction 
spatially was minimized by using a sufficiently wide beam.  The pulse duration 
and applied power were chosen such as small temperature elevations were 
induced, thus eliminating the effect of conduction.  Thus, we believe that the 
technique used for measuring the absorption was very accurate.  The higher the 
absorption measured, the more reliable the data.  Lower values indicate that the 
measurement is affected by conduction and this would lower the temperature 
gradient or the focus is not placed close enough to the thermocouple. 
 
 
Figure 5.2 Block diagram of the absorption measurement system 
 
5.2.4 ACOUSTICAL POWER CALIBRATION 
 In order to measure the absorption, the peak intensity at the focus is required.  
This can be found by measuring the total acoustical power delivered and the half-
intensity beam width of the focused transducer.  In this experiment, the acoustical 
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power delivered by the transducer was measured using the ultrasound power 
meter (Precision Advanced, Model UPM-DT-10).  The transducer was driven by a 
signal generator (Tektronix, Model TM 5003) through an RF-power amplifier 
(Kalmus, 50W1000A, 1 MHz - 1000 MHz, Advanced Test Equipment Corp, CA, 
USA).  The transducer was immersed in the bath of the power meter's tank 
containing a force balance and an ultrasonic absorber, which is placed 1-2 cm 
from the transducer surface.  The measurement was taken a few seconds after the 
power was applied to the transducer, until measurement stabilization was 
established.  The acoustical power was measured as a function of signal generator 
voltage.  Power was measured by converting the force applied to the balance into 
acoustical power.  
 
5.2.5 INTENSITY FIELD MEASUREMENT 
The intensity beam of a transducer was estimated using a needle hydrophone of 
active element diameter of 0.5 mm (Specially Engineering Associate, San Jose, 
CA).  The transducer under test was connected to the transmitter of a high 
frequency pulser-receiver (Panametrics 5050PR) which sends an echo-pulse to the 
hydrophone.  The hydrophone was connected to the receiver input of the pulse-
receiver, and then its signal was amplified by another pulser-receiver (Panametrics 
Model 5601) and digitized using an A/D card (Gage, IL, USA) at the rate of 50 
MHz. The three dimensional intensity profile was obtained by moving the 
hydrophone laterally and axially, using stepper motors (Velmex, Inc, NY, USA) 
through a stepper driver (Velmex).  The average intensity at the focus was 
estimated from the ratio of power and the area of the lateral half-intensity beam.  
For this transducer, the peak intensity was twice the average intensity (proved 
analytically and experimentally).  The peak intensity was also measured directly 
using a calibrated ultrasonic Hydrophone (Specialty Engineering Associate, San 
Jose, CA), and both methods measured the same peak intensity (difference was 
about 1%). 
 
5.2.6 ULTRASONIC TRANSDUCER 
A spherically focused transducer of 40 mm was also used to elevate the tissue 
temperature using a sharply focused beam in order to compare experimental and 
simulated temperature during typical ultrasonic surgery protocols.  The transducer 
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used was made out of Piezoelectric material (Etalon Inc., Lebanon, IN).  The 
driving frequency was 4 MHz with a focal length of 100 mm.  
 
5.3 TEMPERATURE SIMULATION 
In this section, thermal dose and bioheat equations were used to calculate the 
thermal dose and the temperature versus time respectively (see sections 4.4 and 
4.5). 
 
5.3.1 TEMPERATURE ESTIMATION 
Experimental temperature vs. time profiles were obtained in lamb brain in vitro as 
described in section 5.1.3 and then compared to the corresponding simulated 
profiles described in section 4.4.  The temperature was estimated from the bioheat 
equation by using finite difference techniques described in detail in chapter 4, 
section 4.4.  The estimation of the temperature requires the power density profile 
for a specific transducer, power, and absorption.  The power density was 
calculated by using a computer program, which is described in chapter 4, section 
4.3. 
 
5.3.2 THERMAL DOSE CALCULATION 
Before the attenuation or absorption measurement was taken, the tissue 
temperature and the total applied thermal dose (referenced at 43 C) were 
measured, see section 4.5.  Since the rate at which the temperature increased was 
low, the thermal dose was measured every 1 s.  The thermal dose was measured 
only at one location since a homogeneous tissue sample was always chosen in the 
experiments.  The thermal dose equation was also used to estimate the simulated 
thermal dose based on the temperature history. 
 
5.4 RESULTS 
For the figure 5.3 and figure 5.4, the absorption and attenuation formulas together 
with the thermal dose equation (36) were used. Using a thermocouple, 
temperature was calculated and utilized to derive thermal dose. Figure 5.3 shows 
the attenuation vs. thermal dose referenced at 43C. A significant increase in 
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attenuation was seen for thermal dose higher than 1-1000 min, and the maximum 
attenuation was reached at 10
3 
min when using tissue of lamb brain.   
 
Figure 5.4 shows the effect of thermal dose on absorption in lamb brain.  
Differences in absorption at each temperature were less than 0.2 Np/m-MHz.  The 
trend of absorption observed was similar to the trend seen for attenuation.  
Significant absorption changes occurred at 50C and at a thermal dose of 100 min.  
Maximum absorption was established at 65C and at a dose higher than 103 mins.  
The absorption at 65C was 1.7 times the absorption at 37C.  
 
 
Figure 5.3 Attenuation vs. thermal dose referenced at 43 C for lamb brain 
 
Figure 5.5 shows experimental and simulated temperature profiles for a 4 s pulse 
and applied power of 15 W using a dose dependent absorption based on the results 
of Figure 5.4. This clearly shows the effect of dose dependence of absorption on 
the tissue temperature estimation, which resulted to a few degrees of difference 
between simulated and experimental temperature profiles. 
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Figure 5.4 Absorption vs. thermal dose referenced at 43 C for lamb brain 
 
 
Figure 5.5 Experimental and simulated temperature change vs. time (Power=15W, 
4 sec pulse, F=4 MHz, R=100mm, d=40mm, depth in tissue=15mm). 
 
5.5 DISCUSSION 
The lamb brain attenuation, measured in this study, of about 4.2 Np/m-MHz at 37 
C, is comparable to absorption or attenuation values appeared in the papers by 
Fry et al [128] and Frizzell et al [134]. 
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For low dose, it was seen that the change in attenuation is insignificant.  This 
information is important for hyperthermia applications, because it reveals that any 
variation in the temperature should not be attributed to variation in attenuation.  
The attenuation of soft tissues shows increase with temperature for all three types 
studied above 50 C.  The increase above this temperature is monotonic and 
eventually at some temperatures (about 65 C) a maximum attenuation is reached.  
This maximum attenuation is almost twice the value at physiological temperatures 
(37 C).  The same trend of increasing absorption with temperature was reported 
by Dunn and Brady [126] for frequencies higher than 1 MHz with the result of 
this study (at 4 MHz).  The attenuation vs. temperature study alone does not give a 
sound physical explanation of the effect of heating.  The time the temperature is 
maintained (estimated using the thermal dose) gives more information on the 
physical changes in tissue.  The attenuation vs. thermal dose trend shows that the 
attenuation starts to increase in soft tissues for doses in the range of 100-1000 min 
(thermal dose referenced to 43 C).  This proves that when the thermal dose 
threshold of necrosis is reached the tissue attenuation starts to increase. 
Depending on the tissue type, there is literature that reports the thermal threshold 
of necrosis in minutes at different temperatures.  Damianou et al. [121] 
summarizes the thresholds in equivalent minutes referenced at 43 C for various 
tissues.  Typically, the threshold for all important tissue types varies from 50-240 
min.  Eventually, when high dose is applied (typically 10
7
 min) the tissue reaches 
a state where no more damage is caused (total necrosis), and thus the attenuation 
does not change.   
 
The trend of absorption in lamb brain with temperature and thermal dose showed 
similar behaviour with those seen in the attenuation study.  The attenuation 
changed from 4.2 Np/m-MHz at 37 C to about 9.6 Np/m-MHz at 65 C.  The 
corresponding change in absorption was from 3.3 Np/m-MHz to 5.3 Np/m-MHz.  
Thus, the change of attenuation with temperature was dominated primarily by the 
absorption.  The value of absorption at 37 C (3.3 Np/m-MHz) was about 78.6 % 
of the attenuation at 37 C (4.2 Np/m-MHz).  The corresponding contribution of 
absorption at 65 C is 55.2 %.  The rest of the attenuation is contributed mainly by 
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scattering and then reflection.  Thus, the lower contribution of absorption in the 
attenuation at high temperatures is attributed partly to increases in reflection. 
 
The effect of temperature dependence on absorption has a tremendous impact on 
the tissue temperature elevation.  During the application of short pulse ultrasound 
the temperature elevation depends primarily on the ultrasonic source parameters 
(intensity and pulse duration), and on the absorption of the tissue.  The ultrasonic 
source parameters are accurately determined and controlled.  Thus, the tissue 
absorption remains the key factor for determining the tissue temperature.  
Moreover, for high intensity applications where the tissue temperature is typically 
50-100 C, the change in absorption with temperature can be the dominant factor 
for understanding temperature trends.  In thermal modelling, the change of 
absorption used was chosen from the high rate (applied dose/per min) curve.  The 
simulated temperature was in good agreement with the experimental during HIFU 
exposures only when the effect of temperature was accounted for.  During the 
decaying part, the experimental temperature was higher than the simulated.  When 
the power is off, conduction is the dominant factor for the temperature change, 
therefore the difference between the experimental and simulated temperature is 
attributed to uncertainty in conductivity. Therefore, to achieve an identical 
simulated and experimental values and especially during the decaying part of 
figure 5.5, more accurate values for conductivity must be used, or a smaller Δr, or 
Δt in the simulation program. 
 
By calculating attenuation and absorption, we are now able to calculate the 
temperature elevation at the focal point inside the tissue.  The prediction of lesion 
size requires the knowledge of the thermal dose that causes  necrosis.  The aim is 
to predict the lesion size based on the intensity used or the resulting tissue 
temperature at the focal point. This quantity allows us to execute a theoretical 
study to investigate the effect of various physical parameters on the size and shape 
of the lesions.  At the next chapter, we can observe this temperature elevation as 
well as the lesion size (length and width).  
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CHAPTER 6: THERMAL SIMULATION MODEL FOR 
PREDICTING LESION SIZE DURING SONICATION 
USING HIFU. 
 
6.1 INTRODUCTION 
Once attenuation and absorption are known (chapter 5) a computer model was 
developed that estimates the lesion size based on the transducer characteristics 
(frequency, diameter, degree of focusing), treatment protocol (pulse duration, 
acoustical power), and anatomical site (size, depth, mode of operation).  
 
The cranium presents a particularly difficult challenge because of both high 
attenuation and uneven thickness and density over its extent. The main problems 
in transmitting ultrasound through the skull are HIFU defocusing and lesion 
formation unpredictability. To avoid creating an acoustic window by removing a 
piece of the skull we have used low frequencies.  Low frequencies are proven by 
Hynynen et al [62] to penetrate the skull and easily create a focal point. This 
chapter describes the results regarding lesion size and temperature elevation at the 
focal point in brain tissue.   
 
6.2 TRANSDUCER ARRANGEMENT 
Transducer diameter of 5 cm was assumed in this simulation program in order for 
the whole system to fit in the MRI scanner using our MR compatible positioning 
device (Daminanou et al [145]).  Two different focal points were used; 5 cm deep 
in the tissue to simulate a human brain, and 1 cm deep in the tissue, to simulate a 
rabbits brain.  
 
The modelling parameters are: transducer frequencies are 0.5 MHz, 1 MHz, and 
1.5 MHz, the radius of curvature is 10 cm, the diameter of the transducer is 5 cm, 
and the transducer is located: 
(i) 5 cm from the water-tissue interface (simulate human brain) and 
(ii) 9 cm from the water-tissue interface (simulate rabbit brain).   
The geometrical arrangement of the transducer is illustrated in Figure 6.1. 
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Figure 6.1 Transducer arrangements 
 
6.3 SIMULATION METHODOLOGY 
Using frequency of 0.5 MHz, 1 MHz and 1.5 MHz we have examined the lesion 
length and lesion width at depth of 5 cm and 1 cm deep in the brain tissue. Longer 
pulse durations will assume larger lesions. Therefore, different pulse duration will 
be investigated for different power and for different frequency in order to evaluate 
the size (length and width) of the lesion (figure 6.2 – figure 6.5). 
Temperature distribution at the focal point should be observed in order to avoid 
boiling the tissue in the case that is exceeded 100°C. Therefore, to investigate 
temperature elevation, the properties of the transducer such as frequency, radius of 
curvature, diameter, and acoustical power were varied. The ultrasound field 
distribution was calculated from the water-tissue interface up to a distance which 
was at least 5 cm beyond the focus in a direction parallel to the beam propagation 
and 5 cm radially. Different properties used in the simulations such as tissue 
velocity and brain impedance were given in table 4.1 and table 4.2. Parameters 
used for temperature calculation were given in Table 4.4. Attenuation and 
Diameter 
d=5cm 
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absorption were calculated in chapter 5 and their values were used in the 
simulation program. 
 
A program was written in MatLab to calculate the power field, temperature at the 
focal point, thermal dose and lesion size (length and width). The program requires 
information such as the frequency, radius of curvature, diameter of the transducer, 
acoustic power, attenuation coefficient, distance of transducer from the skin 
(controls depth of focus in the tissue).  The dimensions of the field size can also 
be inputted by the user as well as the spatial step.  Numerical calculations of the 
temperature requires equal spatial step in the radial and axial direction. 
 
6.4 RESULTS 
The effect of applied acoustic power on the lesion size (length and width) under 
different frequencies was investigated.  The lesion length and width increases as a 
function of applied power with the rate of increase dependent upon the pulse 
duration. 
The lesion length and width were simulated for different power and pulse 
duration.  In addition, the temperature distribution was measured for different 
power and pulse duration.  
 
6.4.1 SIMULATION RESULTS FOR LESION SIZE VS. TIME FOR 
DIFFERENT POWER AND FREQUENCY. 
Figure 6.2 shows results from the simulation for the lesion length and lesion width 
distribution when using 0.5 MHz transducer.  The transducer diameter (D) is 5cm 
with a 10cm radius of curvature (R). The focus is at approximately 10cm, 5cm 
deep in the tissue.  The effect of pulse duration on the lesion size was investigated 
using power of 50W, 60W, and 80W.  The lesion length and width are increased 
with increased pulse duration. 
 
Figure 6.3 shows the lesion length and lesion width distribution for the 1 MHz 
transducer.  The transducer diameter (D) is 5cm with a 10cm radius of curvature 
(R). The focus is at approximately 10 cm, 5 cm deep in the tissue.  The effect of 
pulse duration on the lesion size was investigated using power of 20W, 30W, 
40W, 50W, and 60W.  The lesion length and width are increased with increased 
pulse duration. 
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Figure 6.2 A. Lesion length distribution versus pulse duration for the 0.5 MHz 
transducer (power= 50W, 60W, and 80W, D=5 cm and Focal Depth=5 cm); B. 
Lesion width distribution versus pulse duration for the 0.5 MHz transducer 
(power= 50W, 60W, and 80W, D=5 cm and Focal Depth=5 cm). 
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Figure 6.3 A. Lesion length distributions versus pulse duration for the 1 MHz 
transducer (power= 20W, 30W, 40W, 50W, and 60W, D=5 cm and Focal 
Depth=5 cm); B. Lesion width distributions versus pulse duration for the 1 MHz 
transducer (power= 20W, 30W, 40W, 50W, and 60W, D=5 cm and Focal 
Depth=5 cm). 
A 
B 
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Figure 6.4 shows the lesion length and lesion width distribution for the 1.5 MHz 
transducer.  The transducer diameter (D) is 5 cm with a 10 cm radius of curvature 
(R). The focus is at approximately 10 cm, 5 cm deep in the tissue.  The effect of 
pulse duration on the lesion size was investigated using power of 20W, 30W, and 
40W.  The lesion length and width are increased with increased pulse duration. 
 
 
 
 
 
Figure 6.4 A. Lesion length distributions versus pulse duration for the 1.5 MHz 
transducer (power= 20W, 30W, and 40W, D=5 cm and Focal Depth=5 cm); B. 
Lesion width distributions versus pulse duration for the 1.5 MHz transducer 
(power= 20W, 30W, and 40W, D=5 cm and Focal Depth=5 cm). 
A 
B 
85 
 
Figure 6.5 shows the lesion length and lesion width distribution at 1 MHz 
transducer.  The transducer diameter (D) is 5 cm with a 10 cm radius of curvature 
(R). The focus is at approximately 10 cm, 1 cm deep in the tissue.  The effect of 
pulse duration on the lesion size was investigated using power of 20W, 30W, and 
40W.  The lesion length and width are increased with increased pulse duration. 
 
 
 
 
 
Figure 6.5 A. Lesion length distributions versus pulse duration for the 1 MHz 
transducer (power= 20W, 30W, and 40W, D=5 cm and Focal Depth=1 cm); B. 
Lesion width versus pulse duration for the 1 MHz transducer (power= 20W, 30W, 
and 40W, D=5 cm and Focal Depth=1 cm). 
A 
B 
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6.4.2 SIMULATION RESULTS FOR TEMPERATURE VS. TIME FOR 
DIFFERENT POWER AND FREQUENCY. 
 
Figure 6.6 shows the temperature at the focal point for the 0.5 MHz, 1 MHz, and 
1.5 MHz transducers.  The transducers diameter (D) is 5 cm with a 10 cm radius 
of curvature (R). The focus in tissue at approximately 5 cm deep in the tissue, 
except figure 6.6d were the focus is at 1 cm deep in the tissue.  The effect of 
temperature elevation is investigated using power of 20W, 30W, 40W, 50W, 
60W, and 80W.  The temperature is increased with increased pulse duration and 
eventually a saturation point is reached. 
 
 
 
 
A 
B 
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Figure 6.6 Temperature at the focus versus pulse duration for the A. 0.5 MHz 
transducer (power= 20W, 30W, 40W, 50W, 60W, and 80W, D=5 cm and Focal 
Depth=5 cm); B. 1 MHz transducer (power= 20W, 30W, 40W, 50W, 60W, and 
80W, D=5 cm and Focal Depth=5 cm); C. 1.5 MHz transducer (power= 20W, 
30W, and 40W, D=5 cm and Focal Depth=5 cm); D. 1 MHz transducer (power= 
20W, 30W, and 40W, D=5 cm and focal depth=1 cm). 
 
6.4 DISCUSSION 
The simulation results can give us a good indication regarding lesion size (length 
and width) and temperature elevation at the focal point.  Also, the simulation 
results can have a significant contribution in the development of the transducers.  
These results will guide us towards the best sonication system in a faster and more 
appropriated way than using extensive animal experiments. 
 
The simulation results suggest that the lesion size can be controlled by adjusting 
the duration of the sonication and by adjusting the amount of the acoustical 
C 
D 
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power.  Figure 6.2, 6.3, 6.4, and 6.5 shows that the lesion size increases with the 
pulse duration because the longer the duration, the higher the temperature 
elevation and the larger the heated volume at the focal point.  The size of the 
lesions can be changed by varying the focal shape and size, which are controlled 
by the operating frequency and transducer geometry. 
 
Figure 6.2 shows the lesion length and lesion width for 0.5 MHz frequency. 
Lesion size may approach saturation point at higher power but with the risk of 
reaching the boiling point. For example, with pulse duration of 20 s and power of 
50 W, lesion length is 37 mm long and lesion width is 4 mm (adequate lesion). 
With the same pulse duration (20 s) but with power of 80 W the lesion length is 
60 mm and the lesion width is 7 mm which is very large lesion but you may reach 
the boiling point. 
 
Using frequency of 1 MHz, power of 20 W, pulse duration of 20 s and with focal 
depth of 1 cm we have noticed that the lesion length was 32 mm and the lesion 
width was 4.5 mm (figure 6.5). When the focal depth was changed to 5 cm, lesion 
length was increased to 35 mm but lesion width was decreased to 3.8 mm (figure 
6.3). Therefore, the deeper as we go into the tissue, the lesion length is increased 
but the lesion width is decreased. The system behaves the same way for different 
pulse duration and for different power. 
 
Comparing figures 6.5 with 6.3 we can observe that if the focal depth is closed to 
the skin (1 cm deep), then the lesion width is increased and the lesion length is 
decreased (compared to 5 cm depth).  In addition, comparing figures 6.6B with 
6.6D we can observe that the temperature is higher when the focal depth is closed 
to the skin (1 cm). This is happening because intensity drops less at points closer 
to the transducer surface and decreases deeper into the tissue due to the 
attenuation and absorption.  Also, when the focus is closed to the surface, lesion 
length is limited due to the skin boundaries while the lesion witdh is not. As the 
frequency increases from 1 MHz to 1.5 MHz (figure 6.4 and 6.5) and using the 
same power, it was observed that lesion size remains the same. 
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When frequency of 0.5 MHz is used, with focal depth of 5 cm and with any 
power, boiling point is never reached. When higher frequency (1 MHz and 1.5 
MHz) is used with high power, boiling point may be reached. For example, with 
frequency of 1 MHz or 1.5 MHz, pulse duration of 10 s and focal depth of 5 cm, 
any power above 50 W or 30 W respectively will reach the boiling point. Table 
6.1 presents a summary of the simulation results showing the recommended 
parameters that can be used for an ideal HIFU system. 
Table 6.1 Summary of the recommended simulation results 
F = 0.5 MHz (Focal Depth = 5 cm) 
Power (W) Pulse Duration 
(s) 
Temperature 
(°C) 
Lesion: Length/Width 
(mm) 
30 - 80 10 - 50 60.3 – 68.8 19.6 – 51 / 1.85 - 5.5 
 
F = 1 MHz (Focal Depth = 5 cm) 
Power (W) Pulse Duration 
(s) 
Temperature 
(°C) 
Lesion: Length/Width 
(mm) 
20 - 50 4 - 20 64 – 73.7 25.7 – 33.6 / 2.2 – 3.6 
F = 1 MHz (Focal Depth = 1 cm) 
Power (W) Pulse Duration 
(s) 
Temperature 
(°C) 
Lesion: Length/Width 
(mm) 
20 – 40 5 – 20 69 – 86.7 23.6 – 31.6 / 2.9 – 4.5 
 
F = 1.5 MHz (Focal Depth = 5 cm) 
Power (W) Pulse Duration 
(s) 
Temperature 
(°C) 
Lesion: Length/Width 
(mm) 
20 - 50 1 - 5 64.6 – 81.5 15 – 27.1 / 1.2 – 2.6 
 
The following chapter presents experiments in phantoms and excised brain tissue 
in animals in vitro and in vivo. The creation of large and deep lesions is 
demonstrated. Also, the effectiveness of MRI to monitor therapeutic protocols of 
HIFU in the brain is investigated. 
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CHAPTER 7: IN VITRO AND IN VIVO (RABBIT 
BRAIN) PENETRATION OF HIFU USING MR 
IMAGING. 
 
7.1 INTRODUCTION 
Thermal ablation of brain in animals with high intensity focused ultrasound 
(HIFU) was very popular in the 50’s and 60’s [3][135]. HIFU was used in the 
clinical setting by Fry and Johnson [136] and showed that HIFU had the potential 
to treat brain cancer. Several groups such as Britt et al [137] and Guthkelch et al 
[138] have used hyperthermia (heating of several minutes at 43
o
C) to treat brain 
tumours. The clinical trials were abandoned probably due to the inexistence of 
effective imaging modality to guide the therapy. Especially for the case of brain, it 
is extremely important to have absolute control of the ablation in order to avoid 
vital brain tissue damage such as the neurons. Now with the advancement of 
HIFU technology guided by magnetic resonance imaging (MRI), it will be 
possible to conduct clinical studies for brain cancer. Today, there is only one 
clinical study using the ExAblate (MRgFUS Surgery Treatment of Brain Tumors) 
system and is started on November 2011 by InSightec to treat Glioma and 
Metastic Brain Cancer [139]. 
 
Since 1994 several studies by the group of Dr. Hynynen [124], [140], [141], 
[142], [143], [144] demonstrated the creation of lesions in animal brain and the 
use of MRI for monitoring. However, in these studies only pure thermal lesions 
were shown. Also, in the above studies the production of well-controlled large 
lesions was never demonstrated. Currently there is a HIFU system, which is 
guided by MRI developed by Insightech, which treads fibroids [60]. This system 
which is already FDA approved has been deployed in 30 locations worldwide. 
Therefore, HIFU guided by MRI, opens the possibility for treating tumours in 
other organs. 
 
In this chapter, we have explored extensively the use of MRI to image both 
lesions created under thermal and cavitation or boiling mechanisms. Also in this 
work, it was demonstrated the creation of well-controlled large thermal and 
bubbly lesions. Another issue that was never demonstrated in previous studies is 
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the lesion penetration deep in tissue, an issue which is explored in this chapter for 
in vitro and in vivo exposures. 
 
Single element spherically focused transducers of different diameter; different 
focusing and operating frequency (table 7.1) were used in this study. The 
transducer was scanned in a 3-d grid using an MRI compatible mechanical 
positioning device designed and developed by Damianou et al. [145]. The 
positioning device designed is simple, cost effective, portable and universal. By 
universal, we mean that it can be used in any MRI scanner available, since it is 
placed on the table of the MRI scanner and therefore integration with all MRI 
scanners is possible. Also, the current device includes a flexible coupling system, 
and thus it can be used in all the anatomies accessible by HIFU (liver, kidney, 
breast, brain and pancreas). For the experiments in vitro, non-degassed freshly 
excised lamb brain tissue it was used. Lamb brain is a good experimental model 
for easily initiating cavitation, due to the trapped bubbles in the brain vasculature. 
For the in vivo experiments, New Zealand adult rabbits were used. 
 
The main goal of this chapter is to investigate the effectiveness of MRI to monitor 
therapeutic protocols of HIFU in the brain. Thus, we have used the basic pulse 
sequences T1-w and T2-w fast spin echo (FSE). These MRI pulse sequences have 
been successful in other organs regarding their ability to identify thermal lesions. 
For example in muscle the contrast of lesions was investigated by Hynynen et al. 
[146], in kidney by Hynynen et al. and Damianou et al. [147][148], in liver by 
Rowland et al. [149], and in prostate by Rouviere et al. and by Pisani et al. 
[150][151]. We have also use FLAIR since this is the predominant pulse sequence 
used in brain in the clinical setting. 
 
7.2 HIFU/ MRI SYSTEM 
Figure 7.1 shows the block diagram of the HIFU/MRI system which includes the 
following subsystems: 1) HIFU system, 2) MR imaging, 3) Positioning device 
(robot), 4) Temperature measurement, and 5) MRI compatible camera. All 
subsystems are described below. 
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Figure 7.1. Block diagram of the HIFU system under MRI guidance. 
 
7.2.1 HIFU SYSTEM 
The HIFU system consists of a signal generator (HP 33120A, Agilent 
technologies, Englewood, CO, USA), a RF amplifier (250 W, AR, Souderton, PA, 
USA), and a spherically shaped bowl transducer made from piezoelectric ceramic 
of low magnetic susceptibility (Etalon, Lebanon, IN, USA). Two transducers were 
used to create single or large lesion either in vitro or in vivo experiments. For the 
in vitro experiments freshly lamb brains were used and for in vivo experiments 
rabbits were used. Table 7.1 list both transducers used in the experiments and their 
parameters. The transducer was rigidly mounted on the MRI-compatible 
positioning system (MEDSONIC LTD, Limassol, Cyprus) which is described at 
the next page. 
 
Table 7.1 transducer parameters 
 Transducer Focal Depth Diameter Animal / Method 
1. 1 MHz 10 cm 5 cm Lamb Brain / in vitro 
Rabbit Brain / in vivo 
2. 2 MHz 10 cm 5 cm Lamb Brain / in vitro 
Rabbit Brain / in vivo 
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7.2.2 MRI IMAGING 
The 3-d positioning device and the transducer were placed inside a MRI scanner 
(Signa 1.5 T, by General Electric, Fairfield, CT, USA). A brain coil (USA 
instruments, Cleveland, OH, USA) was used to acquire the MRI signal.  
 
7.2.3. POSITIONING DEVICE 
The robot has been developed by Damianou et al. [145] initially for three degrees-
of-freedom (X, Y, Z direction), but it can be easily developed for 5 degrees of 
motion.  Since the positioning device is placed on the table of the MRI scanner its 
height should be around 55 cm (bore diameter of the MRI scanner). The length of 
the positioning device is 45 cm and its width 30 cm. The weight of the positioning 
device is only 6 kg and therefore it can be considered portable. Figure 7.2A shows 
the complete mechanical design of the robot and figure 7.2B shows a photo of the 
robot made out of polyethylene.  
 
The container was filled with degassed water. A plastic membrane was attached in 
the front hole of the container where the skull will be placed in order to avoid any 
air gaps.  The transducer is immersed in the water container which is filled with 
degassed water or saline. The water is poured in a mylar bag. The mylar bag is 
made thin enough to conform to the contours of the target. A circular window is 
opened in the water container in order to allow ultrasound energy to be applied 
through the body. 
 
A 
X direction 
Y direction 
Z direction 
Piezoelectric motor, 
Y axes 
Piezoelectric 
motor, Z axes 
Piezoelectric motor, 
X axes 
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Figure 7.2 A. The robot, the complete mechanical design; B. Photo of the robot. 
 
7.2.4 TEMPERATURE MEASUREMENT 
Temperature of brain tissue at the focal point is measured using a data acquisition 
system (HP 34970A, Agilent technologies, Englewood, CO, USA). Temperature 
is sensed using a 50-μm diameter T-type copper-constantan thermocouple 
(Physitemp Instruments, Inc. New Jersey, USA) which is MRI compatible. The 
thermocouple is placed in the tissue by means of a catheter. The thermocouple 
measures the temperature at the focus. This is achieved by applying low-intensity 
(low enough not to cause tissue damage) and during the application of ultrasound; 
the transducer is scanned accordingly in order to detect the maximum 
temperature. This establishes positioning of the thermocouple in the focus of the 
transducer. The temperature error of the thermocouple is in the order of 0.1
o
C. 
 
7.2.5 MRI COMPATIBLE CAMERA 
In order to monitor the condition of the animal or humans (future use), a MRI 
compatible camera (MRC Systems GmbH, Heidelberg, Germany) was mounted 
on the system. The camera was interfaced by means of a video card. With the aid 
of the MRI compatible camera the researcher can monitor the welfare of the 
animal. 
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7.3 IN VITRO AND IN VIVO EXPERIMENTS 
Various in vitro experiments were carried out to image (using MRI) the lesions 
created in brain tissue using HIFU. The acoustical coupling of Figure 7.3 was 
used for the in vitro and in vivo experiments. With this method, the tissue is 
placed outside the water container, which is filled with degassed water. Due to the 
weight of the water container, the coupling with this method is excellent. This 
method can be described as a superior to inferior approach, meaning that the 
transducer is on top of the tissue. In commercial systems the approach used is 
inferior to superior, meaning that the transducer in below the tissue. 
 
Figure 7.3 Coupling method used for in vitro and in vivo experiments. 
 
The tissue was placed on top of an absorbing material in order to shield adjacent 
tissue from stray radiation from the bottom. The transducer was placed on the arm 
of the positioning device and was immersed in the water tank, thus providing 
good acoustical coupling between tissue and transducer. Any bubbles that may 
have collected under the face of the transducer were removed in order to eliminate 
any reflections. In all experiments, the tissues used were extracted from non-
degassed freshly killed lamb, and the experiment was conducted in the same day. 
Totally 22 lamb brains were ablated for investigating various issues. 
 
For the in vivo experiments, New Zealand adult rabbits were used weighting 
approximately 3.5-4 kg. Totally 8 rabbits were used in the experiments. The 
rabbits were anaesthetized using a mixture of 500 mg of ketamine (100 mg/mL, 
Aveco, Ford Dodge, IA), 160 mg of xylazine (20 mg/mL, Loyd Laboratories, 
Shenandoah, IA), and 20 mg of acepromazine (10 mg/mL, Aveco, Ford Dodge, 
IA) at a dose of 1 mL/kg. The animal experiments protocol was approved by the 
tissue 
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national body in Cyprus responsible for animal studies (Ministry of Agriculture, 
Animal Services). 
 
Using a single element transducer it was very difficult to penetrate through the 
skull and it was also very difficult to locate the focus since the signal was shifted. 
In addition, the presence of the skull in the ultrasonic path not only distorts the 
field by reflection, but may also destroy the underlying tissue in contact with it by 
absorbing ultrasonic energy and dissipating it as heat. A craniotomy adequate in 
extent to permit unimpeded passage of the cone of sound was imperative. The 
extent of the craniotomy depends on the solid angle of radiation and the depth of 
the target from the cranial surface. The larger the angle and the deeper the target, 
the larger the size of craniotomy needed. For the transducer used and a target 
depth of 1 cm, a circular craniotomy of 3 cm in diameter was adequate. 
 
To perform histology on the rabbit brain after a lesion was created and to observe 
under the microscope (Olympus, BX51TF, Tokyo, Japan) how dead cells versus 
live cells appear, a trypan blue was used. Trypan blue is a mark that can be 
applied on living cells without killing them. It can selectively colour dead tissues. 
Live tissues are not coloured. However, it traverses the membrane in a dead cell 
or tissue. The dead cells are shown as a distinctive blue colour under the 
microscope. Using frequency of 1 MHz at the same target of 1 cm, lesion in the 
brain was created. As soon as the lesion was created a trypan blue (0.5 ml/Kg) 
was injected through the ear artery. 
 
To process histology the brain tissues were sliced into very thin sections for 
observation on the light microscope, after they were first processed to prevent cell 
damage. The processing involved a series of steps: 
 Fixation: Chemical fixatives are used to preserve tissue from degradation and 
to maintain the structure of the cell and of sub-cellular components. 
 Dehydration: Water has to be removed from tissues and replace with a medium 
that solidifies to allow thin sections to be cut. 
 Embedment: The tissue samples are placed into molds along with liquid 
embedding material (such as wax) which is then hardened. 
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 Sectioning: A steel knife mounted in a microtome is used to cut 4-10 
micrometer-thick tissue sections which are mounted on a glass microscope 
slide.  
 Staining: Staining is employed to give both contrast to the tissue as well as 
highlighting particular features of interest. 
 Mounting:To preserve and support a stained section for light microscopy, it is 
mounted on a clear glass slide, and covered with a thin glass cover slip. The 
slide and coverslip must be free of optical distortions, to avoid viewing 
artifacts. 
 Observation: Light microscope to make observations on the cellular structure 
of the slices.   
 
7.4 HIFU PARAMETERS 
The in situ spatial average intensity was estimated based on the applied power and 
the half-power width of the beam of the transducer. The details of the intensity 
estimation can be found in Damianou [152]. To create lesions in lamb or rabbit 
brain two transducers (table 7.1) operating at 1 MHz and 2 MHz were used. The 
ultrasound exposure used was 10 s, 20 s, and 30 s with 10 s delay between 
successive firings. In order to create large lesions, a square grid pattern of 4x4 
overlapping lesions was used. The spacing between successive transducer 
movements was 2 mm, which creates overlapping lesions for the intensity and 
pulse duration used. In all experiments, the focal point was at 1 cm inside the 
tissue. 
 
7.5 MRI PROCESSING AND SIMULATION 
The parameters used for the MRI processing were: 
T1-W FSE: TR=500 ms, TE=9 ms, slice thickness=3 mm (gap 0.3 mm), 
matrix=256x256, FOV=16 cm, NEX=1, and ETL=8. 
T2-W FSE: TR=2500 ms, TE=60 ms, slice thickness=3 mm (gap 0.3 mm), 
matrix=256x256, FOV=16 cm, NEX=1, and ETL=8. 
FLAIR: TR=8000 ms, TE=80 ms, slice thickness=3 mm (gap 0.3 mm), 
matrix=256x256, FOV=16 cm, NEX=1, ELT=8, and inversion time=1200-
2200ms. The Region of Interest (ROI) was circular with diameter of nearly 2 mm. 
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The simulated signal intensity for the FSE MRI sequence was estimated based on 
the following Equation:  
       
 
 
    
 
 
   
Where S is the MRI signal, N is the proton density, t is time, T1 is the spin-lattice 
relaxation time, and T2 is the spin-spin relaxation time. The figure of noise was 
taken from values measured during the experiments. The Contrast to noise ratio 
(CNR) was obtained by dividing the difference in the signal intensity of lesion and 
normal tissue by the standard deviation of the noise. 
 
7.6 RESULTS 
The results demonstrates that with this system we were able to create single 
lesions, large lesions (by producing overlapping lesions), lesions deep in the brain 
and it was possible to monitor these lesions using MRI with excellent contrast. In 
addition, we have used trypan blue in order to perform histology on the rabbit 
brain after the creation of lesion. The experimental and simulated results (chapter 
6) are comparable, indicating that the simulation model can be used for guidelines 
to various thermal protocols. Continues ultrasound was applied with pulse 
duration of 20 s using 1 MHz and 2 MHz transducer. In most cases, the lesion size 
(length and width) derived from the simulation results was bigger than the 
experimental. 
 
Before creating large lesions in the brain (protocol to be used for treating 
tumours), we have tested the system in a gel phantom (SEA, Sunnyvale, CA, 
USA). Figure 7.4A shows a photograph of the large lesion created in the phantom 
at a plane perpendicular to the transducer beam. Figure 7.4B shows the 
corresponding photograph in a parallel plane. Figure 7.4C shows the MRI image 
of the result of figure 7.4A using T1–W FSE and figure 7.4D shows the same 
result using T2-W FSE. Figure 7.4E shows the MRI image of figure 7.4B using 
T2-W FSE. With T1-W FSE, we noticed that the contrast is poor because T1 
value of gel and lesion is very similar. With T2-W FSE, we noticed that the 
contrast is satisfactory because T2 value of gel and lesion are sufficiently 
different. In addition, we can observe few small cavitations (the small black spots) 
within the lesion (figure 7.4D). 
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A      B 
 
 C    D    E 
Figure 7.4 Large lesion in a gel phantom; A. photo of a large lesion at a 
planeperpendicular to the transducer beam; B. photo of a large lesion in a parallel 
plane; C. MRI image of figure 7.4A using T1–W FSE; D. MRI image of figure 
7.4A using T2–W FSE; E. MRI image of figure 7.4B using T2-W FSE. 
 
Using transducer with frequency of 1 MHz, single lesions were created in the 
lamb brain. The focal depth insight the tissue was at 1 cm. Single lesions were 
created using acoustic power of 70 W and 42.5 W, with ultrasound exposure of 10 
s and 20 s respectively. Figure 7.5A shows a picture of the lesions created and 
figure 7.5B shows an MRI image of the same lesions. Figure 7.6 shows a lesion 
created using acoustic power of 60 W and with ultrasound exposure of 30 s. 
1 cm 
1 cm 
1 cm 1 cm 
1 cm 
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   A     B 
Figure 7.5 Single lesions; A. picture of the lesions; B. MRI image (T1 FSE TR=500 ms). 
 
 
Figure 7.6 Single lesion (T1-W FSE TR=500 ms using 60W for 30 s, f=1 MHz 
and focal depth=1 cm) 
 
Figure 7.7 shows 3 single lesions in brain in vitro using T1-w FSE.  The lesion on 
the left was created using in situ spatial intensity of 1000 W/cm
2
 for 20 s. The 
other two lesions were created using in situ spatial intensity of 2000 W/cm
2
 for 
20s. The two lesions in the left were created using thermal mechanisms (no 
acoustic emission was detected). The thermal lesions appear bright and the 
contrast with brain tissue is excellent. The lesion in the right was created under 
cavitation (acoustic emission detected) or due to boiling, and results to a cavity 
within the lesion. Therefore, the lesion appears dark, with bright margin (possibly 
in the early stage of the lesion development thermal mechanism existed). 
Although, two lesions were created with the same intensity (2000 W/cm
2
), one of 
the lesions was created under thermal mechanisms, and the other one probably 
under cavitation mechanisms or possibly boiling. Although the intensity used 
would not result to temperatures above boiling, the high temperatures (caused 
possibly by cavitation) resulted possibly to tissue boiling. The presence of bubbles 
3 mm 
3 mm 
3 mm 
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in the vasculature is leading to the conclusion that the cavities formed are 
attributed most likely to cavitation. 
 
 
 
 
 
 
 
 
Figure 7.7 MRI images of three lesions in brain in vitro using T1-w FSE, f=2 
MHz, d=5 cm and focal depth=1 cm. 
 
Figure 7.8 shows MRI images of lesions created in lamb brain in vitro using in 
situ spatial intensity of 2000 W/cm2 for 20 s and monitored using T1-w FSE 
(Figure 7.8A), T2-w FSE (Figure 7.8B), and FLAIR (Figure 7.8C). The 
parameters of these three sequences are described in section 7.5. With T1-w FSE 
the signal of the brain tissue is homogeneous, thus by using T1-w to monitor 
HIFU, the contrast between lesions and brain proves to be the best. T2-w FSE and 
FLAIR provides better anatomical information within the brain (gray and white 
matter are easily distinguished), however the contrast between lesion and brain is 
not of high quality. The reason is that if a lesion of low signal (such as a bubbly 
lesion) falls inside a region of the brain with low signal, then it is difficult to 
separate this type of lesion from brain tissue. The lesions in brain were visible 
approximately 10 minutes after the ablation. 
 
   
A    B   C 
Figure 7.8 Images of large lesions monitored using MRI; A. T1-W FSE; B. T2-W 
FSE and C. FLAIR 
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The effect of TR on the CNR was evaluated using T1-W FSE at different TR 
(from 100 to 1000 ms). Figure 7.8A shows a lesion in brain in vitro using T1-W 
FSE (TR = 500 ms). Figure 7.9 shows the contrast to noise ratio (CNR) between 
lesion and brain plotted against TR for the MRI image of Figure 7.8A. Small 
percentage of experimental error is shown on the CNR vs TR and CNR vs TE 
graphs. 
 
 
Figure 7.9 Contrast to noise ratio (CNR) vs. TR for T1-W FSE in excised lamb 
brain. 
 
The effect of TE on the CNR was evaluated using T2-W FSE at different TE 
(from 10 to 140 ms). Figure 7.8B shows the MRI images of the same lesion as in 
Figure 7.8A using T2W FSE (TE = 60 ms). Figure 7.10 shows the CNR between 
lesion and brain plotted against TE for the brain and lesion of the MRI image of 
Figure 7.8B. 
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Figure 7.10 Contrast to noise ratio (CNR) vs. TE for T2-W FSE in excised lamb 
brain. 
 
Figure 7.11 shows the MRI image of a large lesion in lamb brain in vitro created 
by scanning the transducer on a 4x4 grid using 2000 W/cm
2
 and T1-W FSE 
resulting to a large bubbly lesion. Note that in some location no lesion was created 
due to poor ultrasound penetration and possibly due to the air bubbles trapped in 
the blood vessels. This image shows once more the excellent contrast between 
normal brain and lesions (in this case bubbly lesions). 
 
Figure 7.11 Image of a large lesion in lamb brain in vitro using T1-W FSE with 
f=2 MHz, d=5 cm and focal length=10 cm. 
 
Figure 7.12 shows a lesion in rabbit brain in vivo. Focal depth for all lesions was 
at 1 cm. Single lesion was created using acoustic power of 36 W at exposure time 
of 20 s. Lesion created in the brain was confirmed by MRI. Transducer frequency 
of 1 MHz was used. 
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Figure 7.12 MRI image using T1-W FSE (with TR=500 ms) showing lesion width 
using f=1 MHz, d=5 cm and focal point=10 cm. 
 
Using frequency of 1MHz, focusing at 1 cm deep in the brain and with intensity 
of 1000 W/cm
2
, lesion was created in rabbit brain in in vivo. As soon as the lesion 
was created, a trypan blue was injected through the ear artery. Figure 7.13A 
shows the injection of the trypan blue through the ear artery. After 20 min the 
rabbit was put into sleep and the brain was removed. Figure 7.13B demonstrates a 
picture of the brain showing how the brain appears with the trypan blue. Lesion 
was visible with gross anatomy using trypan blue. Figure 7.14 clearly shows the 
interface between lesion and brain tissue. 
 
 
   A     B 
Figure 7.13 A. injection of the trypan blue; B. lesion as seen with the trypan blue. 
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Figure 7.14 Lesion-brain tissue interface 
 
Figure 7.15 shows ablation in rabbit in vivo using a 4x4 grid with intensity of 
2000 W/cm
2
 for 20 s and f=2 MHz. This large lesion was created using thermal 
mechanisms and therefore the lesion appears bright. With T1, the signal in the 
brain is homogeneous (gray colour) and therefore the contrast with thermal lesion 
is excellent. The contrast of thermal lesions is definitely much better than the case 
of bubbly lesions. Unlike the in vitro case of Figure 7.11 where with this level of 
intensity bubbly lesions were created, in this in vivo example in none of the 16 
lesions a bubbly lesion was produced. This proves our speculation that in vitro 
brain includes bubbles, which are responsible for producing bubbly lesions 
possibly due to cavitation. 
 
Figure 7.15 MRI image of a large thermal lesion in rabbit in vivo using T1-W 
FSE, f=2MHz and focal depth=1 cm. 
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Figure 7.16 shows MRI images using T1-w FSE of a lesion deep in the lamb brain 
(in vitro) using in situ spatial average intensity of 1000 W/cm2 for 20 s. The 
length of the lesions is smaller than expected, only 12 mm, possibly due to the 
reflection caused by the trapped bubbles. Figure 7.17 shows a lesion deep in brain 
in vivo under the same exposure conditions and transducer, and demonstrates that 
good penetration of HIFU in brain can be achieved if no bubbles are present. The 
lesion propagates all the way through the brain and is 20mm long. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16 MRI image using T1-W FSE in vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.17 MRI image using T1-W FSE in vivo. 
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7.7 DISCUSSION 
The procedure of creating lesions in a gel phantom was always used, before 
animal experiments, for quality assurance of the HIFU transducer. It was found 
that the relaxation time T1 of the lesion and gel used are similar and therefore the 
contrast of T1-W FSE is poor, whereas the relaxation time T2 of the lesion and 
gel is sufficiently different resulting to a good contrast using T2-W FSE.  
   
Previous literature [142][143] demonstrated that lesions can be monitored with 
excellent contrast in rabbit brain (in vivo) using T1-W FSE with TR=500 ms. The 
lesions imaged in the previous studies and also in this study appeared bright with 
T1-W FSE, whereas brain tissue appeared gray. However, in the previous studies 
only thermal lesions were shown. In this chapter, we have explored extensively 
the use of MRI to image both lesions created under thermal mechanisms and 
mechanisms that create bubbly lesions (cavitation or boiling). MRI could detect 
the lesion approximately 10 mins after the ablation.  In the study by Chen et al. 
[153], the lesions in the brain appeared in MRI in 15 mins  using T2-weighted 
FSE, which is very close to what we found in this study (10 mins).     
  
The contrast between lesion and brain tissue out of the 3 pulse sequences used it 
was found to be best with T1-w FSE. The signal intensity of the brain tissue is 
homogeneous when using this method, and therefore the contrast with thermal 
lesions or with bubbly lesions is excellent. Best contrast is observed for TR above 
500 ms. This was proved by plotting the CNR vs. TR.  The relaxation time T1 of 
thermal lesions increases, and therefore lesions appear brighter than brain tissue. 
The trend of increasing of T1 due to heating was also reported by Dickinson et al 
[154]. 
  
The three pulse sequences T1-W FSE, T2-W FSE and FLAIR were all able to 
detect lesions. This advantage is attributed to the significant difference in signal 
intensity between the thermal or bubbly lesions and brain tissue. It was observed 
that bubbly lesions appear darker than thermal lesions. Bubbly lesions appear 
dark, due to the air spaces resulting from cavities. This chapter demonstrates that 
non-degassed excised tissue is a good model for easily initiating cavitation. This 
model of cavitation might not be of any significant for clinical use since the 
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cavitation threshold in live tissue is very different from the threshold in the in 
vitro tissue. However, this model of initiating cavitation is very useful for the 
purpose of studying the MRI appearance of bubbly lesions. Cavitation is initiated 
if a blood vessel (which might include trapped bubbles) is targeted. Thus, the 
nature of lesion (thermal or cavitation) in brain in vitro primarily strongly depends 
on the nature of the target and secondarily to the level of intensity. 
 
This is the first study demonstrating creation of large lesions in brain formed by 
scanning the transducer in grid formation. Both thermal and bubbly lesions were 
monitored successfully using T1-W FSE with excellent contrast, proving the 
potential of HIFU to treat reliably tumours in the brain in the future. The proposed 
system effectively creates large lesions in brain and at the same time, these lesions 
are effectively monitored using MRI enabling the accurate determination of the 
margins of these lesions, especially when using T1-W FSE. 
 
The length of the lesions in vivo measured parallel to the ultrasonic beam (i.e. 
deep in the brain) were much higher than the length in in vitro, proving that the 
penetration in the in vitro brain is limited by reflection due to trapped bubbles in 
the blood vessels. 
 
Previous clinical studies [147] proved the feasibility of HIFU to ablate brain 
tissue. Recently, studies have shown the effectiveness of MRI to monitor HIFU in 
the brain of animals [151][152]. Moreover, in the area of the brain ablation several 
studies have shown that the blood brain barrier in the brain can be opened using 
ultrasound [153], which means that HIFU can be combined with drugs in order to 
increase the therapeutic effect. Moreover, it has been shown that transcranial 
transmission is possible by using phased arrays [155][63]. Therefore, in 
conclusion, it has been demonstrated that (a) tumours can respond to HIFU, (b) 
MRI can monitor these changes, (c) drugs can be delivered locally to the brain, 
and (d) transcranial transmission of ultrasound is possible. Therefore, we believe 
that the prospect of treating patients with brain diseases in the clinical setting 
using HIFU is very promising. 
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Table 7.2 presents a summary of the parameters used for the recommended HIFU 
system. 
Table 7.2 Summary of the recommended HIFU system 
Parameters Values 
Frequency (f) 1 MHz 
Intensity (I) 1000-2000 W/cm
2
 
Pulse Duration (PD) 20 – 30 s 
MRI Sequence T1 W FSE 
 
At the next chapter a computer model was used with the main aim to extract the 
acoustic parameters (power, pulse duration, duty factor and pulse repetition 
frequency) that maintains a temperature increase of less than 1ºC during the 
application of pulsed ultrasound. 
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CHAPTER 8: A SIMULATION MODEL FOR 
PREDICTING THE TEMPERATURE DURING THE 
APPLICATION OF MR-GUIDED PULSED FOCUSED 
ULTRASOUND FOR STROKE TREATMENT. 
 
8.1 INTRODUCTION 
Ultrasound can be used for noninvasive treatment in combination with the 
administration of thrombolytic drug in order to dissolve clots located deep in the 
brain without destroying the surrounding tissue [48][156], [157], [158], [159]. 
High intensity focused ultrasound (HIFU) is being used today primarily to 
thermally destroy tissue [160][161].  Heat produced at the focal point is very high 
in a very short period of time.  As a result, temperature elevations in the exposed 
area can ablate the tissue [162][163]. 
 
During the past few years, treatment of ischaemic stroke using ultrasound has 
received great attention.  Most previous studies have used unfocused ultrasound at 
very low intensities.  Several experimental studies have been performed by 
Alexandrov et al. [48], Zenitani et al. [164], Soltani et al. [165], Eggers et al. 
[166], [169], Shaw et al. [167] and Saguchi et al. [168] to investigate the 
effectiveness of sonothrombolysis with, and without, thrombolytic drugs such as 
rt-PA. 
 
Recently, experiments have demonstrated the ability of HIFU to be used for 
noninvasive procedures to dissolve thrombus [108], [156], [157], [170], [171]. 
Maxwell et al. [156][157] reported that Histotripsy therapy using short, high-
intensity, focused ultrasound pulses can cause mechanical breakdown of targeted 
soft tissue by acoustic cavitation, which is guided by real-time ultrasound 
imaging. 
 
The mode of action of ultrasound during sonothrombolys is mechanical. 
Therefore, temperature elevation is the key safety issue in treating patients with 
ischaemic stroke.  It was shown that when the temperature rises to 43ºC and 
above, enough thermal dose is produced to destroy human tissue [120]].  In order 
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to avoid any unwanted effects on human tissue caused by temperature rise, in this 
simulation study a maximum temperature limit was set to 1ºC. 
 
The aim of this study was to control temperature elevation in order to avoid 
heating of the brain during sonothrombolysis. A computer model was used to 
estimate the temperature elevation, based on the transducer characteristics 
(frequency, diameter, degree of focusing), treatment protocol (pulse duration, duty 
factor, acoustical power), and the anatomical site (depth). A single element 
spherically focused transducer of 5 cm diameter, focusing at 10 cm and operating 
at either 0.5 MHz or 1 MHz was considered. For all simulations, the focus was set 
at either 1cm or 2.5cm deep into the tissue. The goal was to extract the acoustic 
parameters (power, pulse duration, duty factor and pulse repetition frequency) that 
maintains a temperature increase of less than 1ºC during the application of pulsed 
ultrasound. 
 
8.2 MATERIAL AND METHODS 
To avoid overheating of the brain tissue, the values of the following parameters 
such as pulse duration, pulse repetition period (PRP), and duty factor were 
investigated. Pulse duration is the amount of time from the beginning to the end of 
a single pulse of ultrasound. PRP is the amount of time from the start of one pulse 
to the start of the next pulse. It includes both the sound “ON” time and “OFF” 
time.  PRP of 1 ms and 1 s are used.  Figure 8.1 shows a diagram explaining PRP. 
Duty factor (DF) is the proportion of time that the ultrasound transducer is 
actually producing sound energy. It is the ratio between pulse duration (sound ON 
time) and PRP (sound ON plus sound OFF time). The DF ranges from 2% to 
100%. The sonication period used in all simulations and experiments are 60 s and 
120 s. 
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Figure 8.1 Timing diagram explaining PRP, DF, and total time. 
 
8.2.1 TEMPERATURE SIMULATIONS 
The power field was calculated by using a computer program, which is described 
in chapter 4, section 4.3. The temperature vs. time history was obtained by solving 
the bio-heat equation proposed by Pennes (1948) numerically [117].  The explicit 
form of this equation is given by: 
 Q+Q+)T-(Tcw+Tk=
t
T
cp mpabb
2
tt 


                 
The temperature distribution at a given time was observed by solving the bio-heat 
differential equation using a finite difference technique (see section 4.3). 
 
8.2.2 TEMPERATURE MEASUREMENT 
A data acquisition board (6251 DAQ, National Instruments, Texas, USA) was 
used to measure the temperature.  An analogue input of the board was used to 
capture the temperature. An Omega M2813-1205 (OMEGA Engineering, INC. 
Stamford, Connecticut, USA) thermocouple-to-analogue connector was used to 
give analogue output (1mv per degree).  This was entered in to the data 
acquisition card and read by custom-made software written in MatLab (The 
Mathworks Inc., Natick, MA). A thermocouple (Omega engineering INC, 
Connecticut, USA) was placed in the thrombus in order to measure temperature 
elevation at the focal point (clot).  
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8.2.3 IN VITRO EXPERIMENTS 
Experiments were carried out to investigate the accuracy of the simulation model.  
Figure 8.2 shows the HIFU system, which consists of a signal generator and RF 
amplifier (100 W, JJ&A Instruments, USA), and a spherically shaped transducer 
made from piezoelectric ceramic of low magnetic susceptibility 
(Piezotechnologies, USA). The transducer operates at 1 MHz and has a focal 
length of 10 cm and diameter of 5 cm. The transducer is mounted on the 3D 
positioning device (MEDSONIC, Cyprus).  Blood clots were obtained by natural 
coagulation of animal blood samples from healthy cows.  Blood was drawn into 
small containers and placed in a 37°C water bath for 3 h and storing the clots in a 
5°C refrigerator for at least 72 h before use in the experiments to allow complete 
clot retraction [173].  The blood clot was placed inside the silicon tube (figure 
8.2).  A thermocouple was inserted in the middle of the clot to monitor 
temperature elevation. During the experiments, temperature was recorded every 
0.2s. 
 
 
Figure 8.2 Schematic diagram of the MR-guided FUS system. 
 
  
 
Water 
Thrombus 
PC 
Signal 
Generator 
Amplif ier 
Temperature reader 
Thermocouple 
Degassed Water 
Positioning device (X,Y,Z) 
PC 
Transducer 
tube 
114 
 
8.3 RESULTS 
The simulation model was tested on thrombi immersed in a water bath. Pulsed 
ultrasound was applied with pulse repetition period of 1 s using a 1 MHz 
transducer. Figure 8.3 compares simulated and experimental temperatures. The 
experimental and simulated results agree well, indicating that the simulation 
model can be used to give guidelines for various sonothrombolysis protocols. 
 
 
Figure 8.3 Simulated and experimental Temperature vs. Time  with Duty 
Factor=5%, Power=20W, f=1MHz, Radius of Curvature=10cm, Transducer 
Diameter=5cm, Focal Depth=1cm, PRP=1s 
 
Figure 8.4 shows the simulated temperature elevation at frequencies of 0.5 MHz 
and 1 MHz with a focal depth (FD) of 2.5 cm. The effect of duty factor on 
temperature elevation was investigated using power of 2.5 W, 5 W, 10 W, and 20 
W. The maximum temperature at steady state increased linearly with duty factor.  
When higher frequency is used, the duty factor needed to maintain safe 
temperature is lower for the same power. 
 
Figure 8.5 shows also the simulated temperature elevation at frequency of 0.5 
MHz and 1 MHz using the same parameters as in figure 8.4 but with a focal depth 
of 1 cm. The trend of temperature is similar as with the focal depth of 2.5 cm. 
With focal depth of 1 cm, temperature rise faster and therefore less duty factor 
required to maintain safe temperature. 
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D 
Figure 8.4 Temperature vs. Duty Factor for different Power at FD=2.5 cm; A. 2.5 
W; B. 5 W; C. 10 W; D. 20 W 
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Figure 8.5 Temperature vs. Duty Factor for different Power at FD=1 cm; A. 2.5 
W; B. 5 W; C. 10 W; D. 20 W 
 
The effect of the applied acoustical power on the temperature elevation is shown 
in figure 8.6, with focal depth of 1 cm and 2.5 cm, PRP=1s, and frequencies of 0.5 
MHz and 1 MHz. With a lower frequency such as 0.5 MHz the duty factor needed 
for different power is almost the same regardless the focal depth, either for 1 cm 
or for 2.5 cm. When the frequency is increased to 1 MHz, safe temperature cannot 
be achieved at any power (5 W, 10 W, and 20 W) except when 2.5 W is used. 
Temperature limit was reached at 10% for 2.5 W and at focal depth of 1cm where 
14% is needed at focal depth of 2.5 cm. Finally, the duty factor allowed 
maintaining safe temperature is higher for lower power. 
 
0 
1 
2 
3 
4 
5 
6 
0 2,5 5 10 15 20 25 30 35 
M
a
x
. 
T
e
m
p
e
ra
tu
re
  
C
h
a
n
g
e
(°
C
) 
Duty Factor (%) 
f=0.5MHz f=1MHz Temperature Limit 
118 
 
 
A 
 
 
B 
 
C 
 
0 
1 
2 
3 
4 
5 
0 10 20 30 40 50 60 70 80 90 100 
M
a
x
. 
T
e
m
p
e
ra
tu
re
  
C
h
a
n
g
e
 (
°C
) 
Duty Factor (%) 
2.5 W 5 W 10 W 20 W Temperature Limit 
0 
1 
2 
3 
4 
5 
6 
7 
0 5 10 15 20 25 30 35 40 45 50 55 
M
a
x
. 
T
e
m
p
e
ra
tu
re
 
 C
h
a
n
g
e
 (
°C
) 
Duty Factor (%) 
2.5 W 5 W 10 W 20 W Temperature Limit 
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
4,5 
0 10 20 30 40 50 60 70 80 90 100 
M
a
x
. 
T
e
m
p
e
ra
tu
re
  
C
h
a
n
g
e
 (
°C
) 
Duty Factor (%) 
2.5 W 5 W 10 W 20 W Temperature Limit 
119 
 
 
D 
Figure 8.6 Temperature vs. Duty Factor; A. f=0.5 MHz, FD=2.5 cm; B. f=1 MHz, 
FD=2.5 cm; C. f=0.5 MHz, FD=1 cm; D. f=1 MHz, FD=1 cm. 
 
 
Figure 8.7 summarizes the effect of applied acoustic power on the duty factor 
which establish safe temperature at frequency of 0.5 MHz. Acoustical power is 
inversely related to duty factor, the higher the power the lower the duty factor. 
 
 
Figure 8.7 Duty Factor that establishes safe temperature vs. Power, f=0.5 MHz,  
Radius of Curvature=10 cm, Transducer Diameter=5 cm, Focal Depth=2.5 cm, PRP=1 s 
 
Figure 8.8 shows simulation results for the safe temperature using a 1 MHz 
transducer.  Two different focal depths were used: 1cm and 2.5cm.  The effect of 
duty factor (DF) on the safe temperature was investigated using power of a) 2.5 
W, b) 5 W, c) 10 W, and d) 20 W. When FD is close to the surface (1 cm deep) 
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the intensity is higher compared to that at 2.5cm and therefore a lower DF needed 
to reach the temperature limit.  Figure 8.9 shows the same results as in figure 8.8 
but at a frequency of 0.5 MHz. Using a frequency of 0.5 MHz, the temperature 
limit was reached at DF=40%, 20%, 10%, and 5% for power of 2.5W, 5W, 10W, 
and 20W respectively for both focal depth (1 cm or 2.5 cm). 
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D 
Figure 8.8 Temperature vs. Duty Factor for different Power and f=1 MHz; A. 
2.5W; B. 5W; C. 10W; D. 20W 
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D 
Figure 8.9 Temperature vs. Duty Factor for different Power and f=0.5 MHz;  
A. 2.5W; B. 5W; C. 10W; D. 20W 
 
 
8.4 DISCUSSION 
It was found that the temperature increases linearly with duty factor. The higher 
the power the lower the duty factor needed to keep the temperature change within 
the safe limit of 1ºC.  Also, the higher the frequency the lower the duty factor 
needed to keep the temperature change to the safe limit of 1ºC. Finally, the deeper 
the target, the higher the duty factor needed to keep the temperature changes to the 
safe limit of 1ºC. 
 
The simulation results provide a good indicator of temperature elevation at the 
focal point.  The temperature increases as a function of applied power with the 
rate of increase dependent upon the duty factor and frequency.  The temperature 
elevation was simulated for different power and duty factor. These results will 
guide us towards the best sonication system in a faster and more appropriate way 
than using extensive animal experiments. 
 
The simulation results agree well with the experimental results. However, further 
experiments either in vitro or in vivo will require, verifying the current simulation 
results. Various pulse protocols will be investigated based on the parameters 
derived from the simulation, to verify that temperature change at the focal point 
will not exceed 1C, which is called “safe temperature”. In addition, the 
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experimental results (in vitro and in vivo) will guide us towards the best possible 
protocol to be used in collaboration with thrombolytic drug and MRI. Most of the 
previews experimental studies have demonstrated temperature elevation above 
3ºC [174][175]. If this temperature elevation cannot be controlled will cause 
unwanted tissue damage during sonication [90]. There are also cases shown by 
Ishibashi et al. [47] and Nedelmann et al. [175] when either low intensities or low 
frequencies are applied and temperature elevation drops below the 3ºC. We have 
shown that temperature elevation can be controlled and kept within the safe region 
by adjusting various parameters such as the duty factor, the operating frequency, 
and the amount of acoustic power.  
 
The simulation results prove that longer duty factors will increase the temperature 
elevation.  Figure 8.6 shows that the temperature increases with increasing duty 
factor.  This happens because greater duty factors allow less time for the tissue to 
cool off, causing the temperature to rise higher than the allowed maximum limit 
of 1C. 
 
Temperatures also increase faster when the focal depth is 1cm deep in the tissue, 
or more slowly when it is 2.5 cm deep in the tissue.  A comparison of the effect of 
frequency in figures 8.4 & 8.5 indicate that if the focal depth is close to the skin (1 
cm), then the temperature rises faster than when the focal depth is deeper below 
the skin (2.5 cm).  This happens because the intensity drops less at points closer to 
the surface and decreases as we go deeper into the tissue due to the attenuation 
and absorption coefficients. In addition, when using 1 MHz frequency, the beam 
at the focal point is narrower and very sharp compared to frequency of 0.5 MHz. 
Figure 8.9 shows that when 0.5 MHz frequency is used, the difference in 
temperature elevation at the focal point of 1 cm and 2.5 cm is very small 
indicating that at lower frequencies the effect of focal depth is smaller compared 
to higher frequencies. Also, as the frequency increases from 0.5 MHz to 1 MHz 
(figures 8.2 to 8.5) under the same power, the temperature elevation is raised 
faster and therefore we need to use much lower duty factors to prevent the 
temperature exceeding the maximum limit. 
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Finally, this simulation model is considered as a very useful tool for providing 
acoustic parameters (frequency, power, duty factor, pulse repetition frequency) 
during the application of pulse ultrasound at various depths in tissue so that safe 
temperature is maintained during the treatment. Table 8.1 presents a summary of 
the parameters used for the recommended HIFU system 
 
Table 8.1 Summary of the recommended HIFU system 
Focal Depth (FD) = 2.5 cm 
Frequency (MHz) Power (W) Duty Factor (%) ΔΤ (ºC) 
0.5 5 - 20 5 - 40 <=1 
1 2.5 - 10 2 - 10 <=1 
Focal Depth (FD) = 1 cm 
Frequency (MHz) Power (W) Duty Factor (%) ΔΤ (ºC) 
0.5 2.5 - 10 10 - 35 1 
1 2.5 - 5 2 - 5 <=1 
 
The following chapter presents experiments in vitro where the ability of MRgFUS 
system to dissolve clots in combination with rt-PA is demonstrated.  The 
evaluation on the effect of intensity, beam area and frequency on the volume of 
the dissolved clot is evaluated, while temperature change maintain below 1C at 
the centre of the clot. 
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CHAPTER 9: APPLICATION OF MR-GUIDED 
FOCUSED PULSED ULTRASOUND FOR DESTROYING 
CLOTS IN VITRO USING THROMBOLYTIC DRUGS. 
 
9.1 INTRODUCTION 
 
The feasibility of ultrasound to enhance thrombolysis was reported in the mid-70s 
by Trubestein et al. [44] and Tachibana [45]. In the following years, several in 
vitro studies by Kimura et al. [49] and Spengos et al. [158] have confirmed the 
above results. In the former studies, the range of intensity ranged from 0.2–2.0 
W/cm
2
 (spatial peak temporal average intensities) and the frequency ranged from 
20 kHz to 2 MHz using unfocused ultrasound. Table 9.1 sumarizes some of the 
characteristics of ultrasound and thrombolysis derived from experiments in vitro. 
 
It is speculated that ultrasound accelerates enzymatic fibrinolysis primarily 
through mechanical mechanisms, by enhancing transport of thrombolytic drugs 
into the clot shown by Francis et al. [176]. Other mechanical effects of ultrasound 
such as cavitation and radiation force are possibly influencing drug transport 
[177][178]. Acoustic cavitation plays a very significant role in ultrasound-
accelerated fibrinolysis [177]. Other theories revolve around the fact that 
ultrasound promotes motion of fluid around the clot, an effect called 
microstreaming [178].  
 
These preliminary findings are promising, and provide insight into understanding 
the potential of ultrasound in dissolving blood clots during ultrasound-assisted 
thrombolysis, which is an important first step in improving thrombolytic efficacy, 
while minimizing unwanted thermal bioeffects. 
 
Birnbaum et al. [179] reported that in vivo arterial clot dissolution can be achieved 
with intravenous microbubbles and transcutaneous ultrasound delivery alone. 
Moreover, a study by Culp et al. [180] has shown the effectiveness of 
transcutaneous ultrasound and intravascular microbubbles in lysing intracranial 
clot in pigs. 
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Table 9.1: Characteristics of Ultrasound and Thrombolysis (Protocol: in vitro) 
Subject Frequency Intensity Mode Duty 
Factor 
Sonication 
Time (min) 
Focused / 
Unfocused 
rt-PA Dose Results First Author 
Human skull, 
tube 
a) 33 KHz 
b) 71 KHz 
a) 0.5 W/cm
2
 
b) 3.4 W/cm
2
 
CW  a) 60 
b) 180 
unfocused 1 mL/100 
μg/mL 
Thrombus weight reduction at: 
a) 33 KHz: 51%  
b) 71 KHz: 46% 
Behrens et al. 
1998 [216] 
1 MHz 524 mW/cm2 PW PRF: 
16KHz 
30 Diagnostic 
ultrasound 
1mL/100mg
/mL 
Recanalization 90% - 
100% 
Spengos et al. 
2000 [158] 
120 KHz Pressure:0.35 
MPa 
PW 50% 
PRF= 
1667 Hz 
30 unfocused 0-10 μg/mL 120 KHz UET maximizes 
lytic efficacy while 
minimize rt-PA exposure. 
Shaw et al. 2008 
[167] 
Thrombus in 
Eppendorf 
pipette tip + 
human temporal 
bone 
1.8 MHz 179 mW/cm2 PW transcrania
l pulsed 
wave 
60 diagnostic 
ultrasound 
10 μg/mL thrombus reduction=78.7% Eggers et al. 2009 
[166] 
tube 
 
40 KHz 0.25 W/cm
2 
CW  60 unfocused 1.0 mg/mL 
 
Fibrolysis: 
60m: 39% 
120m: 93% 
Suchkova et al. 
1998 [187] 
490.6 KHz 0.13 W/cm2 CW  60 unfocused 1.2 mg Recanalization ratio: 66.7% Ishibashi et al. 
2002 [47] 
500 KHz 0.7 W/cm2 CW  1 unfocused 0.5 mg/mL 
(rt_PA + 
BL) 
Clot reduction: 29% Zenitanni et al. 
2008 [164] 
2 MHz TCD Negative 
Acoustic 
Pressure: 0.5, 
1.7, 3.5 MPa 
PW 10000-
cycles 
(5ms) burst 
60 unfocused 522,000 
IU/mL:  
0.9 mL t_PA 
0.1 mL: PBS 
OR 0.1 mL 
optison 
The presence of stable 
cavitation was verified and did 
not impact the stability of 
alteplase. 
Soltani et al. 2008 
[165] 
1 MHz 2.8 W/cm2 
and 36.8 
W/cm2 
PW 10% 60 HIFU 1.0 mg/mL 
 
volume of the dissolved 
clot: 95.3 mm3 
Hadjisavvas et al. 
2012 
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Administration of gaseous microspheres dramatically lowers the threshold for 
cavitation and increases the lytic activity of ultrasound [181]. Because the bubbles 
are destroyed in the process, they must be constantly injected for complete clot 
dissolution. Recent studies have demonstrated that microbubbles can be 
concentrated at the surface of clot by attaching a glycoprotein 2b/3a receptor 
antagonist, which increases their adherence to acute clot, to the bubbles [182].
 
 
Currently there are few but significant clinical trials: a) The CLOTBUST 
(Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound 
and Systemic Recombinant Tissue-Type Plasminogen Activator (rt-PA)) is a 
phase II randomized multi-center international clinical trial [48]. b) The EKOS 
study [183] which involves the insertion of a catheter is now being tested in phase 
II–III Interventional Management of Stroke (IMS) trials. c). The TRUMBI trial 
[55], using transcranial low-frequency ultrasound-mediated thrombolysis in brain 
ischemia in combination with intravenous administration of tPA, and 4). The 
TUCSON trial [56], a phase I–II randomized placebo-controlled, international 
multi-center study, using perfultren-lipid microspheres (MRX 801, Imarx 
Therapeutics, Inc., Tuscon, AZ) which is underway.
 
 
In this chapter the effect of therapeutic ultrasound was examined using the 
synergy of rt-PA to dissolve clot which is placed in a silicone tube model in vitro. 
In the current study higher intensities were used than what was proposed in the 
study by Alexandrov [184]. It was predicted that by using higher intensities, the 
rate of clot destruction would be accelerated. The previous studies mostly make 
use of unfocused ultrasound [168][169][173], thus the intensity levels that could 
be used were limited. In this study, focused ultrasound was investigated and 
therefore higher intensities can be easily applied provided that thermal effects are 
avoided. Therefore, a parametric study was presented which evaluates the effect 
of ultrasonic intensity, beam size and frequency on the dissolved clot volume. In 
order to achieve sufficient penetration through the skull the frequency of 0.5 MHz 
and 1 MHz was used. Focused ultrasound targeting the clot at the focal point or 
slighter off the focus is used with temporal average in situ intensities ranging from 
2.8 W/cm
2
 to 36.8 W/cm
2
.  Various pulse protocols were investigated having as a 
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goal that the temperature change at the clot does not exceed 1C (called safe 
temperature). Safe temperature was set to 1
0
C in order to avoid tissue damage 
resulting from the long duration (around 60 min) that each treatment requires to 
dissolve the thrombus.The current study will give us a good indication regarding 
the optimum protocol to be used using the proposed MRgFUS. 
 
9.2 HIFU SYSTEM 
Figure 9.1 shows the block diagram of the HIFU system which includes the 
following subsystems: a) Focused ultrasound system b) Artery/tissue/clot model, 
c) Positioning device and d) Temperature measurement.  A description of each of 
the subsystems follows below.  
 
9.2.1 FOCUSED ULTRASOUND SYSTEM 
The ultrasound system consists of a radio frequency (RF) generator/amplifier (100 
W, JJ&A Instruments, Duvall, WA, USA), and a spherically shaped transducer 
made from piezoelectric ceramic of low magnetic susceptibility 
(Piezotechnologies, Etalon, Lebanon, IN, USA). Two transducers were used 
operating either at 0.5 MHz or 1 MHz. Both transducers have focal length of 
10cm and a diameter of 5cm. The transducers were navigated by a 3D positioning 
device (MEDSONIC, Limassol, Cyprus).  The 3D positioning device and the 
transducer were utilized inside an MRI scanner (Signa 1.5 T, by General Electric, 
Fairfield, CT, USA). 
 
9.2.2 ARTERY/TISSUE/CLOT MODEL 
The artery is modelled by a clear silicone tube (United States Plastic Corporation, 
Lima OH, USA), the tissue is modelled by a polyaclylimide gel (ONDA 
Corporation, Sunnyvale CA, USA) and the clot is modelled by using coagulated 
blood.   
 
130 
 
 
Figure 9.1 HIFU system for in vitro sonothrombolysis 
 
Production of sample clots 
Blood clots were obtained by natural coagulation of animal blood samples from 
healthy cows.  Blood was drawn into small containers and placed in a 37° C water 
bath for 3 h and then stored in a refrigerator at a temperature of 5° C for at least 72 
h before use in the experiments to allow complete clot retraction [173]. At the 
end, a decision was made based on observation on which clots to be kept for the 
experiments. Theoretically, good clots appear in dark colour. In addition, clots 
were evaluated based on the test results. 
 
Preparation of rt-PA 
The rt-PA was obtained as a lyophilized powder (rt-PA, Activase, Genentech, San 
Francisco, CA, USA) mixed with sterile water as per manufacturer’s instructions.  
A dose of 1mg/mL was administered. 
 
9.2.3 POSITIONING DEVICE 
A manual positioning device (Velmex inc., Bloomfield NY, USA) was used in 
order to navigate the ultrasound transducer. The transducer was mounted on the 
arm of the 3D positioning device. Figure 9.2 shows the photo of the positioning 
device. 
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Figure 9.2 The positioning device 
 
9.2.4 TEMPERATURE MEASUREMENT 
A data acquisition board (6251 DAQ, National Instruments, Texas, USA) was 
used in order to measure the temperature in the clot.  An analogue input of the 
board is used to capture the temperature. An Omega (M2813-1205, OMEGA 
Engineering, INC. Stamford, Connecticut, USA) voltage to temperature converter 
was used to measure temperature using a software written in MatLab (The 
Mathworks Inc., Natick, MA). Figure 9.3 shows a photo of the temperature 
measurement system. A thermocouple (Omega engineering) was placed in the clot 
to locate the focal point of the transducer during the experiments and to measure 
temperature elevation at the focal point.  
 
Figure 9.3 Photo of the temperature measurement system, the omega 
thermocouple-to-analogue connector, National Instruments data acquisition board, 
and the custom made software 
Omega 
M2813-1205 
Data acquisition 
board, PCI6251 
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9.3 IN VITRO EXPERIMENTS 
Various in vitro experiments were carried out to create thrombolysis.  A silicon 
tube was placed 1cm deep inside the polyaclylimide gel and into the container 
filled with degassed water (figure 9.4).  The clot was placed inside the silicon tube 
which is 1 cm deep in the mimicking tissue.  Transducer of 0.5 MHz and US 
exposure alone (US) was used. Thereafter, a thermocouple was inserted, and place 
exactly at the middle of the clot to monitor temperature elevation. During the 
experiments, temperature was recorded in steps of 0.2s. To locate the focal point 
of the transducer and place it exactly at the centre of the clot, the following steps 
were taken: a) Using the 3D positioning device and by moving it in all three 
directions (X, Y, and Z) the transducer was placed on top of the tube (observed by 
eye).  Then, a ruler was used to measure the distance from the centre of the 
transducers concave surface to the middle of the tube (10 cm). b) Then, the signal 
generator was set to a low power continues wave.  At the same time using the 
positioning device, the transducer was moved in all directions and the temperature 
was monitored. c) During ultrasound exposure, if temperature was maximized at a 
certain point indicated that the focus was aimed at the thermocouple. 
 
The transducer was placed on the arm of the positioning device and was immersed 
in the water tank, thus providing good acoustical coupling between thrombus and 
transducer.  Any bubbles that may have collected under the face of the transducer 
were removed in order to eliminate any reflections. 
 
The same experiments were performed but without the polyaclylimide gel for 
better observation on the thrombus condition. The transducer operating at 1 MHz 
was used. Ultrasound exposure alone (US), rt-PA alone and ultrasound exposure 
combined with rt-PA (US + rt-PA) were used.   
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Figure 9.4 Photo of the HIFU system setup in the Lab 
 
Coagulated blood (2 ml) was inserted from one side of the tube and 1 ml of rt-PA 
from the other side. A thin rod was used in order to push the rt-PA towards the 
clot. The artery/clot/tissue was then placed in the container filled with degassed 
water. The transducer was placed at the bottom of a water container. The 
transducer is energized using low intensity and therefore the disturbance of the 
water (jet) indicates the beam. Then the clot was placed accurately on the focal 
beam. Figure 9.5 shows a photo of the above system. This technique provides a 
very fast and accurate placement of the clot in the focal beam. The ultrasound 
temporal average in situ intensity ranged between 2.8 W/cm
2
 and 36.8 W/cm
2
, 
with a duty factor (DF) of 10% and pulse repetition frequency (PRF) of 1 Hz. The 
ultrasound energy was applied for 60 minutes. 
  
Omega 
M2813-1205 Data acquisition 
board 
RF amplifier 
Signal 
generator 
Positioning 
device 
(X,Y,Z) 
Transducer 
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Figure 9.5 Photo of the artery/clot system 
 
9.4 RESULTS 
The goal in this study was to control temperature elevation and to have maximum 
ΔΤ not to exceed the 1C limit.  In order to achieve that various pulsed protocols 
were investigate (table 9.1). Figure 9.6 shows how temperature behaves at the 
centre of the clot under the sonication parameters used in table 9.2. Keeping the 
same power (5W) but tripled the duty factor, the maximum ΔΤ is also tripled (see 
figure 9.6A and 9.6B).  Changing the power from 5W (figure 9.6A) to 10W 
(figure 9.6C) and leave the duty factor the same (10%) the maximum ΔΤ is also 
doubled its value.  Using the same power (10W) but decreasing the duty factor to 
half, the maximum ΔΤ drops from 5C to 3C.  ΔΤ is dropped only by 2C (and 
not 2.5C as in previous case) because PRP was increased from 1 ms to 1 s.  Also, 
by doubled the power and keeping duty factor (5%) and PRP (1s) the same (figure 
9.6D-9.6E), then the maximum ΔΤ was increased from 3C to 5C.  Figure 9.7 
summarizes the changes in temperature elevation (ΔΤ) with respect to power, duty 
factor, and PRP. 
 
Table 9.2 Various sonication parameters 
Case Acoustical 
Power (W) 
Duty 
Factor 
(DF) 
Pulse Repetition 
Period (PRP) 
Count Temperature 
elevation (ΔΤ) 
1 5 10% 1 ms 100 <3C 
2 5 30% 1 ms 300 >3C 
3 10 10% 1 ms 100 >3C 
4 10 5% 1 s 50000 <3C 
5 20 5% 1 s 50000 >3C 
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Ultrasound alone did not manage to liquefy the thrombus. Even though the 
acoustic power was increased from 5W to 30W and duty factor from 5% to 50%, 
the size of the thrombus remained unchanged.  No alterations occurred regarding 
the size of the thrombus.  The same experiment was repeated for different values 
of acoustic power and duty factor.  Table 9.3 shows the sonication parameters 
used in the experiments.  Because of the very high duty factor used, temperature 
elevation was always above 1C. 
 
Table 9.3 Sonication parameters (without rt-PA) 
Power 
(W) 
Acoustical 
Power (W) 
Duty Factor 
(DF) 
Pulse Repetition 
Period (PRP) 
Thrombus size 
10 5 30% 1 ms unchanged 
10 5 50% 1 ms unchanged 
20 10 40% 1 ms unchanged 
40 20 30% 1 s unchanged 
60 30 20% 1 s unchanged 
 
Figure 9.8 shows the silicone tube, which includes the clot (left), rt-PA (right) and 
dissolved clot (red colour). This was the effect of applying focused ultrasound for 
60 minutes using frequency of 1 MHz, PRF of 1 Hz and duty factor of 10%. 
Approximately 6 mm of the clot was dissolved. The volume of the dissolved clot 
was 95.3 mm
3
.  There was no generation of large amounts of clot fragments, 
which are undesirable therapeutically, because they could obstruct distal small 
arteries if used in humans. 
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Figure 9.6 D; A P=5 W, DF=10%, PRP=1ms; B. P=5 W, DF=30%, PRP=1 ms; C. 
P=10 W, DF=10%, PRP=1 ms; D. P=10 W, DF=5%, PRP=1 s; E. P=20 W, 
DF=5%, PRP=1 s. 
A 
B 
C 
D 
E 
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Figure 9.7 Temperature elevation vs power, duty factor, and PRP 
 
 
Figure 9.8 Silicone tube showing the clot (left), the rt-PA (right). The dissolved 
clot which is between the inserted clot and rt-PA appears in red colour. 
 
Figure 9.9A shows the effect of spatial average temporal average (SATA) in situ 
intensity on the volume of the dissolved clot with frequency of 1 MHz, duty factor 
of 10%, and PRF of 1 Hz. As the intensity increases the volume of the dissolved 
clot increases. Going to higher intensities, there is a risk of heating the clot 
(thermal ultrasound).  For this specific experiment, using intensity below 20 
W/cm
2
 achieves a safe temperature (below 1º C) according to the thermocouple 
measurement. Figure 9.9B shows the effect of transducer beam area on the 
volume of the dissolved clot with frequency of 1 MHz, duty factor of 10%, and 
pulse repetition frequency of 1 Hz. The beam area of 20 mm
2
 represents the case 
when the clot was placed on the focal beam. To achieve the 60 mm
2
 beam area 
(derived from simulations), the clot was placed 1cm off the focus, thus achieving 
this large area. In both cases, the same in situ intensity (SATA) was used in the 
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target.  Figure 9.9C shows the effect of the frequency on the volume of the 
dissolved clot using intensity of 36.8 W/cm
2
, duty factor of 10%, and PRF of 1 
Hz. A higher frequency (1 MHz) transducer has a narrow beam (around 1–2 mm) 
and therefore achieves less thrombolysis than a lower frequency (0.5 MHz) 
transducer. 
 
When rt-PA was used alone, under the same parameters used in US+rt-PA, the 
total amount of the dissolved thrombus was around 40%. Figure 9.9D compares 
the two types of treatment after 60 min exposure and under different intensities. 
 
 
 
A  
  
B  
Thermal limit 
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C  
 
 
D  
Figure 9.9 A. The effect of temporal average in situ intensity (SATA) on the volume 
of the dissolved clot with frequency of 1 MHz, duty factor of  10%, and PRF of 1 Hz.; 
B. The effect of transducer beam area on the volume of the dissolved clot with 
frequency of 1 MHz, duty factor of 10%, and PRF of 1 Hz. For both beam areas the 
same temporal average in situ intensity was used; C. The effect of frequency on the 
volume of the dissolved clot using temporal average in situ intensity of 36.8 W/cm
2
, 
duty factor of 10%, and PRF of 1 Hz; D. Comparison between US+rt-PA and rt-PA 
on the total dissolved clot volume after 60 min exposure. 
 
 
 
 
Thermal limit 
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9.5 DISCUSSION 
The results in this study demonstrate the ability of the HIFU system to dissolve 
clots in combination with rt-PA.  The main task in this parametric study is to 
evaluate the effect of intensity, beam area and frequency on the volume of the 
dissolved clot, while maintaining temperature change at the clot below 1C. 
 
In this study, we have shown that higher intensity results to higher volume of 
dissolved clot, but there is a limit of the intensity to be used in order to avoid 
heating of the clot and the surrounding tissue. The goal in this study was to 
achieve temperature elevation not exceeding 1ºC. With lower intensity, the 
volume of the dissolved clot is lower which means longer treatment time. This is a 
limiting factor since for the potential use of this system (treatment of ischaemic 
stroke), time is limited to around 3 hours. With the parameters used in the 
experiment of figure 9.9A it was found that the maximum temporal average in situ 
intensity to use is around 20 W/cm
2
. It was found that the larger the beam area the 
larger the dissolved clot volume. Finally, the lower the frequency, the larger the 
volume of the dissolved clot (figure 9.9C). High frequencies have poor skull 
penetration and a small beam size at the focus, while low frequencies have better 
skull penetration but with the risk of reaching the unpredictable effect of 
cavitation.  
 
The importance of minimizing the thermal effects by monitoring and controlling 
the temperature is sited in many papers. For example in the study by Ishibashi et 
al. [47] a temperature of 3ºC is reported for a 60 min sonication.  In another study 
by Kornowski et al. [174] a temperature of 7º C is reported for a sonication of 60 
minutes which could possibly produce thermal heating if the same protocol was 
applied in humans. In the study by Francis et al. [185], the effect of intensity on 
temperature was demonstrated. By using ultrasound to dissolve clots with 
intensity of 8 W/cm
2
 the temperature produced was 3º C, whereas by decreasing 
the intensity to 2 W/cm
2
 the resulting temperature was 1º C. 
 
The effect of increased fibrinolysis due to increased intensity was shown by 
several studies using unfocused ultrasound.  Also, in the study by Suchkova et al. 
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[186] it was shown that fibrinolysis increases dramatically with intensity and 
above 1 W/cm
2
 no more significant increase is observed.  In the study by 
Suchkova et al. [186] increased fibrinolysis with ultrasound was achieved with 
minimal mechanical disruption of the clot, indicating that enhancement of clot 
dissolution is due primarily to accelerated enzymatic action.  The same trend of 
fibrinolysis due to increased intensity was also seen by Francis et al. [185], 
Suchkova et al. [187] and Nedelmann et al. [188], which were demonstrated that 
fibrinolysis is dependent on the applied ultrasound intensity and on the exposure 
time. The effect of rt-PA dose, repletion frequency and duty factor was already 
shown by Suchkova et al. [187] and therefore not explored in the present study. 
The study by Suchkova et al. [187] and Holland et al. [173] have shown that 
statistically significant enhancement of the fibrinolysis rate was achieved even 
with a 1% duty cycle. The ultrasound efficacy with duty cycles of 10% or less tell 
us that ultrasound quickly produces a change in the clot that persists for a 
significant time after the sound is turned OFF. 
 
In the present study we have used ultrasound and rt-PA alone. Significant 
improvement in the efficacy of this technology could be achieved by using 
microbubbles as it was recently shown by Datta et al. [189] provided that 
uncontrolled cavitation effects are avoided. Even though the ultrasound intensities 
used to achieve a significant thrombolytic effect were relatively low, the safety 
and efficacy of ultrasound thrombolysis requires a careful evaluation in animal 
models, regarding the biological side effects of ultrasound in brain tissue, 
especially if cavitation exists. 
 
For therapeutic applications in the brain, noninvasive external application of 
ultrasound compared to endovascular use of ultrasound [190] has greater 
potential, because it requires neither angiography nor selective catheterization 
[186]. It eliminates the risk of vessel wall damage by the catheter, and it could be 
used for small vessels or vessels that are inaccessible for catheterization. 
 
The results presented in this study correspond to targets that are 1 cm deep. If this 
technology is applied to humans with target ranging from 3-8 cm [188], then to 
get the same intensity (or pressure) as in the 1 cm case (covered by this chapter), 
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one has to increase the power, which might cause excess tissue heating. Therefore, 
the only controlling parameter to reduce the heating is to lower the duty factor. 
Thus, the application of this technology in humans requires extensive parametric 
studies (including intensity, frequency, duty factor, pulse repetition frequency, and 
exposure time) in order to avoid thermal heating. The successful application of 
FUS to improve fibrinolytic therapy in clinical settings will depend critically on 
the choice of ultrasound parameters to maximize fibrinolytic enhancement, while 
limiting unwanted adverse effects such as heating and cavitation. The results 
reported here point to the use of frequency around 0.5 MHz and pulsing to 
optimize thrombolysis and skull penetration and at the same time avoiding 
unwanted heating. Table 9.4 presents a summary of the parameters used for the 
recommended HIFU system. 
Table 9.4 Summary of the recommended HIFU system 
Frequency 
(MHz) 
Intensity 
(W/cm
2
) 
Pulse Duration 
(min) 
Transducer 
Beam 
Duty Factor 
(DF) 
ΔΤ 
1 2.8 - 20 60 At the focus 10% <= 1C 
0.5 36.8 60 At the focus 10% <= 1C 
1 20 60 1 cm off the 
focus 
10% <= 1C 
 
The following chapter presents experiments in vivo. The thrombus model was 
tested in the rabbit carotid and in the ear artery in vivo. Also, the effect of HIFU 
was examined in cooperation with rt-PA to liquefy thrombus which was placed in 
the ear artery of the rabbit in vivo.  
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CHAPTER 10: APPLICATION OF MR-GUIDED 
FOCUSED PULSED ULTRASOUND FOR DESTROYING 
CLOTS IN VIVO USING THROMBOLYTIC DRUGS 
 
10.1 INTRODUCTION 
Stroke is the third cause of death after heart diseases and cancer (see table 2.1). 
Stroke is the number one cause leading to disability. Rt-PA is the only FDA 
approved drug for the treatment of stroke. The therapeutic result of rt-PA is due to 
the opening of canals and the bypassing of the blocked artery and is function only 
to selected patients. However, the success of the method is not yet significant. 
Intracerebral haemorrhages occur within 36 hours in 6.4% of the patients who 
received thrombolytic therapy [192]. 
 
 
Ischaemic stroke is by far the most common kind of stroke, accounting for about 
88% of all strokes. The brain depends on its arteries to bring fresh blood from the 
heart and lungs. When an artery to the brain is blocked then ischaemic stroke 
occurs. If the artery remains blocked for more than a few minutes, the brain cells 
may die. This is why immediate medical treatment is critical. Ischaemic stroke 
can be divided into two main types: thrombotic and embolic. A thrombotic stroke 
occurs when diseased or damaged cerebral arteries become blocked by the 
formation of a blood clot within the brain. In an embolic stroke, a blood clot forms 
somewhere in the body and travels via the arteries to the brain until it reaches a 
vessel small enough to block its passage. 
 
In previous studies, unfocused ultrasound has been proven to accelerate fibrolysis 
and to significantly reduce the size of the thrombus or to restore recanalization 
(table 10.2). In addition, the range of intensity used ranged from 0.2–1.3 W/cm2 
(spatial peak temporal average intensities) and the frequency ranged from 25 kHz 
to 2 MHz using unfocused ultrasound. Table 10.1 sumarizes some of the 
characteristics of ultrasound and thrombolysis derived from experiments in vivo. 
 
In this chapter, the thrombus model was tested in the rabbit carotid and ear artery 
in vivo. Also, the effect of therapeutic ultrasound was examined in cooperation 
with rt-PA to liquefy thrombus which was placed in the ear artery of the rabbit in 
144 
 
vivo. For the first time, HIFU targeting the thrombus at the focal point was used 
with acoustic power of 50W and a frequency of 1 MHz. The goal in this study was 
to investigate the ability of the thrombus to blog the artery and to investigate the 
proposed protocol for its capability to destroy the thrombus. 
 
10.2 FOCUSED ULTRASOUND SYSTEM/ULTRASONIC DOPPLER 
SYSTEM 
The ultrasound system consists of a radio frequency (RF) generator/amplifier (100 
W, JJ&A Instruments, Duvall, WA, USA), and a spherically shaped transducer 
made from piezoelectric ceramic of low magnetic susceptibility 
(Piezotechnologies, Etalon, Lebanon, IN, USA). The transducer used operates at 1 
MHz and has focal length of 10 cm and a diameter of 5 cm. An ultrasonic Doppler 
system (Philips HD7 series Ultrasound Systems, Philips and Neusoft Medical 
Systems Co. Ltd, Shenyang, China) was used to observe the blood flow. 
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Table 10.1: Characteristics of Ultrasound and Thrombolysis (Protocol: in vivo) 
 
Subject Frequency Intensity Mode Duty Factor Sonication 
Time (min) 
Focused / 
Unfocused 
rt-PA Dose Results First Author 
Humans 2 MHz 415 mW/cm2 CW  25m  to 24H TCCD None – aspirin 
250mg 
1 person 
complete 
recanalization, 
83% the rest. 
Cintas et al. 
2002 [217] 
1.8 MHz 179 mW/cm2 PW transcranial 
pulsed wave 
 
60 diagnostic 
ultrasound 
0.9 mg/kg Recanalization: 
With US=57.9% 
Without US: 
22.2% 
Eggers et al. 
2008 [169] 
Rats 185 KHz 1.27 W/cm2 CW  90 unfocused 1mL/100mg/mL 185KHz is 
superior to 1 
MHz diagnostic 
US. 
Behrens et al. 
2001 [216] 
 
25.570 Hz 0.6 W/cm2 PW 20% 60 unfocused 10mg/kg Reduction of 
infract volume 
by 68%. 
Bleeding effects: 
9.3%. 
Daffertshofer et 
al. 2004 [54] 
490 KHz 0.8 W/cm2 CW  60 unfocused 1.2 mg/animal Thrombolysis: 
TUS: 76.2 % 
t-PA: 45 % 
Death: 
TUS: 4.55 % 
t-PA: 4.76 % 
Saguchi et al. 
2008 [168] 
Rabbits 1 MHz 6 W/cm2 PW 10% 60 HIFU 1.0 mg/ml Complete 
Recanalization 
Hadjisavvas et 
al. 2012 
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10.3 ARTERY/TISSUE/CLOT MODEL 
Coagulated blood (thrombus) was inserted through the carotid artery and through 
the ear artery. Blood flow was observed in the brain and in the ear artery before 
and after the insertion of coagulated blood. To observe the blood flow, a Philips 
Ultrasonic Doppler system was used. 
 
Production of sample clots 
Blood clots were obtained by natural coagulation of animal blood samples from 
healthy cows.  Blood was drawn into small containers and placed in a 37° C water 
bath for 3 h and then stored in a refrigerator at a temperature of 5° C for at least 72 
h before use in the experiments to allow complete clot formation [173]. 
 
Preparation of rt-PA 
The rt-PA was obtained as a lyophilized powder (rt-PA, Activase, Genentech, San 
Francisco, CA, USA) mixed with sterile water as per manufacturer’s instructions.  
A dose of 1mg/mL/kg was administered. 
 
10.4 TESTING THE THROMBUS FUNCTIONALITY IN VIVO 
To test the quality of thrombus, New Zealand adult rabbits were used weighting 
approximately 3.5-4 kg. Three rabbits were used in the experiments. The rabbits 
were anaesthetized using a mixture of 500 mg of ketamine (100 mg/mL, Aveco, 
Ford Dodge, IA), 160 mg of xylazine (20 mg/mL, Loyd Laboratories, 
Shenandoah, IA), and 20 mg of acepromazine (10 mg/mL, Aveco, Ford Dodge, 
IA) at a dose of 1 mL/kg. The animal experiments protocol was approved by the 
national body in Cyprus responsible for animal studies (Ministry of Agriculture, 
Animal Services). 
 
The presence of the skull in the ultrasonic path distorts the ultrasonic field by 
reflection and distortion. Therefore, a craniotomy was necessary in order to permit 
unimpeded passage of the sound. The craniotomy should be large enough to 
reveal the whole brain (top view). Figure 10.1 shows the craniotomy and the top 
view of the rabbit brain. For better understanding the structure and location of the 
main brain arteries, CT and MRA images are shown. Figure 10.2 shows a CT 
image of the rabbit’s brain and pointing out the basilar and vertebral arteries 
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[193]. Middle Cerebral Arteries (MCA) were imaged successfully using Magnetic 
Resonance Angiography (MRA). Figure 10.3 shows an MRA image of the rabbit 
MCA.   
 
  
Figure 10.1 A top view of a rabbit brain after a craniotomy was performed. 
 
 
Figure 10.2 a) MRI axial, b) MRI coronal, c) three-dimensional cranial CT of 
basilar and vertebral arteries in rabbit[193] 
Brain tissue 
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Figure 10.3 MRA image of a rabbit MCA 
 
A cut was made at the side of the rabbit neck to extract the carotid (figure 10.4).  
Figure 10.5 shows a photo how the ultrasonic probe is used to scan the blood flow 
on top of the brain and the carotid artery. Figure 10.6 shows the displacement of 
the catheter into the carotid. A 24 G over the needle standard intravenous catheter 
was used. Through the catheter the thrombus (clot) was inserted into the carotid 
and the blood flow was observed in the brain using a Doppler ultrasound. 
 
 
Figure 10.4 Extracting the carotid. 
Carotid 
width=2mm 
1 cm 
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   A     B 
Figure 10.5 A. Ultrasonic imaging probe placed on top of the brain; B. Ultrasonic 
imaging probe placed on the exposed carotid. 
 
 
Figure 10.6 The displacement of the catheter into the carotid.   
 
The ultrasonic probe was placed on top of the brain and continuously monitored 
the blood flow from the moment that the thrombus was injected through the 
catheter until the rabbit died (stroke was the cause of death).   
 
10.5 DETECTION OF THROMBUS USING MRI 
MRI contrast between blood and clot (thrombus) has been tested. Figure 10.7A 
shows a picture of the container made by ABS. The ABS material is MRI 
compatible. Figure 10.7B shows the container before it was placed in the MRI 
scanner (Signa 1.5 T, by General Electric, Fairfield, CT, USA). In the middle of 
the container, there was a canal of 3 mm width simulating an artery. On the same 
path, there was another trunk where the thrombus was placed. On the left and on 
the right of the canal two lamb brains were placed. The general idea was to have 
an artery drawn inside the brain and to investigate the potential of the MRI to 
Catheter 
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distinguish between blood and thrombus. To image the thrombus, T1 and T2 W 
FSE MRI sequence were used (T1-W FSE: TR=500 ms, TE=9 ms and T2-W FSE: 
TR=2500 ms, TE=60 ms). 
 
 
  A     B 
Figure 10.7 A. MRI compatible container; B. Artery/thrombus/brain tissue model. 
 
10.6 THROMBOLYSIS IN VIVO 
10.6.1 COUPLING METHOD 
A new coupling method was used for the in vivo experiments. A long transducer 
holder (figure 10.8) was developed for better accuracy and control when focusing 
the beam. The transducer was mounted on a metallic stand and water was injected 
through one of the 2 holes at the top of the holder (figure 10.9). As the water was 
injected from one hole, air escaped from the other hole. Caution was taken to 
avoid any bubbles inside the holder. A thin membrane was placed at the bottom of 
the holder. For localization, a thermocouple was used. A plastic circular cover 
with a hole in the centre was placed above the thermocouple (figure 10.10). The 
transducer was aligned with the circular cover and then the cover was removed. 
Localization was accurate within 1 mm (figure 10.10). 
 
Figure 10.8 Long transducer holder. 
10 mm 
Canal width=3mm 
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Figure 10.9 Transducer setup showing the two holes on top of the holder.  
 
 
Figure 10.10 Transducer localization. 
 
10.6.2 THROMBUS MODEL 
For the following experiments, both ears of the rabbit had to be shaved (figure 
10.11).  
 
Figure 10.11 Shaving rabbit ears. 
 
Hole #1 
Hole #2 
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There are many ways by which the middle cerebral artery (MCA), the 
external/internal carotid, or any other artery can be blocked in order to provoke 
thrombosis or a stroke in experimental animal models. Some of the methods used 
are: injection of a foreign or autologous thrombus, microemboli, 
electrocoagulation, microvascular clips, etc. Table 10.2 summarizes the most 
popular thrombus models used in animals. 
 
Two different methods of experiments were performed; first to investigate the 
functionality of the thrombus (method A) and second to destroy thrombus using 
focus ultrasound and rt-PA (method B). 
Method A: through the ear artery, 1 ml of thrombus [10] was injected (figure 
10.12) and the blood flow was monitored by a Doppler ultrasound. As soon as the 
thrombus was injected degradation of the blood flow was noticed. A few minutes 
later there was no flow at all (figure 10.20B). The thrombus has totally blocked 
the ear artery. With this method neither ultrasound nor a thrombolytic drug were 
applied. 
Method B: The ear artery was punctured very carefully using a small hammer 
(figure 10.13A). When the artery was damaged (injured), the clot started to 
construct (figure 10.13B). At the same time, the blood flow was monitored using 
the Doppler ultrasound. Eventually, after 20 minutes, the ear artery was 100% 
blocked. No blood flow was observed (figure 10.21B). 
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Table 10.2: Thrombus model in animals 
Thrombosis 
Models 
Animal Model of injection / 
Method(Area) 
Thrombus formation Ref. 
Ferric chloride-
induced 
thrombosis  
Rats carotid-artery thrombus formation by 
chemical damage to the vessel 
wall via topical administration 
of FeCl3 
Heran et al 
[194] 
Venous  Rats inferior vena cava induce stasis of blood in the 
inferior vena cava 
Sato et al 
[195] 
Arteriovenous 
Shunt Model  
Rats, 
Rabbits 
placed in-line between the 
carotid artery and the 
jugular vein 
formation of a “mixed” 
thrombus (platelet and fibrin-
dependent) 
Wiley et al 
[196], 
Wong et al 
[197] 
Disseminated 
Intravascular 
Coagulation  
Rats, 
Mice 
 Systemic thrombosis or 
disseminated intravascular 
coagulation (DIC) 
Yamazaki 
et al [198] 
Wessler Rabbit 
Model  
Rabbits  jugular vein a stasis is produced in the 
jugular vein and a 
thrombogenic substance, such 
as thrombin, is placed in the 
stasis “pouch” 
Wessler et 
al [199] 
Thrombin-Induced 
Rabbit Femoral-
Artery 
Thrombosis  
Rabbits A clot is introduced into 
an isolated segment of 
femoral artery 
by injection of thrombin, 
calcium chloride, and fresh 
blood via a side branch 
Shebuski et 
al [200] 
Folts Coronary 
Thrombosis 
Model.  
Dogs, 
Rabbits  
stenosed coronary arteries 
of open-chest femoral or 
carotid artery 
Partial obstruction of the 
coronary artery with a plastic 
Lexan cylinder results in episodic 
cyclical reductions in coronary 
blood flow that are caused by 
platelet-dependent thrombus 
formation 
Folts et al 
[201] 
Copper Coil-
Induced Canine 
Arterial 
Thrombosis  
Dogs The spiral was inserted 
through the coronary-vessel 
wall in open-chest dogs. 
Insertion of the 
thrombogenic coils via the 
left carotid artery under 
fluoroscopic guidance in 
closed-chest dogs 
spiral wires constructed of 
aluminum-magnesium alloy 
inserted into the coronary 
circulation of dogs to produce 
slowly developing occlusive 
thrombi 
Blair et al 
[202], 
Kordenat et 
al [203] 
Canine femoral 
arterial  
Dogs, 
Rabbits 
uses the same 
thrombogenic coils, but 
does not require 
fluoroscopy 
 Bush et al 
[204] 
Thrombin-Induced 
Clot Formation in 
the Canine 
Coronary Artery  
Canine coronary-artery 
thrombosis 
The vessel was intentionally de-
endothelialized by external 
compression with blunt forceps 
Gold et al 
[205] 
Injury-Induced 
(Electrolytic) 
Arterial 
Thrombosis in the 
Canine  
Dogs electrode was placed 
directly into the coronary 
artery of an open-chest, 
anesthetized dog 
anodal current was delivered to 
the intravascular lumen of a 
coronary artery in the dog via a 
stainless-steel electrode 
Romson et 
al [206] 
Arteriovenous 
Shunt Model in 
Baboons  
Baboons exteriorized chronic 
arteriovenous shunt 
a thrombogenic segment is 
placed in an exteriorized 
chronic arteriovenous shunt 
Todd et al 
[207] 
Venous 
Thrombosis 
Cats, 
Baboons 
 rely primarily on stasis in which 
blood flow is interrupted for 
varying periods of time to induce 
clot formation 
Eppehimer 
et al [208], 
Wakefield 
et al [209] 
Rabbit Auricular 
artery 
Rabbits Direct injection of 1 ml of 
thrombus 
Artery was carefully 
injured 
Thrombus was injected into the 
auricular artery 
Thrombus formation after 20min 
Hadjisavva
s et al. 
2012 
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Figure 10.12 injection of the thrombus. 
 
   A      B 
Figure 10.13 A. Creation of clot (thrombus) using a hammer; B. Clot formation. 
 
Once the blockage of the ear artery was confirmed using the Doppler ultrasound 
(no blood flow was observed), then the ultrasound and rt-PA (US + rt-PA) therapy 
was applied. Figure 10.14 demonstrates the localization method used on the 
rabbits ear. The thermocouple was only used to find the focal point. The focal 
point was found when temperature rose fast during continuous ultrasound 
exposure and dropped fast when the ultrasound exposure was turned off. A 
1mg/ml/kg rt-PA was injected in the ear artery (figure 10.15A). Then, a 60 min 
ultrasound exposure using 50W of acoustic power, pulse rate of 10 Hz, frequency 
of 1 MHz and duty factor of 10% was applied. Figure 10.15B shows the setup of 
the ultrasonic system. 
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   A      B 
Figure 10.14 A. Thermocouple placements on clot for localization; B. Transducer 
target for quick localization 
 
 
 
   A      B 
Figure 10.15 A. injection of rt-PA; B. Ultrasonic system setup. 
 
 
10.7 RESULTS 
 
Currently available MRI methods to determine arterial occlusion are depended on 
different parameters such as blood flow, blood longitudinal relaxation time and 
sequence parameters [210]. Signal intensity, which is based on these parameters, 
may make analysis of thrombolysis complicated. Even though different 
publications by Johnstone et al [211], Corti et al [212] and Schmitz et al [213] 
have demonstrate the ability of the MRI to point out the location of a thrombus, 
some others such as Johansson et al [214] and Peter et al [215] have shown the 
difficulty of differentiating between the blood and thrombus. Corti et al. [204] 
have demonstrated that MRI sequences (T1-W and T2-W) have the potential to 
image thrombus at the carotid. Thrombotic and normal carotid arteries were 
identified correctly in the axial images using black-blood technique. Figure 10.16 
shows the axial black-blood T2-W MRI image of a 24-hour-old thrombus.  
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The potential of the MRI to distinguish between blood and clot in a custom-made 
system using MRI T1 W FSE and T2 W FSE, values of blood and clot are similar 
and therefore contrast is very poor. Figure 10.17 demonstrates that the contrast 
between blood and clot is the same. 
 
Figure 10.16 A. axial black-blood T2-weighted magnetic resonance images 
showing a 24-h old thrombus; B. the arrows indicate the thrombus in the injured 
right carotid artery, and the asterisk indicates the non injured left carotid artery; C. 
the appearance of the thrombus on the magnetic resonance image correlates 
closely with the matched histologic section shown in C (Corti et al. [212]). 
 
 
  A     B 
Figure 10.17 MRI images A. using T1 FSE; B. using T2 FSE. 
 
Using Doppler ultrasound, images of the blood flow at the brain tissue and at the 
carotid were captured.  Figure 10.18A demonstrates scan images of the blood flow 
brain 
blood 
clot 
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at the carotid and figure 10.18B demonstrates scan images of the blood flow at the 
top of the brain, both before the thrombus injection.  
  
A 
  
B 
Figure 10.18 Blood flow using Doppler ultrasound; A. At the carotid; B. At the top of the 
brain. 
 
Figure 10.19 show scan images of the blood flow in the brain after the thrombus 
was injected into the carotid via a catheter.  It was observed that the blood flow 
was decreasing with respect to time and in approximately 2 ½ minutes there was 
no flow at all causing death. 
 
Using method A, when 1 ml of thrombus was injected in the ear artery, a similar 
behaviour occurred as when it was placed in the carotid. The Doppler ultrasound 
was placed on the ear artery before and after the thrombus to monitor the blood 
flow. Ten minutes after the injection of the thrombus, the ear artery was totally 
blocked. Figure 10.20 show scan images of the blood flow at the ear artery before 
and after the injection of the thrombus. 
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A B 
  
C D 
Figure 10.19 Blood flow after the injection of a thrombus using a Doppler ultrasound;  
A. after 1 min; B. after 1½ min; C. after 2 min; D. after 2½ min 
 
 
 
   A      B  
Figure 10.20 Blood flow; A. before the thrombus injection; B. after the thrombus 
injection. 
 
 
Using method B, as soon as the artery was totally blocked the thrombolytic drug 
(rt-PA) was injected and ultrasound exposure (US) was initiated. Figure 10.21A 
shows a scan image of the blood flow at the ear artery before the creation of the 
thrombus, figure 10.21B shows the blood flow after the obstruction of the artery 
from the thrombus, and figure 10.21C shows the blood flow after 
sonothrombolysis (US + rt-PA) was applied. 
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   A      B 
  
   C    
Figure 10.21 Blood flow; A. before thrombus creation; B. after artery occlusion; 
C. after sonothrombolysis. 
 
10.8 DISCUSSION 
The results in this study demonstrate the ability of the ultrasonic system to 
evaluate the quality of the thrombus and to dissolve the thrombus in combination 
with rt-PA. It was shown that when a thrombus (coagulated blood) was inserted 
via catheter in the exposed carotid artery (figure 10.6) the blood flow was blocked 
in the brain and within 2 to 3 mins the rabbit died due to a stroke. In order to test 
the functionality of the thrombus on a different artery (ear artery), the same but 
smaller amount of thrombus was used. The thrombus was injected in the ear artery 
(figure 10.12) and the blood flow was observed using a Doppler ultrasound. After 
10 mins, there was no indication of blood flow at the ear artery. Therefore, 
coagulated blood is a good model for clot since it can cause a stroke. 
 
To create a clot model, a different technique was also used (see method B). The 
ear artery was injured using a small hammer. Monitoring the blood flow at all 
times, it was noticed that in approximately 20 mins after the creation of the 
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trauma, there was no blood flow at all. Therefore, both methods proved to be 
sufficient for creating a clot model. 
 
MRI T1 W FSE and T2 W FSE sequence were used to image the thrombus in an 
in vitro experiment. The values of blood and clot are very similar and therefore 
contrast is poor. This is a limiting factor since the potential use of the MRI system 
towards the treatment of ischaemic stroke is inadequate. 
 
The new coupling technique was proven easy and functional. The transducer 
could be easily rearranged either manually or automatically (placed on control by 
a computer robot) anywhere on the animal. Coupling was excellent in avoiding air 
bubbles to stand between the transducer and the tissue. Focusing the beam 
sometimes it was time consuming. With this simple method, focusing was done 
fast and accurately. 
 
The main goal in this study was to dissolve the thrombus using sonothrombolysis. 
Ultrasound and rt-PA (US + rt-PA) were used alone. With the parameters used in 
the experiment of figure 10.15 it was found that the thrombus was completely 
dissolved. Blood flow was resumed as it was before the creation of the thrombus. 
Table 10.3 presents a summary of the parameters used for the recommended 
HIFU system. 
 
Table 10.3 Summary of the recommended HIFU system 
Frequency 
(MHz) 
Intensity 
(W/cm
2
) 
Pulse Duration 
(min) 
Duty Factor 
(DF) 
Mode Pulse 
Rate 
1 6 60 10% PW 10 H 
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CHAPTER 11: CONCLUSION AND FUTURE WORK 
11.1 CONCLUSION 
The aim of this thesis was to develop a HIFU system that is guided with MRI 
imaging for two brain applications (cancer and stroke) and to perform in vitro 
(freshly excised lamb brain) and in vivo (rabbit brain) studies in order to 
investigate thermal protocols created by HIFU, or mechanical protocols 
(thrombolysis) using HIFU in combination with thrombolytic drugs. Such 
research will shed more light in how we can utilise HIFU in the treatment of brain 
tumours and in the treatment of stroke. 
 
In this study, it was found that for low temperatures the change in attenuation was 
insignificant.  The attenuation vs. temperature study alone does not give a sound 
physical explanation of the effect of heating.  The time the temperature was 
maintained (estimated using the thermal dose) gives more information on the 
physical changes in tissue.  The attenuation vs. thermal dose trend shows that the 
attenuation starts to increase in soft tissues for doses in the range of 100-1000 min 
(thermal dose referenced to 43 C).  This proves that when the thermal dose 
threshold of necrosis was reached the tissue attenuation starts to increase. In lamb 
brain, temperature and thermal dose showed similar behaviour with those seen in 
the attenuation study. Thus, the change of attenuation with temperature was 
dominated primarily by the absorption. During the application of short pulse 
ultrasound the temperature elevation depends primarily on the ultrasonic source 
parameters (intensity and pulse duration), and on the absorption of the tissue.  The 
ultrasonic source parameters are accurately determined and controlled.  Thus, the 
tissue absorption remains the key factor for determining the tissue temperature.  
Moreover, for high intensity applications where the tissue temperature is typically 
50-100C, the change in absorption with temperature can be the dominant factor 
for understanding temperature trends.   
 
The simulated temperature was in good agreement with the experimental 
temperature during HIFU exposures.  During the decaying part, the experimental 
one was higher than the simulated.  When the power was off, conduction was the 
dominant factor for the temperature change, therefore the difference between the 
162 
 
experimental and simulated temperature was attributed to uncertainty in 
conductivity. By calculating attenuation and absorption, it was possible to 
calculate the temperature elevation at the focal point inside the tissue.  The 
prediction of lesion size requires the knowledge of the thermal dose that causes 
necrosis.  The aim was to predict the lesion size based on the intensity used on the 
resulting tissue temperature at the focal point. This quantity allowed us to execute 
a theoretical study to investigate the effect of various physical parameters on the 
size and shape of the lesions for brain tissue. 
 
The simulation results gave us a good indication regarding lesion size (length and 
width) and temperature elevation in brain tissue.  Based on the simulation results 
the transducers were developed. The simulation results suggested that the lesion 
size could be controlled by adjusting the duration of the sonication and by 
adjusting the amount of the acoustic power. Also, depending on the focal depth (5 
cm and 1 cm deep into the tissue), the lesions size could be increased or 
decreased.  When the focal point was closer to the skin, then the lesion width was 
increased and the lesion length was decreased. 
 
This is the first study, demonstrating creation of large lesions both in vitro and in 
vivo in brain formed by scanning the transducer in grid formation. Both thermal 
and bubbly lesions were monitored successfully using all three MRI sequences 
(T1-W FSE, T2-W FSE and FLAIR) with excellent contrast, proving the potential 
of HIFU to treat reliably tumours in the brain in the future. The proposed system 
effectively creates large lesions in brain and at the same time, these lesions are 
effectively monitored using MRI enabling the accurate determination of the 
margins of these lesions, especially when using T1-W FSE. The length of the 
lesions created in in vivo, measured parallel to the ultrasonic beam (i.e. deep in the 
brain), was much higher than the length in in vitro, proving that the penetration in 
the in vitro brain is limited by reflection due to trapped bubbles in the blood 
vessels. 
 
Previous literature demonstrated that lesions can be monitored with excellent 
contrast in rabbit brain (in vivo) using T1-W FSE with TR=500 ms. The lesions 
imaged in the previous studies and also in this study appeared bright with T1-W 
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FSE, whereas brain tissue appeared gray. However, in the previous studies only 
thermal lesions were shown. In this study, the use of MRI was explored 
extensively to image both lesions created under thermal mechanisms and 
mechanisms that create bubbly lesions (cavitation or boiling). The contrast 
between lesion and brain tissue out of the three pulse sequences used was found to 
be best with T1-W FSE. The signal intensity of the brain tissue is homogeneous 
when using this method, and therefore the contrast with thermal lesions or with 
bubbly lesions is excellent. Best contrast is observed for TR above 500 ms. This 
was proved by plotting the CNR vs. TR.  The relaxation time T1 of thermal 
lesions increases, and therefore lesions appear brighter than brain tissue. 
  
The three MRI pulse sequences T1-W FSE and T2-W FSE and FLAIR were all 
able to detect lesions. This advantage was attributed to the significant difference 
in signal intensity between the thermal or bubbly lesions and brain tissue. It was 
observed that bubbly lesions appeared darker than thermal lesions. Bubbly lesions 
appear dark, due to the air spaces resulting from cavities. This study has 
demonstrated that non-degassed excised tissue is a good model for easily initiating 
cavitation. This model of cavitation might not be of any significance for clinical 
use since the cavitation threshold in live tissue was very different from the 
threshold in the in vitro tissue. However, this model of initiating cavitation was 
very useful for studying the MRI appearance of bubbly lesions. Cavitation was 
initiated if a blood vessel (which might include trapped bubbles) was targeted. 
Thus, the nature of lesion (thermal or cavitation) in brain in vitro primarily 
depends on the nature of the target and secondarily to the level of intensity. 
Therefore, in conclusion, it has been demonstrated that tumours could respond to 
HIFU and MRI could monitor these changes. 
 
In addition, the simulation results provide a good indicator of temperature 
elevation at the focal point during the treatment of a stroke using pulsed focused 
ultrasound. The temperature increases as a function of applied power with the rate 
of increase dependent upon the duty factor and frequency.  The temperature 
elevation was simulated for different power and duty factor. It was found that the 
temperature increased linearly with duty factor. The higher the power the lower 
the duty factor needed to keep the temperature change within the safe limit of 1ºC. 
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Also, the higher the frequency the lower the duty factor needed to keep the 
temperature change to the safe limit of 1ºC. This simulation model has provide us 
with the values needed for the acoustic parameters such as frequency, power, duty 
factor and pulse repetition frequency during the application of pulse ultrasound at 
various depths in tissue so that safe temperature (1ºC) is maintained during the 
treatment. 
The ability of this HIFU system to dissolve clots in combination with rt-PA in an 
in vitro model was also demonstrated.  The main task in this parametric study was 
to evaluate the effect of intensity, beam area and frequency on the volume of the 
dissolved clot, while maintaining temperature change at the clot below 1C. It was 
shown that higher intensity results to higher volume of dissolved clot. However, 
there was a limit of the intensity to be used in order to avoid heating of the clot 
and the surrounding tissue and to achieve temperature elevation not exceeding 
1ºC. With lower intensity the volume of the dissolved clot was lower which meant 
longer treatment time. This is a limiting factor since for the potential use of this 
system (treatment of ischaemic stroke), time is limited to around 3 hours. It was 
also found that the maximum temporal average in situ intensity (SATA) to use is 
around 20 W/cm
2
. It was also found that the larger the beam area the larger the 
dissolved clot volume. Finally, the lower the frequency, the larger the volume of 
the dissolved clot. The ultrasound efficacy with duty cycles of 10% or less tell us 
that ultrasound quickly produces a change in the clot that persists for a significant 
time after the sound was turned OFF. In the present study, ultrasound and rt-PA 
alone was used. Even though the ultrasound intensities used to achieve a 
significant thrombolytic effect were relatively low, the safety and efficacy of 
ultrasound thrombolysis requires a careful evaluation in animal models, regarding 
the biological side effects of ultrasound in brain tissue, especially if cavitation 
exists. 
 
The ability of this HIFU system to dissolve clots in combination with rt-PA in an 
in vivo model was also proven. In this study, the ability of the ultrasonic system to 
evaluate the quality of the thrombus and to dissolve the thrombus in combination 
with rt-PA was demonstrated. The thrombus was injected in the ear artery and the 
blood flow was observed using a Doppler ultrasound. After 10 mins there was no 
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indication of a blood flow at the ear artery. A different technique was also used to 
create thrombus. The ear artery was injured using a small hammer and the blood 
flow was monitored. It was noticed that in approximately 20 mins after the 
creation of the trauma, there was no blood flow at all. Therefore, both methods 
provided, are very good for creating a thrombus. 
 
The main aim was to dissolve the thrombus using sonothrombolysis. Ultrasound 
and rt-PA were used alone. For 60 min ultrasound exposure using 50W of 
acoustic power, frequency of 1 MHz, pulse rate of 10 Hz, and duty factor of 10% 
thrombus was completely dissolved. Blood flow was resumed as it was before the 
creation of the thrombus. 
 
Finally, the ability of a single element HIFU to penetrate through a human skull 
was tested. The goal was to provide preliminary evidence as for the trust of the 
mechanism that was used, first to monitor the temperature at the focal point with 
and without the skull and second to investigate the ultrasound propagation through 
a skull phantom.  It was proven that higher frequency has poor skull penetration 
and a small beam size at the focus, while low frequencies have better skull 
penetration but with the risk of reaching the unpredictable effect of cavitation. It 
was demonstrated that using a frequency of 0.5 MHz versus 1 MHz, ultrasound 
propagation through the phantom skull was higher.  With these low changes of 
temperature, the conduction effect was small and therefore this temperature 
change was related to intensity. Therefore, with 0.5 MHz approximately 60% of 
the ultrasonic intensity propagates. Finally, it was found experimentally using 
MRI (detection of temperature using FSPGR) that this system has the ability to 
penetrate the skull especially if the frequency is around 0.5 MHz. 
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11.2 FUTURE WORK 
The proposed system in this research successfully creates large lesions in the brain 
and at the same time, these lesions are successfully monitored with excellent 
contrast using MRI (T1-W FSE) enabling the accurate determination of the 
margins of these lesions. In addition, the successful application of FUS to improve 
fibrinolytic therapy in clinical settings will depend critically on the choice of 
ultrasound parameters to maximize fibrinolytic enhancement, while limiting 
unwanted adverse effects such as heating and cavitation. The results reported in 
this study point to the use of frequency around 0.5 MHz and pulsing to optimize 
thrombolysis and skull penetration and at the same time avoiding unwanted 
heating. For treating tumours located deep in the brain and for dissolving 
thrombus causing an acute ischaemic stroke, further extensive clinical studies will 
be needed before this technology is applied to humans.  
 
There is a scope for future work utilizing this HIFU technology such as: 
 The investigation of the capability of HIFU in destroying tumours located 
deep in the brain. This can be accomplished by conducting experiments in 
animals with larger brains than the ones used in this research such as pigs or 
lambs. 
 
 The determination if  tumours are totally destroyed after a HIFU therapy is 
still uncertain. Adding MR spectroscopy (MRS) to the present system (HIFU 
and MRI) will make it more trustworthy. MRS has the potential to provide 
metabolic evidence of tumour activity that may be an important guide for 
therapeutic decisions. MRS can distinguish cancerous tissue from healthy 
tissue. Eventually, MRS will replace the more invasive needle biopsy. Even 
though the existing systems are quite mature as far as therapeutic ultrasound is 
concerned, they present the disadvantage that even with the use of MRI there 
is an uncertainty that all the cancerous cells are destroyed. The proposed 
ultrasonic system will make use of an MRS in order to distinguish what 
substances of tissue are damaged by thermal ablation. 
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 The efficiency of therapeutic ultrasound in cooperation with rt-PA to liquefy 
thrombus in vivo was examined only in the ear artery of the rabbit. Further 
studies are required in order to examine when thrombus is injected or formed 
at different arteries such as the carotid or the femoral artery and to investigate 
the potential of the current system to effectively dissolve the thrombus. To 
avoid removing a piece of the skull, a phased array system will be also utilised 
combined with rt-PA to investigate its ability of dissolving the thrombus when 
a brain artery such as MCA or basillar or vertebral artery is blocked. 
 
 The success of a HIFU system combined with rt-PA to dissolve thrombus 
demonstrated in this research by protecting the structure of the artery must be 
confirmed with histological analysis during which the absence of internal wall 
rupture will be verified. Histology on the rabbit’s ear artery will be performed 
to investigate the structure of the artery after HIFU exposures. The 
macroscopic study will verify whether any of the samples has any evidence of 
tissue rupture after a HIFU treatment. 
 
 
 
 
168 
 
REFERENCES 
 
[1] John G. Lynn, Raymund L. Zwemer, Arthur J. Chick, and August E. Miller. “A 
New Method For The Generation And Use Of Focused Ultrasound In 
Experimental Biology”. The Journal of General Physiology. 1942; 26, 179-193. 
[2] Fry FJ: “Precision high intensity focusing ultrasonic machines for surgery” 
AmJ Phys Med. 1958; 37:152–156. 
[3] Fry WJ, Mosberg WH Jr, Barnard JW, Fry FJ. “Production of focal destructive 
lesions in the central nervous system with ultrasound”. J Neurosurg. 1954; 
11:471–478. 
[4] Jolesz FA, Hynynen K. “Magnetic resonance image-guided focused ultrasound 
surgery”. Cancer J 8 [Suppl 1]:S100–S112, 2002. 
[5] Jolesz FA, Hynynen K, McDannold N, Tempany C. “MR imaging-controlled 
focused ultrasound ablation: A noninvasive image-guided surgery”. Magn 
Reson Imaging Clin N Am. 2005; 13:545–560. 
[6] Human Anatomy and Physiology, Fifth Edition. Elaine N. Marieb, 
Benjamin/Cummings, 2000. 
[7] The Human Brain: An Introduction to Its Functional Anatomy, Fifth Edition. 
John Nolte, Mosby, 2002. 
[8] http://www.rightdiagnosis.com/  
[9] http://www.abta.org (World Health organization (WHO), The World Health 
report 2002) 
[10] Woydt M, Krone A, Soerensen N, Roosen K. Ultrasound-guided 
neuronavigation of deep-seated cavernous haemangiomas: clinical results 
and navigation techniques. Br J Neurosurg. 2001; 15(6):485-95. 
[11] Julow J, Viola A, Major T, Mangel L, Bajzik G, Repa I, Sagi S, Valalik I, 
Emri M, Tron L, Nemeth G.Volumetric changes following 125I interstitial 
brachytherapy of gliomas, Ideggyogy Sz. 2005; 58(3-4):120-32. 
[12] Boisserie G, Cornu P, Dormont D, Sahel M, Hardiman C, Tep B, Mandin 
AM, Barret C, Faillot T, Delattre JY, Monjour A, Poisson M, Marsault C, 
Philippon J, Simon JM, Baillet F, Mazeron JJ. Iridium 192 brachytherapy of 
supra-tentorial high grade glioma recurring in irradiated areas: technique 
and preliminary results of the Pitie-Salpetriere hospital group, Bull Cancer 
Radiother. 1996; 83(3):144-52. 
169 
 
[13] Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S. Long-term results 
of gamma knife surgery for growth hormone-producing pituitary adenoma: 
is the disease difficult to cure? J Neurosurg. 2005; 102:119-23. 
[14] Gralla J, Nimsky C, Buchfelder M, Fahlbusch R, Ganslandt O. Frameless 
stereotactic brain biopsy procedures using the Stealth Station: indications, 
accuracy and results. Zentralbl Neurochir. 2003; 64(4):166-70. 
[15] Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen PK, Sawaya R, 
Maor MH. The role of tumour size in the radiosurgical management of 
patients with ambiguous brain metastases. Neurosurgery 2003; 53(2):272-
80; discussion 280-1. 
[16] Paleologos TS, Dorward NL, Wadley JP, Thomas DG. Clinical validation of 
true frameless stereotactic biopsy: analysis of the first 125 consecutive 
cases. Neurosurgery 2001; 49(4):830-5. 
[17] Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K, 
Tominaga K. Detection of brain metastasis in potentially operable non-small 
cell lung cancer: a comparison of CT and MRI. Chest. 1999; 115(3):714-9. 
[18] Furie DM, Provenzale JM. Supratentorial ependymomas and 
subependymomas: CT and MR appearance. J Comput Assist Tomogr. 1995; 
19(4):518-26. 
[19] Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. Linac radiosurgery 
for high-grade gliomas: the University of Florida experience. Int J Radiat 
Oncol Biol Phys. 1995 Apr 30; 32(1):205-10. 
[20] Tanaka T, Kobayashi T, Kida Y, Oyama H, Niwa M. The results of gamma 
knife radiosurgery for malignant skull base tumours. No Shinkei Geka. 
1996; 24(3):235-9. 
[21] Hou Y, Tang J, Ma Z, Qiu B, Liu Y. Therapy for intracranial lesions by 
gamma knife. Hunan Yi Ke Da Xue Xue Bao. 1997; 22(4):347-50. 
[22] Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery 
CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ.  Brachytherapy of 
glioblastoma recurring in previously irradiated territory: predictive value of 
tumour volume. Int J Radiat Oncol Biol Phys. 2002; 53(1):67-74. 
[23] Kida Y, Kobayashi T, Mori Y. Gamma knife radiosurgery for low-grade 
astrocytomas: results of long-term follow up. J Neurosurg. 2000; 93: 3:42-6. 
170 
 
[24] Landy HJ, Schwade JG, Houdek PV, Markoe AM, Feun L. Long-term 
follow-up of gliomas treated with fractionated stereotactic irradiation. Acta 
Neurochir Suppl. 1994; 62:67-71. 
[25] Taratuto AL, Monges J, Lylyk P, Leiguarda R. Superficial cerebral astrocytoma 
attached to dura. Report of six cases in infants. Cancer 1984; 54(11):2505-12. 
[26] http://www.emedicine.com or http://www.cancercompass.com 
[27] http://www.strokecenter.org/patients/stats.htm 
[28] Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol. 
2005; 12:78-84 
[29] Lloyd-Jones D, Adams R, Carnethon M. Heart disease and stroke statistics–
2009 update: a report from the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:e21-181 
[30] Orso F, Baldasseroni S, Maggioni AP. The role of thrombolysis in acute 
ischaemic stroke. Herz. 2008; 33:498-506 
[31] The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study 
Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 
1995; 333:1581-8  
[32] Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for 
acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008; 
79:1093-9 
[33] Gonzalez ER. Intracoronary thrombolysis to abort heart attacks: wave of the 
future? JAMA. 1981; 245:11-3 
[34] Multicentre Acute Stroke Trial–Italy G. Randomised controlled trial of 
streptokinase, aspirin, and combination of both in treatment of acute ischaemic 
stroke. Lancet. 1995; 346:1509-14 
[35] The Multicenter Acute Stroke Trial – Europe Study G. Thrombolytic therapy 
with streptokinase in acute ischaemic stroke. N Engl J Med. 1996; 335:145-50 
[36] Donnan G, Davis S, Chambers B, et al. Streptokinase for acute ischaemic 
stroke with relationship to time of administration: Australian Streptokinase 
(ASK) Trial Study Group. JAMA.1996; 276:961-6 
[37] Wahlgren N, Ahmed N, D valos A, et al. Thrombolysis with alteplase for acute 
ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST): an observational study. Lancet. 
2008;369:275-282  
171 
 
[38] Hacke W, Kaste M, Fieschi C. Intravenous thrombolysis with recombinant 
tissue plasminogen activator for acute hemispheric stroke. The European 
Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-25 
[39] Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo-controlled 
trial of thrombolytic therapy with intravenous alteplase in acute ischaemic 
stroke (ECASS II).  Lancet. 1998; 352:1245-51 
[40] Clark WM, Wissman S, Albers GW. Recombinant tissue-type plasminogen 
activator (Alteplase) for ischaemic stroke 3 to 5 hours after symptom onset: the 
ATLANTIS Study: a Randomized Controlled Trial. JAMA 1999; 282:2019-26 
[41] Association of outcome with early stroke treatment: pooled analysis of 
ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-74 
[42] Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4.5 hours 
after acute ischaemic stroke. N Engl J Med. 2008; 359:1317-29 
[43] Major Ongoing Stroke Trials. Stroke 2008; 39:e154-62 
[44] R. Trubestein, H.R. Bernard, F. Etzel, A. Sobbe, A. Cremer, U. Stumpff. 
Thrombolysis by ultrasound, Clin. Sci. Mol. Med. 1976; 51: 697–698. 
[45] K. Tachibana, S. Tachibana. Ultrasonic vibration for boosting fibrinolytic 
effects of urokinase in vivo, Thromb. Haemost. 1981; 46: 211. 
[46] Mahon BR, Nesbit GM, Barnwell SL. North American clinical experience with 
the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. 
AJNR Am J Neuroradiol. 2003; 24(3): 534-538. 
[47] Ishibashi T, Akiyama M, Onoue H, Abe T, Furuhata H. Can transcranial 
ultrasonication increase recanalization flow with tissue plasminogen activator? 
Stroke 2002; 33(5): 1399-1404. 
[48] Alexandrov AV, Molina CA, Grotta JC. Ultrasound-enhanced systemic 
thrombolysis for acute ischaemic stroke. N Engl J Med. 2004; 351(21): 2170-
2178. 
[49] M. Kimura, S. Iijima, K. Kobayashi, H. Furuhata. Evaluation of the 
thrombolytic effect of tissue-type plasminogen activator with ultrasound 
irradiation: in vitro experiment involving assay of the fibrin degradation 
products from the clot. Biol. Pharm. Bull. 1994; 17: 126–130. 
[50] M. Akiyama, T. Ishibashi, T. Yamada, H. Furuhata. Low-frequency ultrasound 
penetrates the cranium and enhances thrombolysis in vitro. Neurosurgery 1998; 
43: 828–832. 
172 
 
[51] M. Daffertshoffer, M. Hennerici. Ultrasound in the treatment of ischaemic 
stroke. Lancet Neurol. 2003; 2: 283–290. 
[52] S. Behrens, K. Spengos, M. Daffertshofer, S. Wirth, M. Hennerici. Potential 
use of therapeutic ultrasound in ischaemic stroke treatment. Echocardiography 
2001; 18: 259–263.  
[53] M. Daffertshofer, M. Hennerici. Sonothrombolysis: experimental evidence. 
Front Neurol. Neurosci. 2006; 21: 140–149. 
[54] M. Daffertshofer, Z. Huang, M. Fatar, M. Popolo, H. Schroeck, W. 
Kuschinsky. Efficacy of sonothrombolysis in a rat model of embolic ischaemic 
stroke. Neurosci. Lett. 2004; 361: 115–119. 
[55] M. Daffertshofer, A. Gass, P. Ringleb. Transcranial low frequency ultrasound-
mediated thrombolysis in brain ischemia: increased risk of hemorrhage with 
combined ultrasound and tissue plasminogen activator. Stroke. 2005; 36: 1441–
1446. 
[56] Barreto A, Sharma V, Lao A, Schellinger P, Amarenco P, Sierzenski P, 
Alexandrov A, Molina C. Safety and dose-escalation study design of 
Transcranial Ultrasound in Clinical SONolysis for acute ischaemic stroke: the 
TUCSON Trial. Int J Stroke. 2009; 4: 42-48. 
[57] Eggers J, König I R, Koch B, Händler G, Seidel G. Sonothrombolysis With 
Transcranial Color-Coded Sonography  and Recombinant Tissue-Type 
Plasminogen Activator in Acute Middle Cerebral Artery Main Stem Occlusion: 
Results From a Randomized Study. Stroke 2008; 39;1470-1475; 
[58] Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, 
Mardor Y. “Magnetic resonance imaging-guided, high-intensity focused 
ultrasound for brain tumour therapy”. Neurosurgery 2006; 59:949–956. 
[59] Zderic V, Keshavarzi A, Noble ML, Paun M, Sharar SR, Crum LA, Martin 
RW, Vaezy S. Hemorrhage control in arteries using high-intensity focused 
ultrasound: A survival study. Ultrasonics 2006; 44:46–53. 
[60] Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, Hesley 
G, Kim HS, Hengst S, Gedroyc WM. Clinical outcomes of focused ultrasound 
surgery for the treatment of uterine fibroids. Fertil Steril. 2006; 85(1):22-9. 
[61] Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized 
delivery of Herceptin to the mouse brain by MRI-guided focused 
173 
 
ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S 
A. 2006; 103:11719–11723. 
[62] Hynynen K, Clement GT, McDannold N, Vykhodtseva N, King R, White 
PJ, Vitek S, Jolesz FA. 500-element ultrasound phased array system for 
noninvasive focal surgery of the brain: A preliminary rabbit study with in 
vitro human skulls. Magn Reson Med. 2004; 52: 100–107. 
[63] Pernot M, Aubry JF, Tanter M, Thomas JL, Fink M. High power transcranial 
beam steering for ultrasonic brain therapy. Phys Med Biol. 2003; 48(16):2577-
89. 
[64] Jacques and Pierre Curie, 
http://www.pccontrol.co.uk/piezoelectric_effect.htm 
[65] Lee De Forest, http://people.clarkson.edu/~ekatz/scientists/deforest.htm 
[66] Paul Langévin, http://www.ob-ultrasound.net/langevin.html 
[67] Ronald V. Christie MB, Ch.B. and Alfred L. Loomis. “The Relation Of 
Frequency To The Physiological Effects Of Ultra-High Frequency 
Currents”, The Journal of Experimental Medicine. The Rockefeller Institute 
for Medical Research New York 1929; 49: 303-321 
[68] Fry WJ, Meyers R. “Ultrasonic method of modifying brain structures”. 
Confin Neurol. 1962;  22: 315–327. 
[69] Cosman BJ, Hueter TF. “Instrumentation for ultrasonic neurosurgery”. 
Electronics 1959; 5:53–57. 
[70] Leksell L. “Echoencephalography. II. Midline echo from the pineal body as 
an index of pineal displacement”.  Acta Chir Scand. 1958; 115:255–259. 
[71] Fry FJ, Goss SA. “Further studies of the transkull transmission of an intense 
focused ultrasonic beam: Lesion production at 500 kHz”. Ultrasound Med 
Biol. 1980;  6: 33–38. 
[72] Fry FJ, Goss SA, Patrick JT. Transkull focal lesions in cat brain produced 
by ultrasound. J Neurosurg. 1981; 54: 659–663. 
[73] Heimburger RF. Ultrasound augmentation of central nervous system tumour 
therapy. Indiana Med. 1985; 78: 469–476. 
[74] Jolesz F A and Zientara G P. “MRI-guided laser-induced thermotherapy: 
basic principles Laser Induced”, Interstitial Thermotherapy ed G M¨uller 
and A Roggan. Washington, DC: SPIE Opt. Eng. Press. 1995; 294–324 
174 
 
[75] History of MR guided Focused Ultrasound: A literature review, ExAblate® 
2000, Vol. 1, No. 1, Insightec. 
[76] Lynn JG, Zwemer RL, Chick AJ, Miller AG. A new method for the 
generation and use of focused US in experimental biology. Gen Physiol. 
1942;  26: 179-193. 
[77] Fry WJ, Barnard JW, Fry FJ, Krumins RF, Brennan JF. Ultrasonic lesions in 
the mammalian central nervous system. Science. 1955; 122: 517-518. 
[78] Lizzi FL. High-precision thermotherapy for small lesions. Eur Urol. 1993; 
23: 23-28. 
[79] Coleman DJ, Lizzi FL, Driller J, Rosado AL, Chang S, Iwamoto T, 
Rosenthal D. Therapeutic ultrasound in the treatment of glaucoma. I. 
Experimental model. Ophthalmology. 1985; 92: 339-336. 
[80] Coleman DJ, Silverman RH, Iwamoto T, Lizzi FL, Rondeau MJ, Driller J, 
Rosado A, Abramson DH, Ellsworth RM. Treatment of glaucoma with 
highintensity focused ultrasound. Ophthalmology. 1986; 93: 831-833. 
[81] Vallancien G, Harouni M, Veillon B, Mombet A, Brisset J, Bougaran J. 
Focused extracorporeal pyrotherapy. Eur Urol. 1993; 23: 48-52. 
[82] Vallancien G, Harouni M, Guillonneau B, Veillon B, Bougaran J. Ablation 
of superficial bladder tumours with focused extracorporeal pyrotherapy. 
Urology. 1996; 47:204-207. 
[83] Gail Ter Haar GR, Clarke RL, Vaughan MG, Hill CR. Trackless surgery 
using focused ultrasound: Technique and case report. Min Inv Ther. 1991; 
1: 13-15. 
[84] Visioli AG, Rivens IH, ter Haar GR, Horwich A, Huddart RA, Moskovic E, 
Padhani A, Glees J. Preliminary results of a phase I dose escalation clinical 
trial using focused ultrasound in the treatment of localized tumours. Eur J 
Ultrasound. 1999; 9: 11-18. 
[85] Wu F, Wang ZB, Chen WZ, Wang W, Gui YZ, Zhang M, Zheng GQ, Zhou 
YJ, Xu GL, Li M, Zhang CW, Ye HY, Feng R. Extracorporeal high 
intensity focused ultrasound ablation in the treatment of 1038 patients with 
solid carcinomas in China: An overview. Ultrasonics Sonochem. 2004; 11: 
149-154. 
[86] Bo Xie, Jiajun Ling, Weiming Zhang, Xueqin Huang, Jihua Zhen and 
Yanzhe Huang. The efficacy of high-intensity focused ultrasound (HIFU) in 
175 
 
advanced pancreatic cancer. Chinese Journal of Clinical Oncology. 2008; 5: 
183-186. 
[87] Kennedy JE, terHaarGR, Wu F, Gleeson FV, Roberts IS, Middleton MR, 
Cranston D. Contrast-enhanced ultrasound assessment of tissue response to 
high-intensity focused ultrasound. Ultrasound Med Biol. 2004; 30: 851-854. 
[88] Kennedy JE, Wu F, ter Haar GR, Gleeson FV, Phillips RR, Middleton MR, 
Cranston D. High-intensity focused ultrasound for the treatment of liver 
tumours. Ultrasonics. 2004; 42: 931-935. 
[89] Okuno T, Ganaha F, Lee CO, Shimizu T, Osako K, Oka S, Lee KH, Chen 
WZ, Zhu H, Park SH, Qi Z, Shi D, Song HS. Feasibility of extracorporeal 
HIFU using Chongqing Haifu-knife as an adjunct to the endovascular 
therapy for breast conservation particularly in patients with recurrent breast 
carcinoma, 4th International Symposium on Therapeutic Ultrasound, 
Tachibana K, ter Haar GR (eds.), ISTU, Kyoto. 2004; pp. 66. 
[90] Hynynen K, Darkazanli A, Unger E, Schenck JF. MRI-guided noninvasive 
ultrasound surgery. Med Phys. 1993; 20: 107-115. 
[91] Hynynen K, Pomeroy O, Smith DN, Huber PE, McDannold NJ, Kettenbach 
J, Baum J, Singer S, Jolesz FA. MR imaging-guided focused ultrasound 
surgery of fibroadenomas in the breast: A feasibility study. Radiology. 
2001; 219: 176-185. 
[92] Tempany CMC, Stewart EA, McDannold N, Quade BJ, Jolesz FA, 
Hynynen K. MR imaging-guided focused ultrasound surgery of uterine 
leiomyomas: A feasibility study. Radiology. 2003; 226: 897-905. 
[93] Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M. 
Tissue ablation in benign prostatic hyperplasia with high-intensity focused 
ultrasound. Eur Urol. 1993; 23: 39-43. 
[94] Chaussy C, Thuroff S. High-intensity focused ultrasound: Complications 
and adverse effects. Molec Urol. 2000; 4: 183-187. 
[95] Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Due A, 
Desgrandchamps F, De La Rosette J, Gelet A. High-intensity focused 
ultrasound and localized prostate cancer: Efficacy results from the European 
multicentric study. J Endourol (2003) 17: 673-677. 
176 
 
[96] Daum DR, Smith NB, King R, Hynynen K. In vivo demonstration of 
noninvasive thermal surgery of the liver and kidney using an ultrasonic 
phased array. Ultrasound Med Biol 25:1087–1098, 1999. 
[97] White PJ, Clement GT, Hynynen K. Longitudinal and shear mode 
ultrasound propagation in human skull bone. Ultrasound Med Biol 32:1085–
1096, 2006. 
[98] Hynynen K. The threshold for thermally significant cavitation in dog’s thigh 
muscle in vivo. Ultrasound Med Biol. 1991; 17:157–169. 
[99] Samir Mitragotri. Healing sound: the use of ultrasound in drug delivery and 
other therapeutic applications. American Institute of Ultrasound in 
Medicine. 2005, 4(3): 255-260. 
[100] Miller DL, Song J. Tumour growth reduction and DNA transfer by 
cavitation-enhanced high intensity focused ultrasound in vivo. Ultrasound 
Med Biol 2003; 29:887–93. 
[101] Nightingale K, Soo MS, Nightingale R. Acoustic radiation force impulse 
imaging: in vivo demonstration of clinical feasibility. Ultrasound Med Biol. 
2002; 28:227–35. 
[102] Lizzi FL, Muratore R, Deng CX. Radiation-force technique to monitor 
lesions during ultrasonic therapy. Ultrasound Med Biol. 2003; 29: 1593–
605. 
[103] Frenkel V, Li KCP. Potential role of pulsed-high intensity focused 
ultrasound in gene therapy. Oncol 2006; 2: 111–9. 
[104] Cohen ZR, Zaubermann J, Harnof S, Mardor Y, Nass D, Zadicario E, 
Hananel A, Castel D, Faibel M, Ram Z. Magnetic resonance imaging-
guided focused ultrasound for thermal ablation in the brain: A feasibility 
study in a swine model. Neurosurgery 2007; 60:593–600. 
[105] Hynynen K, Colucci V, Chung A, Jolesz F. Noninvasive arterial occlusion 
using MRI-guided focused ultrasound. Ultrasound Med Biol. 1996; 
22:1071–1077. 
[106] Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. 
Targeted delivery of doxorubicin to the rat brain at therapeutic levels using 
MRI-guided focused ultrasound. Int J Cancer 2007; 121:901–907. 
[107] Frenkel V, Etherington A, Greene M, Quijano J, Xie J, Hunter F, Dromi S, 
Li KC. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumour 
177 
 
model: Investigation of potential enhancement by pulsed-high intensity 
focused ultrasound exposure. Acad Radiol. 2006; 13:469–479. 
[108] Stone MJ, Frenkel V, Dromi S, Thomas P, Lewis RP, Li KC, Horne M 3rd, 
Wood BJ. Pulsed-high intensity focused ultrasound enhanced tPA mediated 
thrombolysis in a novel in vivo clot model, a pilot study. Thromb Res. 2007; 
121:193–202. 
[109] Lindstrom PA. Prefrontal ultrasonic irradiation—A substitute for lobotomy. 
AMA Arch Neurol Psychiatry. 1954; 72:399–425. 
[110] Lele PP. Concurrent detection of the production of ultrasonic lesions. Med 
Biol Eng. 1966; 4:451–456. 
[111] Lele PP. Production of deep focal lesions by focused ultrasound—Current 
status. Ultrasonics 1967; 5:105–112. 
[112] J. C, Bamber, C. R. Hill. Ultrasonic Attenuation And Propagation Speed In 
Mammalian Tissues As A Function Of Temperature. Ultrasound In Med. & 
Biol. 1979; 5: 149-157. 
[113] S. A. Ooss, L. A. Frizzell, F. Dunn. Ultrasonic Absorption And Attenuation 
In Mammalian Tissues. Ultrasound In Med. & Biol. 1979; 5: 181-186 
[114] O'Neil, H. Theory of focussing radiators. J. Acoust. Soc. Am. 1949; 21:516-
526. 
[115] Swindell W, Roemer RB, Clegg ST. Temperature distributions caused by 
dynamic scanning of focused ultrasound transducers. IEEE ultrasonic Symp. 
1982; 745-749 
[116] Fan X, and Hynynen K. "The effect of wave reflection and refraction at soft 
tissue interfaces during ultrasound hyperthermia treatments," J. Acoust. Soc. 
Am. 1992; 91 (3), 1727-1736. 
[117] Pennes, M. Analysis of tissue and arterial blood temperature in the resting 
human forearm. J. Appl. Physiol. 1948; 1:93-122. 
[118] AH Goodman, R Einstein and HJ Granger. Effect of changing metabolic 
rate on local blood flow control in the canine hindlimb. Circulation 
Research 1978; 43: 769-776. 
[119] Dewey W C, Hopwood L E, Sapareto S A, Gerweck L. E. Cellular 
responses to combinations of hyperthermia and radiation. Radiology. 1977; 
123, 463-474. 
178 
 
[120] Sapareto S, Dewey W. "Thermal dose determination in cancer therapy." Int. 
J. radiation oncology Biol. Phys. 1984; 10: 787-800. 
[121] Damianou C, and Hynynen K. "The effects of various physical parameters 
on the size and shape of necrosed tissue volume during ultrasound surgery," 
J. Acoust. Soc. Am. 1994; 95 (3), 1641-1649. 
[122] Christakis Damianou, M. Pavlou, O. Velev, K. Kyriakou, M. Trimikliniotis. 
High intensity focused ultrasound ablation of kidney guided by ΜRI. Journal of 
Ultrasound Med Biol. 2004; 30 (3): 397-404. 
[123] Damianou C. In vitro and in vivo ablation of porcine renal tissues using High 
Intensity focused Ultrasound. Journal of Ultrasound in Medicine and Biology. 
2003; 29 (9):1321-1330. 
[124] Vykhodtseva N, Sorrentino V, Jolesz FA, Bronson RT, Hynynen K. MRI 
detection of the thermal effects of focused ultrasound on the brain. Ultrasound 
Med Biol. 2000; 26(5):871–880. 
[125] Dunn F. "Temperature and amplitude dependence of acoustic absorption in 
tissue", J. Acoust. Soc. Am. 1962; 34 (10), 1545-1547. 
[126] Dunn F. and Brady J. "Temperature and frequency dependence of ultrasonic 
absorption in tissue". in Proceedings of 8 th International Congress on 
Acoustics. 1974; 366c. 
[127] Gammell P, Le Croissette D, Heyser R. "Temperature and frequency 
dependence of ultrasonic attenuation in selected tissues". Ultrasound in Med 
& Biol. 1979; 5, 269-277. 
[128] Fry F, Reiley C, Dines K, Etchison M, Trauner E. "Absorption in liver at the 
focus of an ultrasonic shock wave field". Ultrasound in Med. & Biol. 1991; 
17 (1), 65-69. 
[129] Robinson T, and Lele P. "An analysis of lesion development in the brain 
and in plastics by high-intensity focused ultrasound at low-megahertz 
frequencies". J. Acoust Soc. Am. 1969; 51 (2), 133-1351. 
[130] Bamber J, and Hill C. "Ultrasonic attenuation and propagation speed in 
mammalian tissues as a function of temperature". Ultrasound in Med. & 
Biol. 1979; 5, 149-157. 
[131] Kossoff G, Kelly-Fry E, Jellins J. "Average velocity of ultrasound in the 
human female breast". J. Acoust. Soc. Am. 1973; 53 (6), 1730-1736. 
179 
 
[132] Fry W, and Fry R. "Determination of absolute sound levels and acoustic 
absorption coefficients by thermocouple probes-theory". J. Acoust. Soc. 
Am. 1954; 26 (3), 294-310. 
[133] Bamber J, and Nassiri D. "Effect of gaseous inclusions on the frequency 
dependence of ultrasonic attenuation in liver". Ultrasound in Med. & 
Biology. 1985 11 (2), 293-298. 
[134] Frizzell L, Carstensen E, Davis D. "Ultrasonic absorption in liver tissue". J. 
Acoust. Soc. Am. 1979; 65 (5), 1309-1312. 
[135] Lele PP. A simple method for production of trackless focal lesions with 
focused ultrasound. J. Physiol. 1962; 160:494-512. 
[136] Fry F. and Johnson LK., (1978) Tumour irradiation with intense ultrasound. 
Ultrasound Med. Biol. 4(4):337-41. 
[137] Britt RH, Lyons BE, Pounds DW, Prionas SD. Feasibility of ultrasound 
hyperthermia in the treatment of malignant brain tumours. Med Instrum. 1983; 
7(2):172-7. 
[138] Guthkelch AN, Carter LP, Cassady JR, Hynynen KH, Iacono RP, Johnson PC, 
Obbens EA, Roemer RB, Seeger JF, Shimm DS. Treatment of malignant brain 
tumours with focused ultrasound hyperthermia and radiation: results of a phase 
I trial. J Neurooncol. 1991; 10(3):271-84. 
[139] http://clinicaltrials.gov/ct2/show/NCT01473485. ExAblate (Magnetic 
Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors, 
November 2011. 
[140] Vykhodtseva NI, Hynynen K, Damianou C. Pulse duration and peak intensity 
during focused ultrasound surgery: theoretical and experimental effects in rabbit 
brain in vivo. Ultrasound Med Biol. 1994; 20(9): 987-1000. 
[141] Hynynen K, Vykhodtseva NI, Chung AH, Sorrentino V, Colucci V,  Jolesz FA. 
Thermal effects of focused ultrasound on the brain: determination with MR 
imaging. Radiology 1997; 204(1): 247-53. 
[142] Hynynen K. McDannold N. Vykhodtseva N. Jolesz F. Noninvasive MR 
Imaging–guided Focal Opening of the Blood-Brain-Barrier in Rabbits. 
Radiology 2001; 230:640-646. 
[143] Hynynen K, McDannold N, Martin H, Jolesz F, Vykhodtseva N. The threshold 
for brain damage in rabbits induced by bursts of ultrasound in the presence of 
180 
 
an ultrasound contrast agent (optison). Ultrasound in Med. & Biol.  2003; 29 
(3):  473–481. 
[144] Hynynen K, McDannold N, Sheikov N, Jolesz F, Vykhodtseva N.  Local and 
reversible blood–brain barrier disruption by noninvasive focused ultrasound at 
frequencies suitable for trans-skull sonications. NeuroImage 2005; 24: 12–20. 
[145] Damianou C, Ioannides K, Milonas N. ‘Positioning device for MRI-guided 
high intensity focused ultrasound system’. Computer-Assisted Radiology and 
Surgery. 2008; 2 (6): 335-345. 
[146] Hynynen K, Darkazanli A, Damianou DC, Unger E, Schenck JF. (1992) MRI-
guided ultrasonic hyperthermia, RSNA meeting. 
[147] Hynynen K, Damianou CA, Colucci V, Unger E, Cline HH, Jolesz FA. MR 
monitoring of focused ultrasonic surgery of renal cortex: experimental and 
simulation studies. Journal of Magnetic Resonance Imaging. 1995; 5(3): 259-
266. 
[148] Christakis Damianou, M. Pavlou, O. Velev, K. Kyriakou, M. Trimikliniotis.  
High intensity focused ultrasound ablation of kidney guided by ΜRI. Journal of 
Ultrasound Med Biol. 2004; 30 (3): 397-404. 
[149] Rowland IJ, Rivens I, Chen L, Lebozer CH, Collins DJ, ter Haar GR, Leach 
MO. MRI study of hepatic tumours following high intensity focused ultrasound 
surgery. British Journal of Radiology. 1997; 70: 144-53. 
[150] Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D. 
Transrectal high-intensity focused ultrasound ablation of prostate cancer: 
Effective treatment requiring accurate imaging. Eur J Radiol. 2007; 63(3): 317-
327. 
[151] Pisani L, Ross A, Diederich C, Nau W, Sommer F, Glover G, Butts K. Effects 
of spatial and temporal resolution for MR image-guided thermal ablation of 
prostate with transurethral ultrasound. J Magn Reson Imaging. 2005; 22(1): 
109-18. 
[152] Damianou C. In vitro and in vivo ablation of porcine renal tissues using High 
Intensity focused Ultrasound Journal of Ultrasound in Medicine and Biology. 
2003; 29 (9): 1321-1330. 
[153] Chen L, Bouley D, Yuh E, D;Arceuil H, Butts K. Study of focused ultrasound 
tissue damage using MRI and histology. J Magn Reson Imaging. 1999; 10(2): 
146-53.  
181 
 
[154] Dickinson RJ, Hall AS, Hind AJ, Young IR. Measurement of changes in tissue 
temperature using MR imaging. J Comput Assist Tomogr. 1986; 10: 468–472. 
[155] Fry FJ, Sanghvi NT, Morris RF, Clendenon JL, Dines KA, Patrick JT, Goss 
SA. Ultrasonic diagnostic system for interactive interrogation of adult brain 
through intact skull. Invest Radiol. 1982; 7(5): 463-9. 
[156] Maxwell AD, Owens G, Gurm HS, Ives K, Myers DD Jr, Xu Z. 
Noninvasive Treatment of Deep Venous Thrombosis Using Pulsed 
Ultrasound Cavitation Therapy (Histotripsy) in a Porcine Model. J Vasc 
Interv Radiol. 2010 Dec 29. 
[157] Maxwell AD, Cain CA, Duryea AP, Yuan L, Gurm HS, Xu Z. Noninvasive 
thrombolysis using pulsed ultrasound cavitation therapy - histotripsy. 
Ultrasound Med Biol. 2009; 35(12): 1982-94. 
[158] K. Spengos, S. Behrens, M. Daffertshofer, Carl E. Dempfle And M. 
Hennerici. Acceleration Of Thrombolysis With Ultrasound Through The 
Cranium In A Flow Model. Ultrasound In Med. & Biol. 2000; 26(5): 889–
895. 
[159] J. Eggers, Inke R. König, B. Koch, G. Händler and G. Seidel. 
Sonothrombolysis With Transcranial Color-Coded Sonography and 
Recombinant Tissue-Type Plasminogen Activator in Acute Middle Cerebral 
Artery Main Stem Occlusion: Results From a Randomized Study. Stroke 
2008; 39; 1470-1475. 
[160] G.T. Clement. Perspectives in clinical uses of high-intensity focused 
ultrasound. Ultrasonics 2004; 42: 1087–1093. 
[161] Chuan-Xing Li, Guo-Liang Xu, Zhen-You Jiang, Jian-Jun Li, Guang-Yu 
Luo, Hong-Bo Shan, Rong Zhang, Yin Li. Analysis of clinical effect of 
high-intensity focused ultrasound on liver cancer. World J Gastroenterol 
2004; 10(15): 2201-2204. 
[162] C. Damianou, Ioannides K., Hadjisavvas V., Milonas N., Couppis A, Iosif 
D. ‘In vitro and in vivo brain ablation created by high intensity focused 
ultrasound and monitored by MRI’. IEEE Transaction on Ultrasonics, 
Ferroelectrics and Frequency Control, 2009; 56(6): 1189-1198. 
[163] Kennedy JE. High-intensity focused ultrasound n treatment of solid 
tumours. Nat Rev Cancer 2005; 5:321–7. 
182 
 
[164] Zenitani T, Suzuki R, Maruyama K, Furuhata H. Accelerating effects of 
ultrasonic thrombolysis with bubble liposomes. J Med Ultrasonics 2008; 
35:5-10. 
[165] Soltani A, Prokop A, Vaezy S. Stability of alteplase in presence of 
cavitation. Ultrasonics 2008; 48:109-116. 
[166] Eggers J, Ossadnik S, Seidel G. Enhanced clot dissolution in vitro by 1.8-
mhz pulsed ultrasound. Ultrasound in Med. & Biol. 2009; 35(3): 523–526. 
[167] Shaw G, Meunier J, Lindsell C, Holland C. Tissue plasminogen activator 
concentration dependence of 120 khz ultrasound-enhanced thrombolysis. 
Ultrasound in Med. & Biol. 2008; 34(11): 1783–1792. 
[168] Saguchi T, Onoue H, Urashima M, Ishibashi T, Abe T, Furuhata H. 
Effective and safe conditions of low-frequency transcranial  ultrasonic 
thrombolysis for acute ischaemic stroke: neurologic and histologic 
evaluation in a rat middle cerebral artery stroke model. Stoke. 2008; 39: 
1007-1011. 
[169] Jürgen Eggers, Inke R. König, Björn Koch, Götz Händler, Günter Seidel. 
Sonothrombolysis With Transcranial Color-Coded Sonography and 
Recombinant Tissue-Type Plasminogen Activator in Acute Middle Cerebral 
Artery Main Stem Occlusion: Results From a  Randomized Study. Stroke 
2008; 39; 1470-1475. 
[170] Kim YS, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused 
ultrasound therapy: an overview for radiologists. Korean J Radiol. 2008; 
9(4): 291-302. 
[171] Frenkel V, Oberoi J, Stone MJ, Park M, Deng C, Wood BJ, Neeman Z, 
Horne M 3rd, Li KC. Pulsed high-intensity focused ultrasound enhances 
thrombolysis in an in vitro model. Radiology 2006; 239(1):86-93. 
[172] Joshua E. Soneson, Matthew R. Myers. Gaussian representation of high-
intensity focused ultrasound beams J. Acoust. Soc. Am. 2007; 122(5): 2526-
2531. 
[173] Holland CK, Vaidya SS, Datta S, Coussios C-C, Shaw GJ. Ultrasound 
enhanced tissue plasminogen activator thrombolysis in an in vitro porcine 
clot model. Thromb Res 2008; 121: 663-673. 
183 
 
[174] R. Kornowski, R. S. Meltzer, A. Chernine, Z. Vered, A. Battler. Does 
External Ultrasound Accelerate Thrombolysis? Results From a Rabbit 
Model. American Heart Ass.1994; 89: 339-344. 
[175] M. Nedelmann, P. Reuter, M. Walberer, C. Sommer, B. Alessandri, D. 
Schiel, N. Ritschel, O. Kempski, M. Kaps, C. Mueller, G. Bachmann, T. 
Gerriets. Detrimental Effects Of 60 Khz Sonothrombolysis In Rats With 
Middle Cerebral Artery Occlusion. Ultrasound in Med. & Biol. 2008; 
34(12): 2019–2027. 
[176] Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of 
recombinant tissue plasminogen activator into clots. Ultrasound Med. Biol. 
1995; 21: 419–424.  
[177] Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of 
ultrasound-potentiated fibrinolysis in vitro. Blood. 1993; 81:2636–2643.  
[178] Polak JF. Ultrasound energy and the dissolution of thrombus. New Engl. J. 
Med. 2004; 351:2154–2155.  
[179] Birnbaum Y, Luo H, Nagai T, Fishbein  MC, Peterson TM, Li S, Kricsfeld 
D, Porter TR, Siegel RJ. Noninvasive in vivo clot dissolution without a 
thrombolytic drug: recanalization of thrombosed iliofemoral arteries by 
transcutaneous ultrasound combined with intravenous infusion of 
microbubbles. Circulation. 1998; 97: 130–134.  
[180] Culp WC, Erdem E, Roberson PK, Husain MM. Microbubblepotentiated 
ultrasound as a method of stroke therapy in a pig model: preliminary 
findings. J. Vasc. Interv. Radiol. 2003; 14: 1433–1436.  
[181] Holland CK, Apfel RE. Thresholds for transient cavitation produced by 
pulsed ultrasound in a controlled nuclei environment. J. Acoust. Soc. Am. 
1990; 88: 2059–2069.  
[182] Schumann PA, Christiansen JP, Quigley RM, McCreery TP, Sweitzer RH, 
Unger EC. Targeted-microbubble binding selectively to GPIIb IIIa receptors 
of platelet thrombi. Invest. Radiol. 2002; 37: 587–593.  
[183] The IMS Study Investigators Combined intravenous and intraarterial 
recanalization for acute ischaemic stroke: the interventional management of 
stroke study. Stroke 2004; 35: 904–912.  
184 
 
[184] Alexandrov AV, Wojner AW, Grotta JC. CLOTBUST Investigators 
CLOTBUST: design of a randomized trial of ultrasound-enhanced 
thrombolysis for acute ischaemic stroke. J Neuroimaging. 2004; 14:108-12. 
[185] Francis CW, Onundarson PT, Carstensen EL, Blinc A, Meltzer RS, Schwarz 
K, Marder VJ. Enhancement of Fibrinolysis In Vitro by Ultrasound. J. Clin. 
Invest. Volume 1992; 90: 2063-2068. 
[186] Suchkova V, Siddiqi, Carstensen EL, Dalecki D, Child S, Francis CW. 
Enhancement of Fibrinolysis With 40-kHz Ultrasound. Circulation 1998; 
98: 1030-1035. 
[187] Suchkova V, Carstensen EL, Francis CW.  Ultrasound Enhancement Of 
Fibrinolysis At Frequencies OF 27 TO 100 kHz. Ultrasound in Med. & 
Biol. 2002; 28: 377–382. 
[188] Nedelmann M, Martin B, Lierke EG, Heimann A, Kempski O, Hopf HC. 
Low-Frequency Ultrasound Induces Nonenzymatic Thrombolysis In Vitro.  
J Ultrasound Med. 2002; 21:649–656. 
[189] Datta S, Coussios C, Ammi A, Mast TD, De Courten-Myers G, Holland C. 
Ultrasound-Enhanced Thrombolysis Using Definity® As A Cavitation 
Nucleation Agent. Ultrasound in Med. & Biol. 2008; 34: 1421–1433. 
[190] Shlansky-Goldberg RD, Cines DB, Sehgal CM. Catheter-delivered 
ultrasound potentiates in vitro thrombolysis. J Vasc Interv Radiol. 1996; 7: 
313–320. 
[191] American Stroke Association, Stroke Statistics 2006. 
[192] Schellinger P, Jansen O, Fiebach J, Heiland S. Steiner T, Schwab S, Pohlers 
O. Ryssel H, Sartor K,  Hacke W. Monitoring Intravenous Recombinant 
Tissue Plasminogen Activator Thrombolysis for Acute Ischaemic Stroke 
With Diffusion and Perfusion MRI. Stroke 2000; 31(6): 1318-1328. 
[193] http://www.surgicalneurologyint.com/article.asp?issn=2152-
7806%3Byear=2011%3Bvolume=2%3Bissue=1%3Bspage=29%3Bepage=2
9%3Baulast=Sasani. 
[194] Heran  C, Morgan S, Kasiewski C, Bostwick J, Bentley R, Klein S. 
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat 
model of carotid artery thrombosis. Eur. J. Pharmacol. 2000; 389, 201–207. 
[195] Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H. 
Antithrombotic effects of YM-60828, a newly synthesized factor Xa 
185 
 
inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. 
Pharmacol. 1998; 123, 92–96. 
[196] Wiley MR, Weir LC, Briggs, S, Bryan NA, Buben J, Campbell  C. 
Structure-based design of potent, amidine-derived inhibitors of factor Xa: 
evaluation of selectivity, anticoagulant activity, and antithrombotic activity. 
J. Med. Chem. 2000; 43, 883–899. 
[197] Wong AG, Gunn AC, Ku P, Hollenbach SJ, and Sinha U. Relative efficacy 
of active site-blocked factors IXa, Xa in models of rabbit venous and 
arterio- venous thrombosis. Thromb. Haemostasis. 1997; 77(6): 1143–1147. 
[198] Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani, C. Effects 
of DX-9065a, an orally active, newly synthesized and specific inhibitor of 
factor Xa, against experimental disseminated intravascular coagulation in 
rats. Thromb. Haemostasis. 1994; 72: 393–396. 
[199] Wessler S. Studies in intravascular coagulation. I. Coagulation changes in 
isolated venous segments. J. Clin. Invest. 1952; 31: 1011–1014. 
[200] Shebuski RJ, Storer BL, and Fujita T. Effect of thromboxane synthetase 
inhibition on the thrombolytic action of tissue-type plasminogen activator in 
a rabbit model of peripheral arterial thrombosis. Thromb. Res. 1988; 52: 
381–392. 
[201] Folts JD, Crowell EB, and Rowe GG. Platelet aggregation in partially 
obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 
365–370. 
[202] Blair E, Nygren E, and Cowley RA. A spiral wire technique for producing 
gradually occlusive coronary thrombosis. J. Thorac. Cardiovasc. Surg. 
1964; 48: 476–485. 
[203] Kordenat R. K. and Kezdi P. Experimental intracoronary thrombosis and 
selective in situ lysis by catheter technique. Am. J. Heart. 1972; 83: 360–
364. 
[204] Bush LR, Mellott MJ, Kanovsky SM, Holahan MA, and Patrick DH. A 
model of femoral artery thrombolysis in dogs. Fibrinolysis. 1989; 3: 107–
114. 
[205] Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB. 
Coronary thrombolysis with recombinant human tissue-type plasminogen 
activator. Circulation. 1984; 70: 700–707. 
186 
 
[206] Romson JL, Haack DW, and Lucchesi BR. Electrical induction of coronary 
artery thrombosis in the ambulatory canine: a model for in vivo evaluation 
of antithrombotic agents. Thromb. Res. 1980; 17: 841–853. 
[207] Todd ME, McDevitt EL, and Goldsmith EI. Blood-clotting mechanisms of 
nonhuman primates: choice of the baboon model to simulate man. J. Med. 
Primatol. 1972; 1: 132–141.  
[208] Eppehimer MJ. and Schaub RG. P-selectin-dependent inhibition of 
thrombosis during venous stasis. Arterioscler. Thromb. Vasc. Biol. 2000; 
20(11): 2483–2488. 
[209] Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrobleski 
SK.  Venous thrombosis prophylaxis by inflammatory inhibition without 
anticoagulation therapy. J. Vasc. Surg. 2000; 31(2): 309–324.  
[210] Reese T, Bochelen D, Sauter A, Beckmann N, Rudin M. Magnetic 
resonance angiography of the rat cerebrovascular system without the use of 
contrast agents. NMR Biomed. 1999; 12: 189–196. 
[211] Johnstone MT, Botnar RM, Perez AS, Stewart R, Quist WC, Hamilton JA, 
Manning WJ. In vivo magnetic resonance imaging of experimental 
thrombosis in a rabbit model. Arterioscler Thromb Vasc Biol. 2001; 21: 
1556–1560. 
[212] Corti R, Osende JI, Fayad ZA, Fallon JT, Fuster V, Mizsei G, Dickstein E, 
Drayer B, Badimon JJ. In vivo non-invasive detection and age definition of 
arterial thrombus by MRI. J Am Coll Cardiol. 2002; 39: 1366–1373. 
[213] Schmitz SA, Winterhalter S, Schiffler S, Gust R, Wagner S, Kresse M, 
Coupland SE, Semmler W, Wolf KJ. USPIO-enhanced direct MR imaging 
of thrombus: preclinical evaluation in rabbits. Radiology 2001; 221: 237–
243. 
[214] Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fujii DK. A targeted 
contrast agent for magnetic resonance imaging of thrombus: implications of 
spatial resolution. J Magn Reson Imaging. 2001; 13: 615–618. 
[215] Peter D. Schellinger, Olav Jansen, Jochen B. Fiebach, Sabine Heiland, 
Thorsten Steiner, Stefan Schwab, Olivia Pohlers; Henning Ryssel, Klaus 
Sartor, Werner Hacke. Monitoring Intravenous Recombinant Tissue 
Plasminogen Activator Thrombolysis for Acute Ischaemic Stroke With 
Diffusion and Perfusion MRI. Stroke. 2000; 1318-1328. 
187 
 
[216] Behrens S, Spengos K, Daffertshofer M, Schroeck H and Dempfle C E. 
Transcranial ultrasound-improved thrombolysis: diagnostic vs. therapeutic 
ultrasound. Ultrasound Med. Biol. 2001; 27: 1683–9. 
[217] Cintas P, Pavy Le Taron A, Larrue V. High rate of recanalization of middle 
cerebral artery occlusion during 2-MHz transcranial color-coded Doppler 
continuous monitor without thrombolytic drug. Stoke. 2002; 33: 626-628. 
  
188 
 
APPENDIX 
 
JOURNALS 
 
1. C Damianou, K Ioannides, V HadjiSavvas, N Milonas, A Couppis, D Iosif, M 
Komodromos, F Vrionides. ‘Thermal ablation system using high intensity 
focused ultrasound (HIFU) and guided by MRI’. Therapeutic Ultrasound 
2007; 6: 123-128. 
 
2. C Damianou, Ioannides K, Hadjisavvas V, Milonas N, Couppis A, Iosif D. ‘In 
vitro and in vivo brain ablation created by high intensity focused ultrasound 
and monitored by MRI’. IEEE Transaction on Ultrasonics, Ferroelectrics and 
Frequency Control 2009; 56(6): 1189-1198. 
 
3. Mylonas N, Ioannides K, Hadjisavvas V, Iosif D, Kyriacou P, Damianou C. 
’Evaluation of fast spin echo MRI sequence for an MRI guided high intensity 
focused ultrasound system for in vivo rabbit liver ablation’. J. Biomedical 
Science and Engineering, 2010; 3: 241-246. 
 
4. Christakis Damianou, Kleanthis Ioannides, Venediktos Hadjisavvas, Nikos 
Mylonas,  Andreas Couppis, Demetris Iosif, Panayiotis A. Kyriacou. MRI 
monitoring of lesions created at temperature below the boiling point and of 
lesions created above the boiling point using high intensity focused 
ultrasound. J. Biomedical Science and Engineering, 2010; 8: 763-775. 
 
5. Venediktos Hadjisavvas, Kleanthis Ioannides, Michalis Komodromos, Nikos 
Mylonas, Christakis Damianou. Evaluation of the contrast between tissues and 
thermal lesions in rabbit in vivo produced by high intensity focused ultrasound 
using fast spin echo MRI sequences. J. Biomedical Science and Engineering. 
2011; 4: 51-61. 
 
6. Venediktos Hadjisavvas, Christakis Damianou. Temperature estimation of 
focused ultrasound exposures for stroke treatment. J. Biomedical Science and 
Engineering 2011; 4(5):410-417 
 
 
CONFERENCES 
 
1. C. Damianou, N. Milonas, V. HadjiSavvas, A. Couppis, D. Iosif, K. Ioannides, 
‘Thermal ablation system using High Intensity Focused Ultrasound (HIFU) 
and guided by MRI’ CARS 2008 Computer Assisted Radiology and Surgery, 
June 25-28, Barcelona, Spain ,2008 (Abstract). 
 
2. C. Damianou, K. Ioannides, V. HadjiSavvas, N. Milonas, A. Couppis, D. Iosif, 
M. Komodromos F. Vrionides, ‘Thermal ablation system using high intensity 
focused ultrasound (HIFU) and guided by MRI’, International Society of 
Therapeutic Ultrasound, Minneapolis, 10-13 September, 2008 Ultrasound in 
Medicine & Biology, 1438, 35(8):218. 
 
189 
 
3. C.Damianou, K. Ioannides, V. HadjiSavvas, N. Milonas, A. Couppis, D. Iosif, 
M. Komodromos, F. Vrionides, ‘High intensity focused ultrasound (HIFU) 
system guided by MRI’. 12th World Congress of the World Federation for 
Ultrasound in Medicine and Biology, 30 August – 3 September 2009, Sydney 
Convention & Exhibition Centre, Sydney, Australia Ultrasound in Medicine & 
Biology, 35(8):367. 
 
4. C.Damianou, N. Milonas, V. HadjiSavvas, A. Couppis, D. Iosif, K. Ioannides,  
Evaluation of the contrast between tissues in rabbit in vivo and thermal lesions 
produced by HIFU using fast spin echo MRI sequences in liver, kidney, heart, 
brain and pancreas. International Society of Therapeutic Ultrasound, Aux En 
Provence, France, 23-26 September, 2009 AIP Conf. Proc. 1215, pp. 44-48. 
 
5. C. Damianou, K. Ioannides, N. Mylonas, V. HadjiSavvas, A. Couppis, D. Iosif 
‘Liver ablation using a high intensity focused ultrasound system and MRI 
guidance’, 9th International Conference on Information Technology and 
Applications in Biomedicine, November 5-7, 2009, Larnaca, Cyprus (4 
Pages). 
6. V. HadjiSavvas, C. Damianou, K. Ioannides, N. Mylonas, , A. Couppis, P. 
Kyriakou, D. Iosif, , T. Hadji Charambous, G. Parea, ‘Penetration of high 
intensity focused ultrasound in vitro and in vivo rabbit brain using MR 
imaging’, 9th International Conference on Information Technology and 
Applications in Biomedicine, November 5-7, 2009, Larnaca, Cyprus (4 
Pages). 
 
7. C. Damianou, V. Hadjisavas, K. Ioannides, G. Parea, ‘Therapeutic system for 
brain cancer and stroke using high intensity focused ultrasound (HIFU) under 
MRI guidance’.  14 th Conference on Biomedical Engineering (ICBME), 
Singapore 1-6 Aug, 2010 (Abstract). 
8. C. Damianou, V. Hadjisavas, K. Ioannides, G. Parea, ‘Brain diseases therapy 
using high intensity focused ultrasound (HIFU) under MRI guidance.  
EUROSON, August 22-25, Denmark 2010 (Abstract). 
9. N. Mylonas, V. Hadjisavvas, C. Damianou, An MR compatible positioning 
device for treating brain cancer and stroke using high intensity focused 
ultrasound (HIFU) under MRI guidance, 10th meeting of the International 
Society of Therapeutic Ultrasound, ISTU10, Tokyo, Japan, June 9-12, 2010 
(Poster). 
 
10. V. Hadjisavvas, K. Ioannides, C. Damianou, Application of MR-guided 
focused pulsed ultrasound for destroying clots in vitro using thrombolytic 
drugs. 10
th
 meeting of the International Society of Therapeutic Ultrasound, 
ISTU10, Tokyo, Japan, June 9-12, 2010; pp 126-131. 
 
11. V. Hadjisavvas, C. Damianou, A simulation model for predicting temperature 
during the application of MR-guided focused ultrasound for stroke treatment 
190 
 
using pulsed ultrasound, 10
th
 meeting of the International Society of 
Therapeutic Ultrasound, ISTU10, Tokyo, Japan, June 9-12, 2010; pp 253-258. 
 
12. V. Hadjisavvas, N. Mylonas, K. Ioannides, C. Damianou, An MR-compatible 
phantom for evaluating the propagation of high intensity focused ultrasound 
through the skull, 11th meeting of the International Society of Therapeutic 
Ultrasound, ISTU11, New York, USA, April 11-13, 2011 (Poster). 
 
13. C. Damianou, V. Hadjisavvas, K. Ioannides, An MR-Compatible Plastic 
Phantom for Evaluating the Propagation of High Intensity Focused Ultrasound 
Through the Skull, 13
th
 World Congress of Ultrasound in Medicine and 
Biology, WFUMB 2011, Vienna, Austria, August 26-29, 2011 (Abstract). 
 
14. Yiallouras C, Marinos I, Alexis A, HadjiSavvas V, Milonas N, Damianou C. 
A software platform controlling an MRI guided focused ultrasound system for 
cancer therapy. 12
th
 IEEE International Conference on BioInformatics and 
BioEngineering, November 11-13, 2012, Larnaca, Cyprus (4 Pages). 
 
 
